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ABSTRACT 
Non-invasive respiratory support (NIV) is associated with a high prevalence of local side- 
effects which may be associated with induction of upper airway inflammation. This thesis 
examines the effect of NIV on the upper and lower airway by examining bronchial epithelial 
cell cultures, healthy subjects, obstructive sleep apnoea (OSA), and chronic obstructive 
pulmonary disease (COPD) patients. The rationale for this thesis is based on reports 
suggesting that continuous positive airway pressure (CPAP) may induce early upper airway 
inflammation, and discusses the relationship between upper and lower airways in COPD. 
To examine the addressed rationale we used both an in vitro and in vivo approach. In vitro, 
we examined the release of the inflammatory cytokines from a human bronchial epithelial 
cell line over time-intervals using CPAP therapy. In vivo studies investigated whether 
induction of nasal inflammation was associated with the development of systemic 
inflammation, nasal symptoms, and changes in nasal mucociliary clearance after a short 
period of CPAP therapy. Results were investigated further in OSA by investigating whether 
induction of nasal inflammation was associated with the development of systemic 
inflammation, nasal symptoms, airway obstruction, and impaired adherence to CPAP 
therapy and quality of sleepiness over a six months follow-up period. Additional pilot data 
obtained involved a comparison of local and systemic inflammatory indices in COPD 
patients using and not using NIV. 
The key finding was that CPAP is pro-inflammatory. The in vitro data showed that CPAP 
resulted in the release of inflammatory mediators from cultured human bronchial epithelial 
cells, in a time-and-pressure-dependent manner. Meanwhile, in vivo data from healthy 
control subjects showed CPAP was associated with dose (pressure) response changes in 
nasal and systemic inflammatory markers, reduced nasal function, and the development of 
nasal symptoms. The development of nasal symptoms was associated with the degree of 
functional impairment and nasal inflammatory response. These in vitro and in vivo results 
were novel in reporting the effects of CPAP in this way, providing new data on the 
mechanisms of CPAP intolerance in the crucial, early phase of therapy. Furthermore, the 
long-term CPAP study with OSA resulted in nasal inflammation, reduction in nasal 
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mucociliary function, and significant other adverse effects. However, sleep quality and the 
perceived benefits of therapy improved over time, despite the presence of side-effects.  
These results have important implications for clinical practice, since it demonstrates a 
relationship between nasal symptoms, mucociliary clearance, inflammation and compliance 
in patients with OSA initiating and continuing CPAP therapy. Further investigation of 
strategies to combat the initial side-effects and nasal inflammation associated with this 
treatment modality might target the epithelial lining of the nose in an attempt to address the 
origin of the inflammatory response. In addition, educational and support strategies to 
improve patients‟ tolerance of side effects may further increase compliance with nasal 
CPAP treatment for OSA patients. 
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ABBREVIATIONS 
°C  Degree Celsius 
AASM American Academy of Sleep Medicine 
AAT Alpha1-antitrypsin  
AECOPD Acute exacerbation of chronic obstructive pulmonary disease 
AHI Apnoea-Hypopnoea Index 
AHR Airway hyperresponsiveness 
ALI Acute lung injury 
ANOVA Analysis of Variance 
AR Acoustic rhinometry 
ARDS Acute Respiratory Distress Syndrome 
BEAS-2B Bronchial epithelial cell line 
BMI Body-mass index 
BODE Body mass index, obstruction, dyspnea, exercise capacity 
index 
cm Centimeter 
CO Carbon monoxide 
CO2 Carbon dioxide 
COPD Chronic Obstructive Pulmonary Disease 
CPAP Continuous positive airway pressure 
CRP C-reactive protein 
CSA Cross sectional area 
CT Computed Tomography 
CV Coefficient of variation 
CXCR Chemokine receptor 
D-MCA Distance of cross-sectional area from nasal orifice 
EBC Exhaled breath condensate 
ECM Extracellular matrix 
ECP Eosinophil cationic protein 
8 
 
EDS Excessive daytime sleepiness 
EEG Electroencephalography 
ELISA Enzyme-linked immunosorbent assay 
EPAP Expiratory positive airway pressure 
EPO Erythropoietin 
ESS Epworth Sleepiness Scale 
ETDA Ethylenediaminetetraacetic acid 
FeNO Fractional exhaled nitric oxide 
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FVC Forced vital capacity 
GOLD Global Initiative for Chronic Obstructive Lung Disease 
GPRD General Practice Research Database 
GSH Glutathione 
H2O Water (hydrogen dioxide) 
ICAM-1 Inter-Cellular Adhesion Molecule-1 
ICC Intraclass correlation coefficients 
IF Inflammatory factors 
IFN-γ Interferon-gamma 
IL Interleukin 
IPAP Inspiratory positive airway pressure 
IPPV Intermittent positive pressure ventilation 
Kg Kilogram 
L Liter 
MCA1 First minimum cross-sectional area 
MCA2 Second minimum cross-sectional area 
MMP Matrix metalloproteinases 
MPO Myeloperoxidase 
MRI Magnetic Resonance Imaging 
MSLT The multiple sleep latency test 
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N Number 
NaCl Sodium chloride 
nCPAP Nasal continuous positive airway pressure 
NHS National Health Service 
NIV Non-invasive ventilation 
MCC  mucociliary clearance 
NO Nitric oxide 
O2 Oxygen 
OSA Obstructive sleep apnoea 
P Pressure 
PaCO2 Partial arterial pressure of carbon dioxide 
Paw Airway pressure 
PBS Phosphate buffered saline 
PEEP Positive end-expiratory pressure 
PEFR Peak expiratory flow rate 
PND Post-nasal drip 
R Pearson correlation co-efficient 
RDI Respiratory disturbance index 
Rho Spearman rank correlation co-efficient 
RMM Rhinomanometry 
rpm revolutions per minute 
S Second 
SaO2 Blood oxygen saturation 
SGRQ St. George‟s Respiratory Questionnaire 
STT Saccharin transit time 
SD Standard deviation 
STT Saccharin transit time 
T Temperature 
TIMP Tissue inhibitors of matrix metalloproteinases 
TCC Total cell count 
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TGF-β Transforming growth factor-beta 
TNF-α Tumour necrosis factor-alpha 
UARS Upper airway resistance syndrome 
UK United Kingdom 
μm Micrometer 
USA United States of America 
V Volume 
v/v volume for volume 
V2-5 Volume of nasal cavity between the 2
nd
 and 5
th
 cm from nasal 
orifice 
VEGF Vascular endothelial growth factor 
VIP Vasoactive intestinal peptide 
VT Tidal volume 
w/v Weight/volume 
WHO World Health Organization 
WOB  Work of breathing 
VEGF Vascular endothelial growth factor 
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1 
INTRODUCTION 
  
This thesis concerns the pro-inflammatory effects of non-invasive respiratory support (NIV) 
in vivo in healthy subjects, obstructive sleep apnoea (OSA) and chronic obstructive 
pulmonary disease (COPD), and in vitro of human bronchial epithelial cell-culture. The aim 
of this introductory chapter is to explain the rationale behind the research topic, by 
reviewing and discussing the existing literature. 
 
1.1 OVERVIEW OF THE RESPIRATORY SYSTEM 
The human respiratory tract is the major gas exchange system of the body. The system 
consists of complex organs and tissues that mainly include the nose, pharynx, trachea, and 
lungs. These organs help to capture oxygen from the environment and transport it into the 
lungs [1]. The primary function of the respiratory system is to supply air into the lungs, 
thereby facilitating the diffusion of oxygen into the blood stream so that the oxygen can be 
further distributed to all body parts. It also receives the waste CO2 from the blood and 
exhales it. This is achieved through breathing, during the inhalation of oxygen and 
exhalation of CO2 [2]. This gaseous exchange is called respiration. 
28 
 
 
The breathing mechanisms are facilitated by the respiratory system. The term respiration 
consists of two processes: internal and external respiration. External respiration (breathing) 
is the process of inhaling oxygen from the air and exhaling carbon dioxide into the air. This 
process occurs in the respiratory tract, which starts at the nose and mouth. Oxygen enters 
through the nose and the mouth to the respiratory system, passing through the larynx and the 
trachea, which become narrower, shorter and more numerously branching airways as they 
penetrate deeper into the lung. The trachea divides into right and left main bronchi, which 
divide into lobar, then segmental bronchi that continuous down to the terminal bronchioles.  
The terminal bronchioles divide into respiratory bronchioles that lead to tiny sacs called 
alveoli (Figure 1) [3]. The inhaled oxygen passes into the alveoli and then diffuses into the 
arterial blood through the capillaries. The CO2 follows the same route out of the lungs 
during exhalation. During breathing, the diaphragm contracts and passively relaxes, thereby 
drawing air into the lungs and exhaling the CO2 out of the lungs.  
 
Figure 1: The first 16 generations (Z) make up the conducting airways, and the last 7, the 
respiratory zone (or the transitional and respiratory zones). 
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1.1.1 Structure of Upper Airway 
The upper airway is an essential and vital part of the respiratory tract, as it helps in 
conducting air into the lungs [4]. Its anatomical structure and functional features influence 
the properties of the inhaled air. Additionally, the upper airways also play an important role 
in the protection of the lower airways [5]. The upper respiratory tract mainly consists of 
three valve-like structures: the nasal cavity, pharynx, and larynx (Figure 2). These 
particular regions regulate the airflow by a phenomenon known as airway collapse. It has 
also been described as a complex organ concerned with digestive, defensive, and 
vocalisation processes [6]. 
 
  Figure 2: Basic Structure of the Upper Respiratory Tract.  
1.1.1.1 Parts of the Upper Respiratory Tract: 
The upper respiratory airways extend from the mouth and the nose to the larynx. The upper 
respiratory system is responsible for filtering airborne particles, humidify and warm the 
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inspired gasses inhaled. It is also used for olfaction. The following are brief descriptions for 
the important parts of the upper airway: 
 • Nasal cavity: The nasal cavity comprises of the nose, nasal fossa, and paranasal sinuses. 
The nose is the primary structure of entry for inhaled air entering the respiratory tract, 
therefore, the mucosal epithelium lining (pseudostratified ciliated columnar epithelium with 
goblet cells) the nasopharyngeal airways are exposed to high concentrations of inhaled 
allergens and other particulate matters. The normal respiratory epithelium is coated with 
mucus, which lubricates and humidifies the epithelium and acts as a protective system by 
entrapping bacteria and other particulates for removal by mucociliary clearance [7]. 
• Pharynx: This is a fibromuscular tube connecting the nasal cavity and the mouth with the 
lower respiratory tract and the esophagus. The pharynx interior is often separated into three 
sections: the nasopharynx, oropharynx, and laryngopharynx. Here, the throat divides into 
the trachea and oesophagus and a small flap of cartilage, called the epiglottis, separates 
both, preventing food from entering into the trachea [8]. 
• Larynx: This tube connects the pharynx and the trachea, and is known as the voice box, as 
it consists of vocal cords that are responsible for speech. It protects the trachea using the 
glottis, which closes during swallowing [8].  
1.1.2 Structure of Lower Airway 
The lower respiratory airways extend from the trachea to the alveoli. The entire lower tract 
is protected by the ribcage, vertebral column, and sternum bone. Lower respiratory airway 
structures include the trachea, right and left mainstem bronchi, segmental bronchi, and 
terminal bronchioles through the many branches of the respiratory tree to the level of 
alveolar system, where the gas exchange occurs. The gas exchange process takes place in 
the alveoli, small air sacs at the end of the respiratory bronchioles. 
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1.1.2.1 Parts of the Lower Respiratory Tract: 
The lower respiratory airways consist of a series of branching tubes, which become 
narrower and shorter as they penetrate deeper into the lung (Figure 1). The following are 
brief descriptions for the important parts of the lower airway: 
• Trachea: A flexible tube that has an inner diameter of about 2 cm and that is 
approximately 12 cm long. It extends from the edge of the larynx, conducting air from the 
larynx into the lungs where it divides into two main bronchi [9]. Its inner membrane is 
covered with tiny hair-like structures called cilia that help to eliminate dust particles out of 
the respiratory tract through coughing before it enters the lungs [10]. The trachea is a 
cartilaginous and membranous tube surrounded by 15-20 C-shaped semi-circular cartilage 
rings at the front and side that protects the trachea and regulates its opening to allow the 
expansion of the oesophagus during the swallowing process.  
• Bronchi: The trachea divides into two main tubes called bronchi, one entering the left and 
one entering the right lung. Each main bronchus will further divide into lobar, then 
segmental bronchi. This process will continue down to the end, to the terminal bronchioles, 
which are the smallest conducting airways without alveoli. The main function of the 
conducting airways is conducting inhaled air to the gas exchange regions of the lung [8].  
• Bronchioles: Terminal bronchioles divide into respiratory bronchioles and alveolar ducts. 
Respiratory bronchioles sometimes have alveoli resulting from its walls and alveolar ducts 
are completely contains alveoli, as illustrated in Figure 2. Bronchioles are smaller airways 
that carry the inspired air on to the inside walls of the lungs, where the alveoli allow the 
oxygen to be absorbed by the blood cells, and oxygenate the blood for transfer throughout 
the body [11-12].  
• Alveoli: These are individual hollow cavities contained within the alveolar sacs (or ducts). 
Alveoli have very thin walls that allow the gaseous exchange of oxygen and CO2 for the 
body's metabolisms. They are surrounded by a network of capillaries, into which the 
inspired gasses pass. The number of alveoli is a key structural determinant of the lung 
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architecture. Human lungs have a mean number of 480 million alveoli with a mean size of 
4.2 × 106 μm3 (roughly a diameter of 200 μm) [13]. 
• Lungs: The lungs are the vital organs for the respiration process. They are located in the 
thoracic cavity and are covered with pleural membranes. The right lung has three lobes, 
while the left lung has only two lobes [14]. The lungs include the bronchi, the alveoli, 
connective tissues, blood vessels, lymph vessels and nerves [15]. Lungs are responsible for 
respiration, since the exchange of gasses takes place in them. The lungs supply the heart 
with oxygenated blood through the pulmonary veins and take off the deoxygenated blood 
through the pulmonary arteries. The elasticity of the lungs facilitates the inhalation and 
exhalation of air [10]. 
• Diaphragm: The diaphragm is a dome-shaped, broad band of internal skeletal muscle, 
which lies underneath the lungs, attached to the lower ribs, sternum and lumbar spine, 
forming the base of the thoracic cavity [16]. The diaphragm separates the thoracic cavity 
(heart, lungs and ribs) from the abdominal cavity, and performs an important function in 
respiration. The diaphragm functions in breathing by contracting and relaxing itself during 
inhalation and exhalation, respectively [17]. 
• Accessory muscles of respiration:   
The accessory muscles are responsible for assisting the diaphragm during breathing in 
patients suffering from breathing difficulties (e.g COPD), or in individuals who have 
undertaken vigorous exercise. The major accessory muscles of inspiration include the 
scalenes and the sternocleidomastoid muscles in the neck, the serratus anterior, and the 
pectoral muscles, the upper trapezius and latissimus dorsi muscle, and the erector spinae 
muscles. However, during expiration, the accessory muscles assist in exhalation when 
airway resistance becomes elevated. These muscles include rectus abdominis, external and 
internal abdominis obliquus muscles, transverses abdominis, and internal intercostals 
muscles [8]. 
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1.2 CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP) 
1.2.1 Definition and History 
CPAP is a supportive, positive pressure throughout the entire respiratory cycle (inspiration 
and expiration), when breathing spontaneously [18]. The CPAP system is delivered using a 
tight-fitting face or nasal mask and a valve, usually at a pressure of 5 - 10 cm H
2
O, against 
which the patient exhales [19-21]. The CPAP valve should be a low resistance type [22]. 
CPAP has been demonstrated as an effective treatment for patients with OSA [23]. Other 
treatment options are generally less effective, including oral-appliance devices [24] and 
uvulopalatopharyngoplasty [25]. OSA is a prevalent condition closely associated with the 
global obesity epidemic, and is characterised by repetitive, partial or complete collapse of 
the upper airway during sleep, causing impaired gaseous exchange and sleep disturbance 
[26].  
CPAP is a treatment that uses air pressure to keep the airways patent (Figure 3) [32]. It was 
introduced by Sullivan and his colleagues in 1981, and has become the initial choice for the 
management of OSA, and can completely abolish apnoeas when effective pressure levels 
are used during sleep [27]. It has now become the standard treatment for OSA [28]. It 
prevents intermittent pharyngeal obstruction (a major pathogenetic mechanism in OSA) by 
acting as a “pneumatic splint”, thus maintaining a patent airway throughout the respiratory 
cycle in order to maintain an open airway during sleep, which obviates the effects of airway 
collapsibility [29-31]. 
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Figure 3: CPAP Device: the principle of CPAP operation in resolving the airway obstruction during 
sleep. 
 
Before the 1960s, nearly all ventilation techniques for mechanical ventilation were non-
invasive. In 1980, clinical evidence began to show that the benefits of intermittent positive 
pressure ventilation (IPPV) were often exaggerated and could be replaced with other 
simpler and more cost-effective therapies [33]. As IPPV lost favour in clinical practice, 
nasal mask CPAP started to emerge as a highly effective therapy for the treatment of OSA 
[34].
 
  
CPAP comes in two forms. Each form has different indications and applications in the 
clinical setting. The first form is a CPAP generated by a flow generator in the acute setting, 
which is used as a form of respiratory support in the treatment of type I respiratory failure. 
The second form is generated by a small, portable electrically powered compressor, and 
used in the treatment of obstructive sleep apnoea. The focus of this thesis is on the second 
form of CPAP with OSA. 
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1.2.2 Indications and Contraindications of CPAP Therapy 
1.2.2.1 Indications of CPAP Therapy 
It is essential that CPAP is applied in an appropriate form of therapy in patients whom 
clinically beneficial to them. CPAP is not suitable for all patients with respiratory failure 
and any inappropriate use of this therapy may lead to suboptimal treatment. The following 
are indications for CPAP:   
 Treatment of choice for patients with OSA [30].  
 Effective therapy in patients with cardiogenic pulmonary oedema [35-37].  
 
1.2.2.2 Contraindications of CPAP Therapy 
Although CPAP is a safe and effective form of therapy, it requires patient to be alert and 
breathing. If the patient is unable or fails to cooperate with fitting or wearing mask, then 
CPAP therapy is not appropriate. Most of the contraindications to CPAP are listed below 
[35, 38]:    
 Cardiac or respiratory arrest. 
 Severe gastrointestinal obstruction and/or bleeding. 
 Severe haemodynamic instability with or without unstable cardiac angina. 
 Facial surgery or trauma. 
 Fixed upper airway obstruction. 
 Inability to protect the airway: risk of aspiration, viscous or copious secretions. 
 Untreated pneumothorax.   
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1.2.2.3  CPAP-Related Side Effects 
Many side effects can occur during the first few weeks of CPAP use and that leads to poor 
adherence and discontinuation of treatment [39-40]. The most reasons for poor compliance 
in adults include inconvenience, side effects, discomfort, claustrophobia, and expense, 
Table 1 [41].  
 
Table 1: Possible CPAP-related side effects. 
 
CPAP-RELATED SIDE EFFECTS 
 
POSSIBLE CAUSE 
 
 
Interface related 
 
Mask leak, skin abrasion/ulceration, mask allergy, 
conjunctivitis/sore eyes, facial irritation, 
claustrophobia. 
 
Pressure-Related (Airway) Rhinitis, rhinorrhoea, sneezing, sinusitis, headache, 
epistaxis, ear pain, air swallowing/aspiration. 
 
Pressure-Related Mouth leak (dry mouth) or mask leak, pressure 
intolerance, sense of suffocation or difficulty in 
exhaling, tinnitus, aerophobia, pneumoencephalus. 
 
Equipment-Related Noise, smell, tubing condensation, cumbersome 
equipment, spousal intolerance/less intimacy, ramp 
abuse, equipment maintenance and cleaning. 
 
Equipment Failure Machine lifespan, tubing and mask, OSA recurrence. 
 
 
General Periodic limb movements, anxiety, insomnia, 
headache, fatigue/feeling tired, chest discomfort. 
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1.3 BILEVEL POSITIVE PRESSURE AIRWAY THERAPY 
1.3.1 Definition and History 
Bilevel positive pressure airway therapy is a form of NIV, which is defined as “the 
application of positive pressure without airway intubation for the purpose of augmenting 
alveolar ventilation” [42]. This technique is distinguished from invasive ventilatory support, 
which bypasses the upper airway with a tracheal tube, laryngeal mask, or tracheostomy 
(Figure 4) [35, 43]. It has increasingly been used to avoid intubation [44], and eliminates 
the need for intubation or tracheostomy, preventing problems such as injury to the vocal 
cords or trachea, and lower respiratory tract infections [45]. Evidence supports the use of 
NIV with exacerbated COPD, acute cardiogenic pulmonary oedema, and may reduce 
mortality [38, 46].  
 
Figure 4: NIV as an effective therapy in acute exacerbations of COPD [43]. 
 
The concept of mechanical ventilation first evolved as a negative-pressure ventilation when 
the first workable „iron lung‟ was developed in 1876 [47], and was used extensively during 
the polio epidemics of the 1930s and 1960s (Plate 1). The iron lung works by augmenting 
the tidal volume by applying negative extrathoracic pressure. These earliest forms of NIV 
38 
 
fell out of favour as the use of invasive positive pressure ventilation increased during the 
1960s. In the early 1980s, proliferations of NIV began with the introduction of the nasal 
CPAP mask for the treatment of OSA [48]. Moreover, the past decade has seen continuity in 
the use of NIV, largely because of the development of nasal ventilation, which has the 
potential for providing ventilatory assistance with greater convenience, more comfort, 
safety, and less cost than invasive positive ventilation [49]. NIV currently has a definite and 
important role in the management of acute and chronic respiratory failure of many 
aetiologies [43]. 
 
 
Plate 1: An iron lung: Typical equipment available for respiratory failure in 1952: (Image of child in 
iron lung reproduced courtesy of the WHO Global Polio Eradication Initiative) [50]. 
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1.3.2 Physiological Effects of NIV  
Of different aetiologies, the pathophysiology of acute respiratory failure include an 
imbalance between an increased respiratory mechanical load and a decreased capacity of the 
respiratory muscles, decrease in lung gas exchange due to either ventilation-perfusion 
mismatch or intrapulmonary shunt, and deteriorations in cardiovascular function [51]. NIV 
is an effective supportive therapy in unloading the respiratory muscles, decreasing the work 
of breathing and improve lung mechanics in numerous diseases. Table 2 summarises goals 
and indications of NIV in acute and chronic settings [43]. 
Table 2: Goals and indications of NIV in acute and chronic settings. 
 
 GOALS OF NIV 
ACUTE CARE CHRONIC CARE 
Relieve symptoms Relieve & improve symptoms 
Decrease work of breathing Improve quality of life 
Improve gas exchange  Enhance functional status 
Improve patient comfort Avoid hospitalisation 
Decrease length of hospitalisation Increase survival 
Avoid intubation Improve mobility 
 
NIV ACUTE INDICATIONS  NIV CHRONIC INDICATIONS 
COPD exacerbations 
Acute cardiogenic pulmonary oedema 
Respiratory infection in 
immunocompromised state 
Hypoxemic respiratory failure 
Restrictive chest diseases: 
       Neuromuscular diseases 
       Chest wall deformities 
       Kyphoscoliosis 
Postoperative respiratory failure COPD 
Difficulty weaning Nocturnal hypoventilation 
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1.4 PRINCIPLE OF OPERATION FOR NON-INVASIVE VENTILATION  
Noninvasive positive ventilation works by delivering a pressurised gas via external 
interfaces. There are two forms of noninvasive positive ventilation, which is CPAP and 
bilevel positive pressure airway therapy, as mentioned earlier. These devices are relatively 
portable, quiet, and often come with a variety of features designed to enhance patient 
comfort. In thesis, both forms of noninvasive positive ventilation have been used with 
healthy subjects, using CPAP and OSA, and bilevel positive pressure airway therapy, with 
COPD patients.  
 
CPAP 
A basic CPAP device provides the patient with fixed pressure therapy throughout both 
inspiration and expiration. Many of these CPAP devices are equipped with a ramp feature 
that allows a gradual increase in the length of time of the pressure from a low level until 
reaching the final prescribed pressure. 
In obstructive sleep apnoea, application of CPAP acts as a pneumatic “splint” which 
prevents upper airway collapse during sleep. During CPAP therapy, the patient breathes 
from a pressurised circuit against a threshold resistor (water-column, weighted, or spring 
loaded) that maintains consistent pre-set airway pressures from 5 to 20 cm H2O during both 
inspiration and expiration. The expiratory pressures are set above atmospheric pressure and 
therefore both inspiratory and expiratory pressures are increased (Figure 5).
 
This form of 
CPAP is generated by a small and portable electric compressor [52]. 
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Figure 5:
 
A representative tracings of flow, tidal volume, and airway pressure (Paw) during 
administration of CPAP.  
 
 
BILEVEL POSITIVE PRESSURE AIRWAY THERAPY 
A bilevel positive pressure airway device delivers a separately adjustable higher pressure 
level on inspiration, (IPAP) and cycles to a lower pressure on expiration (EPAP) [52]. This 
therapy may be appropriate therapy for the patient who requires a high level of CPAP to 
resolve all respiratory events and for some patients with difficulty exhaling [52-55]. The 
level of pressure difference between the IPAP and EPAP settings provides a pressure-
supported augmentation of tidal volume and unloading of the respiratory muscles that can 
benefit patients who have underlying hypoxemia or hypoventilation, or in patients with 
neuromuscular disorders or COPD [56].  
Such a variable pressure setting between the inspiratory and expiratory cycles would help in 
decreasing the amount of pressure against which the patient exhales, thereby decreasing 
abdominal muscle recruitment and consequent respiratory discomfort during the expiratory 
cycle [57]. However, the greater level of pressure during the inspiratory cycle helps in 
combating the inspiratory flow limitation suffered by the upper airway (Figure 6) [58].  
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Figure 6: A. continuous positive airway pressure of 5 cm H2O with a patient breathing 
spontaneously. B. patient-triggered breath during NIV with an IPAP of 10 cm H2O and EPAP of 5 
cm H2O. C. inspiratory positive airway pressure has been increased to 1 cm H2O. D. inspiratory 
positive airway pressure remains 15 cm H2O, but EPAP has been increased to 10 cm H2O. [Modified 
from reference 58]. 
 
 
 
 
 
 
 
 
 
 
 
A 
 
    CPAP +5  
B 
 
    IPAP +10  
D 
 
    IPAP +15  
C 
 
    IPAP +15  
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Figure 7 below explains and illustrates how obstructive sleep apnoea occurs and the 
principle of CPAP operation in resolving the airway obstruction during sleep [32]. 
 
 
Figure 7: The principle of CPAP operation in resolving the airway obstruction with OSA patient.   
 
A. Normal airways without obstructive sleep apnoea. Patent airways allow the flow of air 
and oxygen into the lungs during inhalation and the flow of carbon dioxide out of the lungs 
during exhalation. 
 
B. OSA may be mild to severe. When the airway is partially blocked, it becomes difficult 
for the air to pass though the upper airways to the lung, which results in snoring.   
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C. At times when the OSA becomes more severe, the airway may become completely 
blocked, and this results in no airflow. This is called apnoea.    
 
D. CPAP is the most common treatment for moderate to severe OSA. Here, a CPAP mask 
fits over the nose and mouth. During inhalation, the CPAP machine works by delivering air 
through the tube and mask into the nose, mouth, and throat. The pressurised air presses on 
the walls of the upper airway, keeping it open. This prevents airways from collapsing. 
 
E. During exhalation, the CPAP machine continues to gently deliver air to keep the airway 
open. The continuous airflow also washes out the exhaled air and carbon dioxide through 
the mask holes. This process continuous throughout the night with each breath, allowing the 
patient to breathe uninterrupted during sleep.  
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1.5 Patient Interfaces for NIV 
Patient interfaces have a major impact on patient comfort, clinical effectiveness, and 
compliance to NIV therapy. Several factors need to be considered when offering interface 
options to the patient to ensure the interface will feel comfortable and fit properly. Table 3 
summarises the characteristics of an ideal NIV interface [59].  
Table 3: Characteristics of an ideal non-invasive ventilation interface and securing system. 
Ideal interface 
Leak-free 
Good stability 
Nontraumatic 
Light-weight 
Long-lasting 
Nondeformable 
Nonallergenic material 
Low resistance to airflow 
Minimal dead space 
Low cost 
Easy to manufacture (for the moulded interfaces) 
Available in various sizes 
 
Ideal securing system 
Stable (to avoid interface movements or dislocation) 
Easy to put on or remove 
Nontraumatic 
Light and soft 
Breathable material 
Available in various sizes 
Works with various interfaces 
Washable, for home care 
Disposable, for hospital use 
 
Facial anatomy differs dramatically from patient to patient, therefore, proper selection of the 
interface size is mandatory to achieve the best clinical results. A variety of NIV interfaces 
are available, including [59]: 
• Mouthpiece: placed between the patients lips and held in place by lip-seal 
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• Nasal mask: covers the nose but not the mouth 
• Nasal pillows: plugs inserted into the nostrils 
• Oronasal: covers the nose and mouth 
• Full-face: covers the mouth, nose, and eyes [49]. 
• Helmet: covers the whole head and all or part of the neck; no contact with the face 
or head [60]. 
 Nasal masks:   
The nasal mask is widely used for the administration of CPAP or bilevel positive pressure 
airway therapy, machines. The standard nasal mask is a triangular or cone-shaped clear 
plastic device that fits over the nose. This mask utilises a soft cuff to form an air seal over 
the skin (Plate 2).  
 
An alternative type of nasal interface is nasal “pillows” or “seals,” which consist of soft 
rubber or silicone pledgets that are inserted directly into the nostrils (Plate 3). Because they 
exert no pressure over the bridge of the nose, nasal pillows are useful in patients who 
develop redness or ulceration on the nasal bridge while using standard nasal masks [43].  
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Plate 2: Different types of nasal masks [59].  
 
Plate 3: Different types of Nasal pillows [59].  
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 Oronasal and full-face masks: 
Oronasal or full-face masks cover both the nose and the mouth (Plate 4). They have been 
used mainly on patients with acute respiratory failure, as these patients generally breathe 
through the mouth to overcome or bypass nasal resistance [61].  
A full-face mask (Plate 5) is made of a soft cuff that seals around the perimeter of the face; 
therefore there is no pressure on areas that an oronasal mask touches. The frame of the full-
face mask includes an anti-asphyxia valve that opens to room air in case of malfunction of 
the machine when airway pressure falls below 3 cm H2O [59]. 
 
 
Plate 4: Different types of Oronasal masks [59]. 
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Plate 5: Different types of Full-face masks [59].  
 
 Mouthpieces: 
Mouthpieces held in place by lipseals have been used since the 1960s to provide NIV 
therapy with chronic respiratory failure (Plate 6) [43]. Mouthpieces are simple and 
inexpensive. The drawback of this interface is that nasal air leaking affects the efficacy of 
NIV. Mouthpieces have been successfully used in patients with neuromuscular disease and 
those with negligible vital capacity, and have enabled tetraplegic patients shift from 
tracheostomies to NIV [62-63]. 
 
   
 
 
Plate 6: Mouthpiece with lipseal (Mallinkrodt). 
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Complications Related to the Mask 
Studies have been conducted to compare the efficacy of various patient interfaces. Navalesi 
et al. [64] found that while nasal masks were better tolerated than nasal pillows or oronasal 
masks, they were less effective at reducing PaCO2. This was attributed to greater air 
leakage. However, McCormick et al. [65] demonstrated that use of nasal and oronasal 
masks resulted in comparable decrease in PaCO2 and respiratory rate. 
Among all these interfaces, nasal masks are the most widely used for both NIV and CPAP. 
Nasal masks are preferable for long term ventilation, but have also been used for acute 
hypercapnic [66] and hypoxemic respiratory failure [67].      
Table 4 lists NIV complications related to masks [68]. The incidence of patient complaint 
due to masks may be as high as 50%, but in most cases, this can be treated with mask 
adjustment or change of mask [68]. 
 
Table 4: Problems related to non-invasive ventilation interfaces. 
 
Problem Incidence 
 
Solutions 
   
Nasal Mask   
     Mask discomfort 30–50% Decrease strap tension 
Re-seat mask 
Try different mask size or type 
     Skin rash 10–20% Topical steroids or clindamycin 
Dermatologic consultation 
     Nasal-bridge sores 5–10% Minimize strap tension 
Use forehead spacer 
Artificial skin 
Switch to different mask type 
     Nasal obstruction Occasional Topical decongestant 
Try oronasal mask 
Oronasal Mask   
     Mask discomfort 30–50% Minimize strap tension 
Try different mask size or type 
     Claustrophobia 10–20% Reassure patient 
Try different mask type 
     Skin rash, nasal bridge sores 
     More dead space 
10–20% 
Depends on 
mask 
Same as for nasal mask sores 
Insert foam rubber to reduce 
dead space 
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Anti-asphyxia valve 
     Aspiration of vomit Rare Quick-release straps 
Mouthpiece   
     Discomfort  Common Reassure patient 
Diminishes with adaptation 
     Hypersalivation, salivary 
retention 
Common Reassure patient 
Diminishes with adaptation 
     Aerophagia Common Reassure patient 
Simethicone 
     Pressure sores on lips, gums Infrequent Decrease strap tension 
Consider custom fitting 
     Orthodontic problems After prolonged 
use 
Remodel mouthpiece 
Consult orthodontist 
Head Straps   
     Discomfort 10–30% Try different strap system 
     Unstable mask Common with 
2-strap system 
Try different mask or strap 
system 
 
 
For this thesis, the Respironics REMstar CPAP device was used for in vivo and in vitro 
studies (Plate 7). All CPAP was delivered at a fixed pressure of 7.5 or 12.5 cmH2O for in 
vivo and a fixed pressure of 4 or 7 cmH2O for in vitro studies. This machine is designed for 
the treatment of adult Obstructive Sleep Apnoea only.  
 
 
 
Plate 7: Non-invasive respiratory support modalities used for this thesis. (A) Respironics REMstar 
CPAP. (B) Respironics Comfort Classic Nasal mask. (C) Disposable air-flow circuit. 
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1.6 Obstructive Sleep Apnoea (OSA) 
1.6.1 Definition  
Obstructive sleep apnoea (OSA) is a form of the common disease of sleep apnoea. It has 
been found to affect 2 to 4% of adult men and about 1 to 2% of adult women [69]. It is 
characterised by repetitive episodes of upper airway partial or complete pharyngeal 
obstruction during sleep [70]. Figure 8 shows the pharyngeal obstruction during sleep and a 
schematic trace for a polysomnography test of OSA [71-72].  
The repetitive closure and opening of airways with this disease causes impaired gaseous 
exchange [28], recurrent arousals, intermittent hypoxaemia, sleep fragmentation, poor sleep 
quality, daytime sleepiness, an increase in cardiovascular risk [73-75] and an increased risk 
of injuries from motor vehicle crashes and industrial injuries [76-77].  
The American Academy of Sleep Medicine (AASM) defines obstructive sleep apnoea as 
„cessation of airflow during sleep for more than 10 seconds, five or more apnoea episodes 
per hour of sleep (apnoea–index), and  oxygen desaturation of at least 4%‟ [78]. 
Severity is assessed by the apnoea-hypopnea index (AHI). OSA can be classified based on 
the number of partial (hypopnoea) or complete (apnoea) airway obstructions per hour, and 
AHI is categorised by the AASM as [78]: 
 Mild (5–14 events per hour)  
 Moderate (15–30 per hour)  
 Severe (>30 per hour)  
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Figure 8: Obstructive Sleep Apnoea. (A) upper airway pharyngeal obstruction during 
sleep [71]. (B) Polysomnography tracing illustrating obstructive sleep apnoea events 
[72].  
 
Mild OSA appears not to be associated with increased risk of mortality, whereas some, but 
not all, data indicate than moderate OSA is associated with an increased mortality risk. 
Severe OSA, however, has consistently been associated with a two- to six-fold increase in 
all-cause mortality [79-80]. 
OSA has a broad spectrum of signs and symptoms, summarized in Table 5. Snoring and 
excessive daytime sleepiness appear to be the most prominent symptoms. 
 
Table 5: Broad spectrum of signs and symptoms of OSA. 
Snoring  
Excessive daytime sleepiness 
Apnoeas during sleep 
Excessive day-time sleepiness 
Choking episodes during sleep 
Arousals 
Irritability and personality change 
Headaches 
Loss of concentration and impaired memory 
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1.6.2 Incidence  
OSA is a common problem, but an underdiagnosed condition [81].
 
The magnitude of this 
problem is underestimated by many health care providers in the medical field. However, the 
OSA incidence rate is increasing due to its association with obesity, and increased public 
awareness, resulting in more patients and family members bringing symptoms to the 
attention of health care providers [82]. 
OSA is now recognized as a major health issue. There are considerable amounts of 
prevalence data on OSA from Western countries, but little is known about the incidence (i.e. 
the occurrence of new cases over a given time interval) or progression (i.e. worsening over 
time) [83]. The incidence of OSA has never been formally investigated, but it was recently 
shown that it is the most common diagnosis among patients referred to diagnostic sleep 
laboratories in the United States, and that it might be especially prevalent among the aged 
[84-86]. More recently, it was shown that about 1% of an unselected inpatient population 
admitted to a general hospital in Italy during a 1-year period had OSA [87].  
There is considerable variation in the estimates of OSA population due to population 
heterogeneity, differences in methodology in measuring sleep, and variation in thresholds 
that differentiate abnormal from normal subjects [88]. The prevalence rates of OSA have 
been estimated within the range of 2 to 10 percent worldwide [26]. Young estimated that the 
prevalence of OSA in a group of 602 middle-aged males was 4 per cent, and 2 per cent for 
middle-aged females, and this is reported to increase with age [83]. Those patients were at 
the minimal diagnostic criteria for sleep apnoea, that is, an AHI > 5 and 3 symptoms of 
daytime hypersomnolence. Excessive daytime sleepiness, not feeling refreshed after 
awakening, and uncontrollable daytime sleepiness, were the 3 symptoms of daytime 
hypersomnolence used in this study. The prevalence of OSA with daytime symptoms is in 
the range of 5% [84]. A large epidemiological survey of people aged between 30 to 60 years 
in the United States showed the prevalence of sleep-related breathing disorder. The disorder, 
defined by an AHI of 5 or more, was 24% for males and 9% for females [83]. However, the 
prevalence rates are higher among elderly people, with up to 60% showing disturbances 
55 
 
during sleep [89]. Several studies have shown a prevalence of 60 percent among patients 
with stroke [90-93], as compared with 4 per cent in the middle-aged adult population [83]. 
Any attempt to determine the prevalence of OSA in the general population is complicated 
by the fact that there is no definition of the syndrome upon which there is general 
agreement. Although it has been suggested that OSA be defined by the occurrence of at 
least 30 apnoeas, with each apnoea of at least 10s duration in 7h of sleep, or by the 
occurrence of at least 5 apnoeas in each hour of sleep [94], there are data suggesting that 
these criteria are too permissive, since multiple sleep apnoeas can occur in normal 
individuals who are completely asymptomatic [95]. Much more information about the 
incidence of sleep apnoea among normal individuals is needed before an adequate definition 
of OSA can be provided [74]. 
The health system in Saudi Arabia relies on the referral system, where the patient is usually 
first examined by the primary health care physician, who assesses and decides the patient‟s 
plan of management. Therefore, early detection and management of patients with sleep 
disorders depends on the significant knowledge and awareness of physicians. 
In Saudi Arabia, sleep medicine as a specialty is relatively new, hence the prevalence of 
sleep disorders among the Saudi population is not well investigated and studies that address 
the size of this problem are limited. The available data indicate that sleep disorders are 
prevalent among Saudis [96]:
 
3 out of 10 Saudi men and 4 out of 10 Saudi women are at 
high risk of OSA [97].
 
Other reported sleep disorders are snoring in 17.9% of children, 
narcolepsy in 40/100,000 Saudis, and 5.2% for restless legs syndrome [97]. 
Previous studies have reported high incidences of side effects during long-term therapy, 
which approached 97% in a large series [98]. 
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1.6.3 Risk Factors for OSA 
There are several risk factors that could predispose an individual to OSA. There is 
increasing evidence that OSA is being considered as an independent risk factor for 
hypertension, glucose intolerance/diabetes mellitus, cardiovascular diseases and stroke, 
leading to increased cardiometabolic morbidity and mortality. The risk factors for OSA 
include advanced age, male sex, obesity, family history, craniofacial abnormalities, 
smoking, alcohol consumption [26], and depression [99]. Moreover, there is increasing 
evidence that OSA is an independent risk factor for an adverse cardiometabolic profile 
[100]. It has been associated with vascular risk factors [87] and increased cardiovascular 
and cerebrovascular morbidity and mortality, although much of the causal role and 
mechanisms are still poorly understood [101].  
A summary of the different risk factors for OSA is given below:  
 Snoring:  It is a risk factor that has been examined in association with OSA. A 
study by Woodhead showed that 35 patients with a history of loud snoring were 
diagnosed with OSA after being examined by a sleep study. It was found that 16 
(46%) of the 35 participants demonstrated OSA [102]. 
 Obesity and body-mass index (BMI) greater than 30 kg/m2: It is a primary 
risk factor for OSA. Several studies have reported that there were association 
between obesity and OSA. According to the Wisconsin Cohort Sleep study, a 
10% increase in weight is associated with a 6-fold risk of developing OSA [103]. 
About two-thirds of patients with OSA are more than 20% above their ideal body 
weight.  
 Male gender: There is a two- to three-fold increased risk for OSA in men, 
related to anatomical and sex hormone differences [104]. 
 Familial association/genetics: Mendelian and familial inheritance patterns of 
upper airway craniofacial structures predisposing to OSA have been reported 
[105]. 
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 Alcohol consumption: Acute consumption may induce apnoeic events in normal 
subjects and worsen the severity of OSA in established patients [104]. 
 Cranial facial structure/craniofacial abnormalities: High and narrow hard 
palate, elongated soft palate, small chin, and abnormal overjet [106]. Imaging 
techniques have described the craniofacial features of OSA patients. These 
include a reduction in the length of the mandible, an inferiorly positioned hyoid 
bone, a retroposition of the maxilla, retrognathia, nasal septal deviation, and 
narrowing of the hard palate [107]. 
 Upper airway soft tissue abnormalities: Macroglossia, lateral peritonsillar 
narrowing, soft palate enlargement, and tonsillar hypertrophy alter the 
configuration of the luminal airway, increasing the risk of OSA [108]. 
 Age: Older subjects (i.e. > 45 years of age) have more than three times the increased 
risk of having OSA. The relationship between age and OSA has been studied by various 
researchers, yielding disparate results with a suggestion of a rise in the prevalence of 
OSA with age [109]. Some researchers [83,110-111] have concluded that this effect 
occurs only up to middle age and that age ceases to be an independent risk factor for 
OSA beyond middle age. However, population studies indicate a higher prevalence of 
OSA in older subjects (aged 60 years and above) compared with middle-aged groups 
[104].  
 Endocrine system: OSA is more common in hypothyroid (especially 
myxedema) and acromegaly patients [112]. In cases of hypothyroidism and 
acromegaly, OSA is mainly related to UA narrowing due to reversible thickening 
of the pharyngeal walls [113]. 
 Race: OSA is more common among African Americans, Mexican Americans, 
Pacific Islanders, and East Asians [114-115].  Moreover, when compared with 
white men, Far East Asian men were less obese but had greater severity of OSA 
[116]. 
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According to the AASM, the following risk factors that increase the likelihood of having 
obstructive sleep apnoea are [82]: 
 Obesity 
 Congestive heart failure 
 Atrial fibrillation 
 Treatment refractory hypertension 
 Type 2 diabetes 
 Nocturnal dysrhythmias 
 Stroke 
 Pulmonary hypertension 
 High-risk driving populations 
 Preoperative for bariatric surgery 
 Patients undergoing upper airway surgery for snoring 
 
1.6.4 Geography  
Geographically, OSA prevalence has been established in few populations other than the 
Western nations. Therefore, the worldwide importance of OSA and its importance racially 
or ethnically prevalence patterns of OSA, is poorly understood. Epidemiologists have 
investigated geographical distributions of disease occurrence to find aetiologic answers, but 
it is always hard to disentangle environmental risk factors, including cultural differences in 
diet and lifestyle, from genetic factors. At current, avaliable data from studies of groups 
other than white subjects are too sparse even to determine with confidence if prevalence 
differs worldwide [84].  
However, in spite of the limitations, different studies have concluded that OSA is prevalent 
in the United Kingdom [117], Northern Europe [118-120], Australia [110], and the United 
States [83, 121]. The estimated prevalence of symptomatic OSA in the United States in the 
early 1990s by Young et al. [83] was 4% among adult men and 2% among adult women. 
Since then, the adult prevalence rates of sleep-disordered breathing have become available 
in many different countries after large-scale epidemiological studies (Table 6) [83, 99, 109-
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110, 122-128]. Interestingly, the prevalence of OSA in developing countries such as India 
and China is in the same order of magnitude as that in the developed countries, despite less 
obesity [129]. Moreover, the prevalence of OSA is similar in both Caucasians and Asians; 
this indicates that OSA is not only common in developed countries, but also in developing 
countries. Inter-ethnic studies suggest that African-American ethnicity may also be a 
significant risk factor for OSA [26]. The increased prevalence of OSA among American 
Indians and Hispanic adults, and increased severity among Pacific Islanders and Maoris, 
have mainly been explained by the increased obesity indices [130]. 
 
Table 6: Recent studies on the prevalence of OSA in different ethnic groups. 
Reference Study population Age, yr Prevalence (%) 
Young et al. [83] American men and 
Women 
30-60 Men: 4*-25
#
 
Women: 2*-19
#
 
Bixler et al. [131] American men 20-100 17
#
 
Bixler et al. [123] American men and 
women 
20-100 Men: 3.9* 
Women: 1.2* 
Duran et al. [124] 
 
Spanish men and 
women 
30-70 Men: 14*-26
#
 
Women: 7*-28
#
 
Ip et al. [132] Chinese men 30-60 4.1*-8.8
#
 
Ip et al. [125] Chinese women 30-60 2.1*-3.7
#
 
Kim et al. [126] 
 
Korean men and women 40-69 Men: 4.5*-27
#
 
Women: 3.2*-16
#
 
Udwadia et al. [127] Indian men 25-65 7.5*-19.5
#
 
Sharma et al. [109] 
 
Indian men and women 30-60 Men: 4.9*-19.7
# 
Women: 2.1*-7.4
#
 
*OSA syndrome is defined as apnoea-hypopnoea index ≥ 5 with excessive daytime sleepiness; # 
OSA is defined as apnoea-hypopnoea index ≥ 5. All these prevalence studies were assessed with 
standard polysomnography. 
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However, in Saudi Arabia sleep medicine specialty is relatively new; hence, the prevalence 
of sleep disorders among the Saudi population is not well investigated and studies that 
address the size of this problem are limited. 
Table 7 shows the status of sleep medicine activity in Saudi Arabia compared to other 
countries [97].
 
Four sleep facilities have the complete setup and staffing to perform the sleep 
studies. One of those facilities had certified technicians, but the other facilities had different 
backgrounds (respiratory therapists, nurses, and electroencephalography (EEG) 
technicians). 
 
Table 7: Sleep Medicine in Saudi Arabia compared to other countries.  
Country  Population  No. of 
sleep 
facilities 
No. of 
sleep 
beds 
No. of 
beds/100,
000 
No. of 
studies/ 
year 
No. if 
studies/year/
100,000 
Saudi Arabia  21,500,000 9 14 0.06 1,536 7.1 
United States 280,000,000 1,292 - - 1,170,000  427.0 
Canada 31,400,000 100 440 1.4 116,000 370.4 
Australia 18,970,000 65 244 1.3 53,500 282.0 
Belgium 10,000,000 50 150 1.5 17,716 177.2 
Spain 40,341,462 63 - 0.29 17,270 45.6 
United Kingdom 58,800,000 84 170 0.3 25,000 42.5 
Japan 126,686,000 146 - - 23,184 18.3 
 
Bahammam et al. [96] demonstrated that the lack of trained sleep technicians able to 
perform polysomnography tests was the most important obstacle to the provision of sleep 
facilities for 80% of the surveyed hospitals. Other important reasons are shown in Figure 9 
from the same study, where the data were collected from 53 major governmental and private 
hospitals and medical centres in Saudi Arabia. This study also showed that only 19 qualified 
sleep medicine physicians were located in a few hospitals in three major cities in Saudi 
Arabia. This number is considered extremely low in a large country geographically 
considered as the world's 13th largest state, with an estimated population of 27 million. 
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Figure 9: Important factors contributing to lack of sleep medicine practice in Saudi Arabia [96]. 
 
Sleep medicine specialty is still underdeveloped in Saudi Arabia in comparison with other 
countries. More serious effort needs to be made at all levels in order to overcome the 
challenging obstacles (addressed in the current studies) to the progress of sleep medicine in 
Saudi Arabia. 
 
1.6.5 Aetiology  
The aetiology of OSA is somewhat complex and misunderstood, but is thought to arise from 
a combination of anatomical and pathophysiological factors, which predispose to narrowing 
of the upper airway [133].  
OSA results from a physical obstruction occurring in the upper airway (during which there 
are still attempts to breathe during sleep), as a result of anatomical and physiological 
abnormalities in pharyngeal structures [99]. The spectrum of obstructive sleep-disordered 
breathing has historically been described as ranging from simple snoring, through upper 
airway resistance syndrome (UARS), to OSA. This concept also implies that, over time, an 
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individual progresses from being normal to developing simple snoring, then UARS and then 
finally OSA. The repeated occurrence of obstructive apnoeas overnight leads to a 
predictable pattern of events: a reduction of inspiratory airflow leading to episodic 
hypoxemia and hypercarbia, an increase in respiratory effort, arousals in order to restore 
normal respiration, fragmented sleep, and in most cases excessive daytime sleepiness [134]. 
The recurrent episodes also increase the output of the sympathetic nervous system activities 
[135], the effect of which is to restore pharyngeal muscle tone and reopen the airway. These 
events, which are mediated by a variety of chemoreceptors in the carotid body and 
brainstem, trigger pathophysiological changes that occur not only in the obstructive sleep 
apnoeas, but also extend into wakeful states during the daytime. For example, during 
daytime wakefulness, an individual with OSA has higher sympathetic activity [136] and 
heightened chemoreflex sensitivity, which generates an increased ventilatory response 
[137]. However, the full pathophysiology of OSA remains somewhat unclear, although the 
relationships between OSA and a range of other long-term health effects are being pieced 
together [99]. 
 
1.6.6 Pathogenesis 
It has been known for some time that sleep apnoea is characterised by recurrent collapse of 
the upper airway during sleep [138]. Most evidence would suggest that a variety of features 
can lead to OSA, and that the combination of these features leading to this disorder in any 
particular patient may vary considerably (Table 8) [139].  
 
Table 8: Phenotypic traits contributing to sleep apnoea pathogenesis. 
Anatomic/Physiologic Trait     Apnoea Predisposition 
 
Upper airway anatomy     Small pharyngeal airway 
Upper airway motor control  Poor muscle responsiveness during 
sleep 
Ventilatory control stability     High loop gain 
Lung volume       Low sleeping lung volume 
Arousal threshold      Low respiratory arousal threshold 
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Patients with OSA have smaller and more collapsible airways than normal. In the awake 
state, the airway is patent because of pharyngeal dilator muscle activation. However, in the 
sleep state, the activity of those muscles is markedly diminished [140] and lung volume 
decreases in the supine position, causing substantial restriction in airflow and resulting in 
hypopnea or apnoea [141]. This mechanical load and CO2 retention activate the pharyngeal 
muscles in order to restore upper airway patency [142-143]. Recruitment of pharyngeal 
dilator muscles can be achieved and upper airway patency is restored without a cortical 
arousal in some individuals, whereas, in others, the arousal is required for effective muscle 
recruitment; this phenomenon has been described as compensatory effectiveness [144]. 
Indeed, after each apnoea, patients with OSA hyperventilate, CO2 drops to the apnoeic 
threshold, expiratory time becomes prolonged, and the upper airway may collapse again. 
Moreover, several reports have described decreased responsiveness of the pharyngeal 
muscles to negative upper airway pressure, due to damage to the sensory nerves in the upper 
airway or to the muscle itself. This damage may be due to inflammation caused by 
vibration, snoring, or trauma [145-148]. Data also support the notion of ventilatory 
variability at sleep-wake transitions as a predictor of OSA severity [149]. In addition, 
humoral and inflammatory mediators released from the visceral adipose tissue may play a 
role in ventilatory regulation. The most studied is leptin, which binds to its receptors in the 
hypothalamus, causing reduced satiety and increased ventilation [150]. Leptin stimulates 
respiratory drive, as shown in leptin-deficient or resistant mice that exhibited features of 
central hypoventilation and obesity [151]. Overall, there are a variety of ventilatory control 
mechanisms that might predispose to an unstable upper airway, including alterations in loop 
gain, impairments in upper airway motor and neural control, and responsiveness, as well as 
humoral mechanisms. 
Hypercapnia at night is an important matter in OSA, especially if chronic obstructive 
pulmonary disease (COPD) is present. This is an overlap syndrome, and there is increasing 
evidence that both diseases cause inflammation and create oxidative stress. McNicholas et 
al. [152] showed how both diseases cause systemic inflammation consequences resulting in 
cardiovascular disease (Figure 10). 
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Figure 10: Both COPD and OSA are systemic inflammatory disorders that cause cardiovascular 
disease via various common pathways. 
 
 
1.6.7 Pathology  
The primary pathophysiologic event that occurs in OSA is complete obstruction or partial 
obstruction of the pharynx during sleep. When an individual is awake, pharyngeal muscles 
are sufficiently activated to maintain patency of the upper airway, while, during sleep, there 
is decreased activation of this musculature [153]. During sleep, the uvula and soft palate 
collapse on to the back wall of the upper airway, then the tongue falls backward causing a 
collapse on the back wall of the upper airway. The uvula and soft palate cause a tight 
blockage and prevent inspired air from entering the lungs. The effort of the diaphragm, 
chest, and abdomen cause the blockage to seal tightly. To breathe, the individual must 
arouse or awaken, causing tension in the tongue, which results in opening of the airway and 
allowing air to pass to the lungs [154].  
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Moreover, in OSA patients, during normal breathing, the narrowing of the upper airway 
progresses to a complete collapse during inspiration, or at end-expiration. When patients 
exert increased breathing effort to inspire against the obstructed airway, it makes the 
situation worse by creating more negative airway pressure. Airway obstruction continues 
until arousal occurs and the result is increased tone of the pharyngeal muscles, which then 
reopen the airway. These „micro-arousals‟ may occur at rates of more than 90 per hour, 
whenever an apnoeic or hypopnoeic event disrupts sleep, with patients usually unaware of 
these events. When these apnoeic events occur, they can result in significant oxygen 
desaturation and decrease the amount of sleep (necessary for physical and psychological 
restoration) [153].  
Sleep apnoea causes a drop in the blood oxygen saturation (SaO2) and an increase in the 
blood's CO2. The drop in SaO2 causes the heart rate to decrease. If the SaO2 continues to 
drop, the heart rate will slow until hypoxia is corrected. However, as the CO2 increases, the 
brain will try to increase the drive to breathe. Figure 11 illustrates the sequence of typical 
pathophysiological events occurring with OSA [155]. 
 
 
Figure 11: Schematic representation of the typical pathophysiological sequence that occurs in OSA 
(shown in grey) and the associated physiological processes. 
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1.6.8 Prognosis  
The prognosis of treated OSA is unclear [156]. Studies on the short-term prognosis for OSA 
have revealed better results in daytime sleepiness and snoring in regular users of continuous 
positive airway pressure (CPAP). These studies showed improvement in cognitive function 
and general health status after four to eight weeks of CPAP treatment [157-159]. However, 
the long-term prognosis of untreated severe OSA is increased mortality, poor quality of life, 
an increase in the likelihood of motor vehicle accidents, hypertension, and cardiovascular 
consequences [160]. 
Limitations of the evidence on OSA prognosis include bias in the selection of participants, 
short follow-up duration, and variation in the measurement of smoking history, alcohol 
consumption and other cardiovascular risk factors. 
Observational studies support a causal association between the increased severity of OSA 
and systemic hypertension [160]. OSA patients with developed cardiovascular disease had a 
significantly higher respiratory disturbance index (RDI) than patients with normal RDI 
[161-163]. Campos-Rodriguez et al. [164] showed that severe OSA is associated with 
cardiovascular death in women, and adequate CPAP treatment might help to reduce the 
cardiovascular consequences. The increased risk of motor vehicle accidents has also been 
associated with OSA as three- to seven-fold, and OSA has been associated with increased 
risk of premature mortality and cardiovascular diseases [160].  
Campos-Rodriguez et al. [165] showed that for patients who used CPAP for more than 6 
hours per night there was an increased survival rate at 5 years (96.4%), compared with those 
who used CPAP for 1 to 6 hours per night (91.3%) and 85.5% for those patients who used 
CPAP for less than 1 hour per night. OSA patients with a history of ischemic stroke who 
regularly used CPAP had decreased mortality, compared with those who did not use their 
CPAP treatment [166]. Baguet et al. [167] reported that left ventricular diastolic dysfunction 
is common in these patients and is related to the severity of oxygen desaturation.  
OSA could trigger an inflammatory metabolic syndrome (increased IL-6, CRP, tumour 
necrosis factor, adhesion molecules, leptin, insulin, and nitrotyrosine) independently of 
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obesity or age [168-171]. Some data showed that these endocrine and cytokine alterations 
are improved with CPAP treatment [172]. However, we showed in our short-term use of 
CPAP with normal subjects that three hours is enough to induce airway and systemic 
inflammation [173].  
With all the evidence suggesting that OSA is an independent risk factor for the development 
of cardiovascular disease and mortality, no definitive randomized studies have investigated 
the effect of CPAP in preventing the potential cardiovascular risks and consequences.  
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1.7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 
1.7.1 Definition 
COPD is a heterogeneous disease that is characterised by poorly reversible expiratory 
airflow limitation. The expiratory airflow limitation tends to be progressive and is 
associated with abnormal inflammatory consequences due to exposure to noxious particles 
or gases [174]. 
COPD has been recently defined by the Global Initiative of Obstructive Lung Disease 
(GOLD) [174] as: 
„a common preventable and treatable disease […] Characterised by persistent 
airflow limitation that is usually progressive and associated with an enhanced 
chronic inflammatory response in the airways and the lung to noxious particles or 
gases. Exacerbations and comorbidities contribute to the overall severity in 
individual patients.‟   
COPD is a leading cause of morbidity and mortality in the world. According to the WHO‟s 
Global Burden of Disease and Risk Factors project in 2001 [175], COPD was the fifth 
leading cause of death in high income countries, accounting for 3.8% of deaths, and the 
sixth in low and middle income countries, accounting for nearly 5% of total deaths. In the 
United Kingdom, COPD is the fifth most common cause of death [176] and a major cause 
of morbidity due to exacerbations of the disease [177]. 
COPD is most commonly caused from tobacco smoking, which triggers an abnormal 
inflammatory response in the lung [178]. It is usually observed in patients who are heavy 
cigarette smokers. COPD is more common in men than in women, probably because there 
are greater number of men smokers than women smokers. COPD has a lifetime risk and its 
comorbidities include ischemic heart disease, coronary artery disease, hypertension, 
anaemia, chest infection, diabetes, congestive heart failure, active pulmonary tuberculosis, 
and lung cancer [179-180]. Patients with COPD normally present with daily symptoms of 
cough and sputum production, and/or breathlessness. 
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Assessment of COPD severity is based on the acuteness of its symptoms, spirometric 
abnormalities, and the presence of complications. GOLD classify the severity of COPD 
according to the spirometric results (Table 9 A-B) [174]. 
 
Table 9-A:  GOLD classification of COPD Severity. 
STAGE CRITERIA 
GOLD 1: Mild FEV1
#
/FVC* <70%, FEV1 ≥80% predicted  
GOLD 2: Moderate FEV1/FVC <70%, 50% ≤ FEV1 <80% predicted 
GOLD 3: Severe FEV1/FVC <70%, 30% ≤ FEV1 <50% predicted 
GOLD 4: Very Severe FEV1 < 30% or FEV
1
 < 50% and the presence of chronic 
respiratory failure 
#
 FEV1 = Forced Expiratory Volume in One Second; *FVC= Forced Vital Capacity 
 
However, GOLD has provided an update to the COPD strategy by introducing a more 
complex multi-dimensional classification. It is not only a spirometric classification. The 
new model of symptom/risk evaluation of COPD adds two additional variables for 
assessments: exacerbation history and a modified Medical Research Council dyspnoea 
score. Based on these factors and the GOLD severity grade, patients fall into one of four 
quadrants (A, B, C, or D) on a 3-axis grid (Table 9-B) [174]. 
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Table 9-B: A new model of the GOLD classification of COPD. 
 
 
COPD is associated with increased upper airway inflammation.  Both upper and lower 
airway inflammation has shown a proportional relationship in those patients. This 
relationship has provided further evidence of pan-airway involvement in COPD [181]. 
Bilevel positive pressure airway therapy has been shown to be an effective modality and a 
recognised intervention in the treatment of acute hypercapnic respiratory failure due to 
exacerbations of COPD, in addition to some stable conditions [57, 62, 182]. However, the 
effect of this modality with stable COPD patients was not investigated. This thesis will 
investigate and discuss the effect of bilevel positive pressure airway therapy with stable 
COPD in Chapter Seven.  
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1.7.2 Incidence  
COPD is a leading cause of chronic morbidity and mortality worldwide. The available data 
for the incidence rates of COPD vary [183-184]. This could be due to differing disease 
criteria [185], and to population differences and environmental factors.  The incidence and 
prevalence rates of COPD show alarming statistics [186-188]. 
Few studies have shown the estimated incidence numbers for COPD. In the United 
Kingdom (UK), a study [189] that examined newly diagnosed COPD patients aged between 
60–85 years, using the UK General Practice Research Database (GPRD), found the overall 
annual incidence of COPD to be 7.2 per 1000 persons in the general population. Another 
recent study [190] established the overall incidence of COPD among patients aged between 
40-89 years to be 2.6 per 1000 persons per year. This study showed that the risk of COPD 
diagnosis is higher for current smokers and those with low BMI, and is reduced by 40% for 
former smokers compared with current smokers.   
In the United States, recent data estimate that 16 million Americans are affected by COPD: 
14 million have chronic bronchitis, and 2 million have emphysema [174, 186]. It is 
estimated that there may be in addition an equal number of American citizens with 
undiagnosed COPD.  
The incidence of COPD varies greatly between countries as estimates are reported in 
different units and over different lengths of time. Most studies reported that the incidence of 
COPD was greater in men than in women [191-194] and the incidence rate was also greater 
in older people, particularly in those aged 75 years and older [190, 195]. 
In Saudi Arabia, unfortunately the COPD incidence rate is not known because of the lack of 
population-based studies. AlGhobain et al. [196] reported that 14.2% of the population of 
smokers in a study had COPD (71 out of 501); this incidence rate is similar to other reported 
data in other countries. Smoking is the main risk factor in Saudi Arabia and the rate of 
smoking is steadily increasing among Saudis. Data are lacking not only for the incidence 
rates of COPD in Saudi Arabia, but also for the severity of the disease.   
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1.7.3 Risk Factors for COPD 
The risk factor for the development of COPD is related to an interaction between 
environmental exposures and genetic factors. The two most common risk factors for COPD 
are cigarette smoking, which accounts for 80% to 90% of all COPD related mortality, and 
alpha1-antitrypsin (AAT) deficiency [197].  
The COPD risk factors are of two types: exposure to noxious stimuli (external 
environmental factors) and host factors (inherent in the patient) (Table 10) [174]. Cigarette 
smoking is the most well-known important risk factor identified for COPD; however, it is 
not the only factor, as there is suggestive evidence from epidemiologic studies that non-
smokers may also develop this disease [198-199]. Data from the Lung Health Study 
highlighted the accelerated decline in FEV1 in smokers, compared with former smokers who 
achieved „sustained quitting‟ [200-201].  
The second well-studied (genetic) risk factor causing COPD is AAT deficiency. AAT 
deficiency plays a major role as a circulatory serine protease inhibitor whose deficiency or 
imbalance with respect to serine proteases in human body causes COPD [197]. Other host 
factors that contribute to the increased risk of COPD include asthma, airway 
hyperresponsiveness, respiratory illness during early childhood, and reduced lung growth 
[202]. 
Although host factors cannot be modified, exposure to noxious stimuli can be prevented and 
controlled. This includes cigarette smoking, occupational and chemical irritants, indoor and 
outdoor pollution, infections, and socioeconomic status [203-205]. Poor socioeconomic 
conditions play an important role in causing a substantial health risk for COPD, as they 
reduce patients‟ access to healthcare, reduce treatment availability, offer fewer opportunities 
for high levels of education, and reduce the standards of housing and related utilities [206-
207]. 
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Table 10: Risk factors for COPD [174]. 
Exposure Factors Host Factors 
Tobacco smoke, especially cigarette 
smoking 
Genetic factors such as alpha1-
antitrypsin deficiency 
Occupational and chemical irritants Airway hyperresponsiveness such 
as immunoglobulin E and asthma 
Indoor and outdoor air pollution Reduced lung growth  
Infections  
Socioeconomic status  
 
1.7.4 Geography 
Globally, COPD is a major cause of morbidity and mortality [208]. Geography plays an 
important role in determining the risk factors of COPD, and provides an understanding of a 
population's general health, and the environment's effect on health and disease. In the 
general population, the incidence of COPD is estimated to be approximately 1% across all 
ages, rising from 8 to 10% or higher in ≥40 years of age [209]. However, many others 
remain large regions in the world with no actual data contributing to these estimates [210]. 
Geography can also be a factor in accessibility to health care [211]. However, not all 
diseases are geographically specific. Diseases such as COPD are not restricted by particular 
geographies, as they occur as a result of common factors such as smoking, air pollution, diet 
and oxidative stress [174]. Potential smokers and polluting agents are found in almost all 
parts of the world, and thus the incidence of COPD worldwide is of no surprise. In the UK, 
geographic and temporal variations in smoking do not entitely account for variations in 
COPD mortality over the last century [212-214]. In the United States, geographic data 
showed that there is discrepancy between population smoking prevalence and COPD 
hospitalization rates [215]. This discrepancy suggests that environmental risk factors could 
have geographically differential relationships with severe COPD hospitalization risk. In 
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western states of the US (e.g. North Dakota, Montana and Wyoming), the prevalence of 
smoking was found to be high, but hospitalization rates for COPD were low [216]. 
However, Brown et al. [217] have described significant state-level geographic variations in 
COPD mortality across the United States, which could be consequences of different 
regional environmental exposures.  
In Saudi Arabia, there are limited data on the prevalence of COPD across the country. 
Despite the high rate of smoking in Saudi Arabia, no study has shown the magnitude of 
COPD prevalence among the Saudi population. The only available data are small and 
hospital-based studies, which are not geographically extensive enough to conclude 
significant results on the extent of the problem [218-219]. 
 
1.7.5 Aetiology  
COPD as a disease is heterogeneous, as are the exacerbations. Despite the wide scientific 
interest in these episodes, there is still debate regarding how exacerbations should be 
defined, their aetiology, and their prognostic significance [220]. Tobacco smoking is the 
main risk factor for COPD. It is responsible for 90% of COPD cases and its effects lead to 
an inflammatory response, cilia dysfunction, and oxidative injury.  
Occupational exposure, air pollution and genetic predisposition are other common 
aetiologies for COPD [174]. Many studies have shown indirect evidence of a viral aetiology 
[221]. These data suggest that 50–70% of exacerbations are due to respiratory infections 
(including bacteria, atypical organisms and respiratory viruses), 10% are due to 
environmental pollution (depending on season and geographical placement), and 
approximately 30% are of unknown aetiology [221-222]. 
Despite the importance of infections, other factors may induce exacerbations in COPD. In a 
study of 1,016 patients with severe COPD, infection was shown as the cause in 51% of 
exacerbation cases. Heart failure was thought to account for 26% of episodes of increased 
symptoms, but about 30% of exacerbations had no identified aetiology [223]. 
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Fletcher and Peto et al. [202] showed that there is a close relationship between the amount 
of tobacco smoked and the decline rate in forced expiratory flow in one second (FEV1), 
although COPD patients vary in susceptibility [224]. 
COPD has a variable natural history, which is characterised by progressive deterioration in 
symptoms, with increased episodes due to acute exacerbations.  Jones et al. [225] showed in 
a large study of 4,951 COPD patients from 28 countries that health-related quality of life, 
measured by the St. George‟s Respiratory Questionnaire (SGRQ), deteriorated faster in 
patients with more severe disease. 
 
1.7.6 Pathogenesis  
COPD is mainly caused by cigarette smoking and affects up to 25% of smokers [226], 
although other factors such as air pollution and occupational exposure to dust and fumes 
may contribute to its development. This causes an inflammatory response in the lungs and 
leads to the pathological characteristic of COPD. This inflammation to the COPD lung is 
often caused initially by cigarette smoke and the increased infiltration of immune cells into 
the lung, but it is not clear why the inflammation persists even after cessation of smoking, 
while other pathologies partly reverse [227]. This inflammation appears to be an 
amplification of the normal inflammatory response of the respiratory tract to chronic 
irritants such as cigarette smoke. Some patients develop COPD even without cigarette 
smoking. The nature of the inflammatory response in these patients is still unclear. Lung 
inflammation is further induced by oxidative stress and imbalance of proteinases in the lung 
[228]. All these mechanisms together lead to the characteristic pathological changes in 
COPD such as mucous hypersecretion, ciliary dysfunction, airflow limitation, gas exchange 
abnormalities, and systemic effects [229-230]. 
A wide variety of inflammatory cells and mediators such as cytokines have been shown to 
increase in COPD patients [231-232]. These inflammatory cells, in association with 
infiltration of macrophages, neutrophils and T-cells, release pro-inflammatory mediators in 
the lung, which induce structural changes in the airways and correlate with the degree of 
progression of COPD (Figure 12) [233-234]. 
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Figure 12:  Effect of cigarette smoke and other triggers on the lung inflammatory response. IF: 
inflammatory factors such as IL-6, IL-8, tumour growth factor beta (TGF-β). ECM: extracellular 
matrix; MMP: matrix metalloproteinases; TIMP: tissue inhibitors of MMP [227].  
 
1.7.7 Pathology 
The pathological hallmarks of COPD are chronic airway inflammation and airways 
obstruction. This inflammatory response and the morphological changes of COPD affect the 
central airways in the proximal and peripheral airways, lung parenchyma and pulmonary 
vasculature [235].  
These pathological changes lead to increased numbers of specific inflammatory cells in 
different parts of the lung, and structural changes resulting from repeated injury and repair 
[236]. Narrowing of the airways causes airflow limitation to and from the alveoli, and 
hypersecretion of the viscous mucus, mucosal and submucosal oedema; hypertrophy and 
airway remodelling, and spasm of the bronchial smooth muscles also occur [237-239]. 
More studies have confirmed that a chronic inflammation is an important component of the 
pathology in both small airway obstruction and emphysematous destruction in COPD [237, 
240]. In a case of exacerbation of COPD, these inflammatory responses are more affected 
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and marked with increased neutrophils and eosinophils, which in turn accelerate the 
progression of lung function deterioration [241].   
 
1.7.8 Prognosis  
COPD is a heterogeneous disease with comorbidities that could have a great impact on 
prognosis [174, 242-244]. Because of the heterogeneousness of the disease, there is no 
single measure that can give an adequate assessment of the severity of the disease in COPD 
patients. Prognosis depends on a number of factors, including environmental exposures 
genetic predisposition, acute exacerbations, and comorbidities [174]. Although short-term 
survival for COPD patients depends on the overall severity of acute illness, long-term 
survival is primarily influenced by the severity of COPD and the presence of comorbidities. 
Commonly, prognosis of COPD depends on the rate of decline in airflow as examined by 
the FEV1. An FEV1 of less than 30% of predicted value means very severe disease; certain 
studies have estimated that more than half of those patients with very severe disease may 
not be expected to survive for four years [245]. In addition to the FEV1, BMI predicts 
prognosis (very low weight is a negative prognostic factor), distance walked in six minutes, 
and degree of shortness of breath with activities. These factors, known as the BODE index 
(body mass index, obstruction, dyspnoea, exercise capacity) can be used to provide data on 
prognosis for 1-year, 2-year, and 4-year survival [246]. Frequent COPD exacerbations and 
the need for multiple intubation and mechanical ventilation for acute respiratory failure in 
COPD patients are other critical markers of poor prognosis [247]. 
Recurrent episodes of acute deterioration caused by exacerbations have been shown to 
significantly contribute to impaired health status in COPD patients [248-249]. Moreover, 
several studies have suggested that the occurrence of exacerbations may influence lung 
function, quality of life, and survival in the long-term [250-253]. 
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1.8 Inflammation in COPD 
COPD is a heterogeneous disease [254], and the most recent definition emphasizes that it is 
a systemic disease [244]. 
Because cigarette smoking is the major risk factor, studies have associated the level of 
cigarette smoking with the increase of pro-inflammatory cytokines (IL-6 and IL-8) [255-
256]. Keating et al. [257] have demonstrated that cigarette smoking induces the recruitment 
of neutrophils to the lung. Airway neutrophils have been shown to increase in chronic 
bronchitis [258] and neutrophil recruitment has been related to airflow reduction [259]. 
However, not all smokers develop COPD and the observed inflammation in COPD is still 
present after patients stop smoking cigarettes [260]. 
In mild COPD, airway inflammation is characterised by T-lymphocytes and macrophages, 
but with increasing severity of the disease, lymphocytes decline and the macrophages are 
accompanied by neutrophils [261]. Systemically, Hurst et al. [262] have reported increased 
inflammation with COPD as the blood CRP, IL-6, IL-8, and sICAM-1 increased. There was 
a significant relationship between neutrophilic lower airway inflammation and the systemic 
inflammatory response at exacerbation [262], even in mild/moderate COPD patients [263].  
The effect of NIV on the inflammatory markers in COPD is poorly studied. The available 
data have shown inconsistency. A recent study, which examined the impact of bilevel 
positive pressure airway therapy on systemic inflammatory response and lung structure in 
patients undergoing subarachnoid block for small or medium surgical procedures [264], 
found no difference between the inflammatory response of patients receiving a single lung 
hyperinflation manoeuvre and a control group. This suggests that lung hyperinflation did 
not further amplify the systemic inflammatory response triggered by the surgical procedure. 
Similarly, Puls and colleagues et al. [265] were unable to detect changes in the systemic 
levels of either inflammatory or anti-inflammatory cytokines in patients with atelectasis 
following lung hyperinflation. In contrast, a recent study in patients with ARDS found an 
association between the use of mechanical ventilation and an increase in cytokine levels, 
both locally in the lung and systemically [266]. 
79 
 
To date, clinical studies have focused on the inflammatory response to NIV in healthy 
subjects without evidence of inflammatory activity. It is not currently known whether the 
use of bilevel positive pressure airway therapy in COPD, a disease that is associated with 
local airway and systemic inflammation, causes further up-regulation of the inflammatory 
response. For this reason, this thesis will further introduce a pilot study on the effect of NIV 
on inflammatory markers. 
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1.9 Inflammation in OSA 
Systemic and airway inflammation associated with OSA may be the cause of cardiovascular 
complications, neurocognitive and metabolic syndrome [267-268]. 
Upper airway inflammation can arise as a result of environmental and physiological factors 
[269]. Nevertheless, OSA inflammation is characteristically distinctive and vital to the 
progression of this condition. Airway inflammation is present in 90% of OSA patients at 
larynx level, and the level of inflammation positively correlates with AHI [270]. 
Furthermore, the intermittent hypoxia that is a hallmark of OSA has been shown to 
stimulate cytokine production [271], which can itself act as a stimulus to systemic 
inflammation [272]. These inflammatory cytokines can lead to compromised endothelial 
function systemically [273] and can induce cardiovascular morbidities [274-275]. 
Studies have demonstrated the association of OSA with nasal inflammation [276-278]. 
Rubinstein et al. [276] have demonstrated a local mucosal increase in polymorphonuclear 
leukocytes and the concentrations of bradykinin and vasoactive intestinal peptide (VIP), 
thereby indicating the presence of nasal inflammation in patients with OSA. It was also 
suggested that nasal inflammation exacerbated upper airway obstruction in OSA. Studies 
have demonstrated increased thickness of uvula mucosa, interstitial oedema and increased 
numbers of leukocytes in the lamina propria of the soft palate of OSA patients, and have 
suggested that inflammation of upper airway soft tissues is significant in the pathogenesis of 
upper airway narrowing during sleep in patients with OSA [277, 279]. 
The potential cause of inflammation in the airways of OSA patients is unclear. However, it 
has been suggested that the combination of mechanical trauma due to snoring, airway 
vibration and forced suction collapse during apnoea is responsible for a local inflammatory 
response [280-281].  
CPAP has been associated with substantial improvement in disease-specific quality of life 
[282], eliminates upper airway collapse during sleep, and improves sleep fragmentation and 
daytime symptoms [283]. Nevertheless, undesirable side effects are frequent during the 
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application of non-invasive ventilation and make CPAP compliance a major clinical 
challenge.  
More than 50% of the patients complain of nasal symptoms, such as nasal congestion, dry 
nose, mouth or throat, and discomfort associated with cold air [284-287]. Such symptoms 
may appear within a few hours of CPAP application, causing the therapy to be discontinued 
prematurely [285, 288]. 
The non-invasive continuous application of the positive pressure to the nasal wall would 
cause mechanical tension to the nasal anatomy. This mechanical tension may aggravate the 
biological reaction in a variety of cells and tissues [289-290], and in the airways [291]. Such 
mechanical tension will eventually lead to an inflamed airway. 
An early upper airway inflammation response has been reported with OSA patients. 
Negative mechanical pressure events were applied to the intraluminal of the upper airways 
in a rat model, which revealed recurrent upper airway collapse, and reopening induces an 
early upper airways pro-inflammatory cascade [292]. Another report stated that mechanical 
stimuli could induce an early upper airway inflammation by the application of a vibration 
akin to snoring in human airway epithelial cells [293], and in the rate soft palate [294]. 
Mechanical stress, however, has been also examined during breathing inspirations in the 
lower airways of the lung. Recurrent inspirations with an increased upper airway resistance 
lead to exerting more forceful negative pressure in order to overcome the high resistance in 
the upper airways. Bronchial inflammation has been observed with those patients, and 
CPAP has demonstrated an increase in the airway hyperresponsiveness (AHR) in bronchial 
mucosa in obstructive sleep apnoea syndrome (OSA) [295]. 
Another important example of mechanical stress is the overdistension that tends to occur 
during invasive mechanical ventilation in adult respiratory distress syndrome (ARDS) 
[296]. With regard to the non-invasive ventilation (NIV) pressure levels, it is interesting to 
find from literature that there is no correlation between the side effects and level of pressure 
used during nasal CPAP with OSA [98, 288]. The mechanical stress to the upper airway 
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induces inflammatory mediators that result in structural and functional consequences, 
thickening of the pharyngeal wall, local myopathy or neuropathy [293, 297]. 
Unfortunately, CPAP itself induces an early nasal, neutrophil-rich, inflammatory response 
in rats (due to the mechanical pressure exerted by the face mask), but this is localised to the 
nasal wall [27].
 
In a clinical study, it was reported that nasal CPAP resulted in an increased 
total inflammatory cell count, thereby indicating local nasal inflammation in patients with 
obstructive sleep apnoea [298]. These findings illustrate the development of local 
hyperacute inflammation due to CPAP treatment at the onset of therapy that is independent 
of the inflammatory process of the disease. The systemic inflammatory effects of CPAP 
therapy are dependent on the duration of therapy. Malbouisson et al. [264] established that 
the lung hyperinflation in healthy individuals, with up to 20 cm H2O CPAP administered by 
a face mask for a short time, resulted in increased cytokine levels, including tumour necrosis 
factor alpha  (TNF-α) and interleukins (IL-1β, IL-6, IL-8, IL-10, and IL-12), which returned 
to normal after 12 hours. Steriopolos et al. [299] reported a marked improvement after 6 
months in inflammatory markers, including lymphocyte count, CD4
+
 cells, TNF-α levels 
and uric acid levels, in patients with good compliance to CPAP therapy; this effect was not 
observed in patients with poor compliance to the treatment. However, Kohler et al. [300] 
did not report a difference in systemic inflammatory markers, high sensitive C-reactive 
protein (CRP), plasma IL-6, interferon gamma (IFN-γ) or adiponectin levels between 
patients receiving therapeutic and sub-therapeutic CPAP treatment for four weeks. 
Significantly lower levels of CRP and IL-6 levels in newly diagnosed OSA patients on 
CPAP treatment for a month (compared to obese control patients) established that nasal 
CPAP decreased inflammatory markers [301]. 
Almendros et al. [294] examined the effects of vibratory stimuli on the upper airway in a 
live-rat model. They subjected the upper airway to vibratory trauma. They then assessed the 
level of expression of the genes coding for tumour necrosis factor-alpha and macrophage 
inflammatory protein 2 in the soft palate. The conclusion was that vibratory stimuli induce 
at least some form of early inflammation in mucosal tissue.  
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Another important example of mechanical stress is the overdistension that tends to occur 
during invasive mechanical ventilation in ARDS [296]. There is evidence that the 
mechanical factor during invasive positive ventilation shows up-regulation of inflammatory 
responses. Figure 13 describes the potential injurious effects and shear force on the lung 
epithelial and endothelial cells [302].     
  
 
Figure 13: Potential mechanisms of ventilator-induced lung injury. Mechanical ventilation induces 
tensile strain and shear forces in the lung. These forces result in increased permeability and 
disruption of the alveolar–capillary barrier. Mechanical forces also induce an increase in the 
concentrations of pro-inflammatory mediators (including IL-1β, tumor necrosis factor alpha, IL-8 
and IL-6) in the distal airspaces of the lung [Modified from reference 302]. 
 
Systemic inflammation in OSA is characterised by increased plasma levels of inflammatory 
markers such as TNF-α, IL-6, CRP, IL-1b, and adhesion molecules  (Table 11) [303-304]. 
The systemic inflammation seen in OSA patients may be independent of obesity [301, 303, 
305]. 
Local airway inflammation has been reported using inflammatory markers in exhaled breath 
and sputum samples [306-307]. 
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Table 11: Identified inflammatory markers in obstructive sleep apnoea. 
Systemic inflammation  Local inflammation  
↑ C-reactive protein  ↑ IL-6  
↑ IL-6  ↑ 8-isopentane  
↑ TNF-α  ↑ neutrophils  
↑ VEGF  ↑ CD4+ T cells  
↑ EPO   
↑↓ Adiponectin  
↑ Reactive oxygen species  
↓ Nitric oxide  
VEGF, Vascular endothelial growth factor; EPO, erythropoietin; ↓, decrease in; ↑, 
increase in.  
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There are very limited data on the effects of nasal CPAP in inducing local inflammation on the upper airway (Table 12).  
Table 12: Summary for the papers reporting changes in inflammatory indices after application of CPAP therapy. 
 
Paper Ref 
Increased 
after CPAP 
Decreased 
after CPAP 
Unchanged after 
CPAP 
Design N= Comments 
Almendros et 
al. Sleep, 2008 
[294] 
Neutrophils in 
nucleated cells 
(%); mRNA of 
MIP-2 
NA 
Gene expressions of 
TNF-alpha, nerve 
growth factor, 
tachykinin -1 receptor 
Prospective 
controlled 
animal study 
32 Male Sprague-Dawley rats 
Skoczynski et 
al. Rhinology, 
2008 
[298] 
 
Total 
inflammatory 
cell count 
 Nasal patency Prospective 42 Clinical study 
Steiropoulos et 
al. Sleep, 2009 
[299] 
Good 
compliance 
group: 
Compliance 
Improved  
 
Total 
Lymphocytes, 
CD4+ cells, 
TNF-alpha 
levels, uric acid 
levels 
Good Compliance  
Prospective 52 
Hospitalised patients. 
Samples obtained at baseline 
and at 6-month follow up. Poor 
compliance 
group: 
Not improved 
NA 
Poor compliance – 
Total lymphocytes, 
CD4+ cells, TNF-
alpha levels, uric acid 
levels. 
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Kohler et al. 
Thorax, 2009 
[300] NA NA 
Highly sensitive CRP, 
IL6, interferon 
gamma, adinopectin 
Randomised 100 
Subjects were randomised to 
therapeutic and sub-
therapeutic CPAP treatment 
for 4 weeks 
Malbouisson et 
al. Braz J Med 
Biol Res, 2010 
[264] 
TNF-alpha, IL-
1beta, IL-6, Il-
8, Il-10, Il-12 
NA NA Randomised 10 Healthy subjects were studied 
Yokoe et al. 
Circulation,  
2003 
[301] NA 
CRP, IL-6, 
spontaneous 
production of 
IL-6 by 
monocytes 
NA Randomised 30  
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1.10 UPPER AND LOWER AIRWAY INVESTIGATION 
 
1.10.1 Background 
 
The aim of the current section in this thesis is to introduce the upper and lower airways 
investigations, highlight their importance, and to discuss the selective methods that are 
important for assessing inflammation in the upper and lower airways in healthy subjects, 
OSA, and COPD patients using NIV.  
The upper and lower airways behave similarly in many ways, including common triggers, 
pathogenic mechanisms, many of the inflammatory cells and mediators, and the treatment 
modalities [308-309]. COPD patients have shown increased nasal symptoms, suggesting a 
link between the upper and lower airways beyond asthma and allergy-associated 
inflammation [310]. In nonasthmatic allergic rhinitis patients, studies have demonstrated a 
signiﬁcant relationship between the upper and lower airways, evidenced by impaired FEV1 
and increased bronchial responsiveness [311-313]. Moreover, a nasal allergen challenge in 
allergic rhinitis patients experiencing nasal symptoms alone can result in bronchial 
inflammation [314], and segmental bronchial provocation has been shown also to induce 
nasal inﬂammation [315]. This inflammatory association between upper and lower airway is 
reflected in a continuous nasobronchial airway inﬂammation process from healthy to 
diseased airways. This process was supported by the work of Chawes et al. [316] who 
showed that there were independent associations between blood eosinophil count, nasal 
eosinophilia, and upper airway patency. In OSA adult patients, evidence of interactions 
between upper and lower airways is a poorly researched field. Data available suggest that 
both local airway and systemic inflammation are implicated in the pathophysiology of this 
seemingly all-mechanical condition [317]. 
Loss of the protective functions of the nose may be responsible for nasobronchial 
inflammation, in which the absorption of inﬂammatory mediators from inflammatory sites 
into the systemic circulation has been shown to induce the release of eosinophils and 
thereby possible systemic propagation of inﬂammation from nose to lung, and vice versa 
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[318]. All these clinical findings suggest that nasal inﬂammation is not a local, but that the 
entire respiratory tract is involved. 
Therefore, the phenomenon of inflammatory “cross-talk” between the nose and lung [319], 
and the concept of a “united airways disease” in which rhinitis and asthma are the upper and 
lower airway manifestations of the same disease process were clinically stated [320]. In 
contrast, this phenomenon was not clinically studied with COPD patient until recently. 
Hurst et al. [321] suggested that a correlation between the degree of upper and lower airway 
inflammation in COPD patients exist. His results suggested that in COPD patients there is 
also a pan-airway inflammatory response, reflecting the pan-airway exposure to cigarette 
smoke.  
The rationale of this thesis is to examine the pro-inflammatory effect of NIV to the airways, 
and further examine the interactions between the upper and lower airway in these 
conditions. The pros and cons of a few of the techniques used in this thesis have been 
discussed in detail in the subsequent sections. 
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1.10.2 Methods of Assessing Upper Airway  
 
 1.10.2.1 Nasal Lavage vs. Other Techniques  
 
The nasal cavity is affected by many conditions including inflammatory diseases. Since it is 
the most accessible part of the respiratory system, the cellular and biochemical composition 
of nasal specimens can be readily evaluated. Obtaining surgical biopsy specimens is an 
option that gives excellent information on cellular events. However, it is invasive and 
associated with a risk of bleeding, and artefacts may occur from the infiltration of local 
anaesthetic. In addition, repeated procedures are problematic, limiting the biopsy‟s use for 
follow-up purposes. Alternatively, the composition of nasal secretions may also aid in the 
diagnosis and follow-up of conditions affecting the upper or lower airways, in particular 
inflammatory and allergic disorders [322-324].  
A variety of methods for obtaining nasal secretion samples have been reported which fall 
into three main categories [325]. The first is the collection of spontaneous secretions, with 
or without stimulation, which can be accomplished with the aid of nose blowing, suction or 
through the collection of dripping secretions. The second category includes dilution 
techniques in which the nasal cavity is washed or sprayed with a fluid then a lavage is 
recovered for examination. In the third category are techniques in which an absorbent 
material such as cotton wool, filter paper in the form of strip or disc, polyurethane foam, or 
cellulose sponge is placed into the nasal cavity.  
Nasal washing (nasal lavage) is a commonly used technique. However, unpredictable 
amounts of fluid losses through swallowing, absorption by nasal mucosa and leakage from 
the nasal orifice all contribute to a variable degree of dilution, resulting in concerns related 
to the repeatability of the technique. Concentrations of interleukin (IL)-6 and IL-8 in nasal 
secretions accurately demonstrate the degree of inflammation since both take part in the 
inflammatory process. Their concentrations in respiratory secretions increase in disease 
states characterised by airway inflammation [322, 326]. High sputum concentrations of 
these two cytokines, for example, have been associated with increased frequency of COPD 
exacerbations [326]. In addition, COPD patients have been found to have an increased IL-8 
concentration in nasal secretions compared to controls [322].  
90 
 
In light of the disadvantages discussed here, when using conventional nasal lavage 
techniques, we developed in our Department a novel and practical method for the collection 
of nasal secretion. The method utilises a paediatric tracheostomy tube with a good seal at 
the nasal orifice. It is less time consuming can be reprocessed for usage, and provides 
comfortable test conditions [327]. This nasal lavage technique is the standardised technique 
in this thesis for upper airways nasal lavage sampling and is described in detail in chapter 
four. 
 
1.10.2.2.1 Acoustic Rhinometry vs. Rhinomanometry vs. Medical 
     Imaging   
 
 
Acoustic Rhinometry (AR) 
 
The clinical use of acoustic rhinometry was first described by Hilberg in 1989 as an 
objective method for examining the patency of the nasal cavity [328]. This technique is non-
invasive, reliable, convenient, easy and quick to perform, requires little patient cooperation, 
and can aid in the assessment of nasal obstruction. AR works by estimating the intranasal 
volume between predefined segments, and cross-sectional areas, through the identification 
of local changes in acoustic impedance using a sound pulse propagating in the nasal cavity 
(Figure 14). Since nasal obstruction is common in a wide range of sinonasal disorders, the 
technique may play an important role in the diagnosis and follow-up of conditions altering 
intranasal dimensions, either permanently or transiently. Nasal mucosal inflammation is the 
most common pathologic cause and, besides viral upper respiratory tract infections, allergic 
rhinitis is the most frequent cause of nasal obstruction [329]. Since nasal obstruction is 
common in a wide range of sinonasal disorders, AR technique was used in this thesis on all 
studied groups to assess the impact of NIV in causing altering intranasal dimensions.  
Since its introduction, AR has been investigated and used in many conditions in adults and 
children including allergic rhinitis, vasomotor rhinitis, nasal, pharyngeal and maxillofacial 
procedures and conditions, and sleep disorders [330]. AR is not only able to detect 
irreversible structural changes but also reversible dynamic changes, providing information 
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on both the location and reversibility of the pathological condition. Correlation and/or 
agreement of the technique with other diagnostic methods including rhinomanometry, 
computed tomography, optical rhinometry, magnetic resonance imaging, direct X-ray 
examination, fiberoptic nasal endoscopy, and clinical findings, has been well-established in 
both clinical and experimental settings [331-339], although AR seems to have some 
limitations in the posterior part of the nose [249, 337, 340] and interchangeable use of 
different methods is not appropriate [341].  
 
 
Figure 14: Diagram of the Acoustic Rhinometry System [342]. 
 
Common clinical and practical uses of AR for the rhinologic surgeon include assessment of 
“mixed” nasal blockage, documentation of nasal alar collapse, and preoperative planning for 
reduction rhinoplasty [342]. It can also be used to examine the positive effect of surgery on 
nasal airway obstruction [329]. As an accurate method for measuring the nasal cavity 
geometry, AR is easy to perform and is potentially useful for the investigation of 
physiological and pathological changes in the nose. In many cases the technique is even 
used for clinical assessments before and after interventions (cg turbinectomy, septoplasty, 
and rhinoplasty) [343-345]. The volume of mucovascular swelling can be quantified 
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expeditiously in a manner that is particularly useful for measuring rapidly changing airway 
dimensions as with nasal challenge tests. Precise measurements pre- and post-intervention 
of nasal valve dimensions can be obtained and recorded. The area-distance graph obtained 
allows visualization of the site of obstruction [331]. The technique offers particular 
advantages in terms of accurate dimensional evaluation of the nasal valve region and the 
structural and mucovascular components of nasal obstruction [342]. 
A study by Morris et al. [346] showed that a small, constricted, minimal and cross-sectional 
area 1 and 2 was predictive of non-adherence to CPAP therapy in OSA patients. He also 
suggested using acoustic rhinometry for evaluating nasal obstruction in OSA [347]. 
AR has been used as an aid for the diagnosis and treatment of OSA. Houser described the 
use of AR findings in mild sleep apnoea [348]. In 2003, Virkula et al. [349] also studied the 
body positions on snorers in sleep apnoea and sleep-disordered breathing using AR.   
Since the repeatability of AR remains unclear, holding important clinical implications, 
particularly for when the method is to be used for the purpose of follow-up, this technique 
has been validated in our Department before using it with all other studied subjects in this 
thesis [350]. The validation is outlined in detail in chapter four. 
 
Rhinomanometry (RMM) 
Rhinomanometry (RMM) is a test of nasal function that measures air pressure and the flow 
rate in the nasal airway during the breathing cycle [351], which is considered dynamic. 
RMM uses an intranasal closed loop system to measure nasal airway resistance. The 
measured values are then used to calculate the resistance of the nasal airway. It quantifies 
nasal breathing parameters and indicates how hard breathing is from the nose. Many factors 
affect nasal airflow. These factors include nose length, the cross-sectional area, transnasal 
pressure, and flow type, whether this be turbulent or laminar [352].The method enables the 
mucovascular and structural components of nasal obstruction to be differentiated and 
quantified and the anterior, posterior or adenoid site and severity of the obstruction to be 
determined [331]. A series of measurements with RMM can determine the response to a 
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topical decongestant of the mucovascular contribution at the time of examination and in the 
decongested nose, which is the degree of severity of structural nasal obstruction [353]. 
RMM is not „medically necessary‟ when assessing clinical cases of nasal obstructive 
symptoms, but, in many clinical situations, it can provide valuable objective information in 
compliance with the requirements of evidence-based medicine [353]. 
A rhinomanometer is a device that can be used to measure nasal inspiratory flow and 
pressure (Figure 15). The device has been designed for the purpose of ascertaining whether 
slight degrees of nasal obstruction are present. Thus, the device will indicate both 
inspiratory and expiratory obstruction. The device works by measuring the distance through 
which a column of water can be moved in a definite time period. During the test, the mouth 
is kept wide open. The device is a glass tube with a wide nose-piece, and a resistance at the 
distal end [354]. It enables accurate measurement of nasal airflow resistance. 
 
Figure 15: Rhinomanometer device (Rhino Comp
®
, Sweden). 
 
It is important to state that there is inadequate evidence of the clinical utility of RMM and 
AR. These tests have not been shown and demonstrated to be superior to physical 
examination, nasal endoscopy or CT imaging in selecting patients who would benefit from 
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surgical management due to nasal obstruction, and do not correlate with a patient's 
subjective perception of nasal obstruction [323, 355]. Published clinical studies suggest that 
both RMM and AR are used in research studies in which objective measurements of nasal 
obstruction may be important to determine treatment effects. However, no data provided a 
detailed analysis of how these two diagnostic studies would be used in the clinical 
management of the patient.  
 
Computed Tomography (CT) Scan and Magnetic Resonance Imaging (MRI) 
CT is an imaging technique based on x-rays. It produces an enormous of data that can be 
manipulated, through a process known as "windowing", in order to demonstrate various 
bodily structures based on their ability to block the X-ray beam [356].  
Clinically, CT and Magnetic resonance imaging (MRI) usually reserved for recurrent or 
complicated diseases and the benefit that the disease severity may be quantified. MRI is a 
method that can be used to illustrate the anatomy of the nasal cavities with no known 
adverse effects on patients. In clinical rhinotology, the use of MRI remains limited due to 
the inability of the technique to directly visualize bone. MRI, however, is useful in mucosal 
structures imaging that are important factors in nasal patency and volume. CT scans have 
been used earlier as a reference in the evaluation of AR accuracy [357]. CT and MRI can be 
used to assess cross-sectional areas and volumes of the nasal airways: however, it is an 
expensive method for evaluating nasal disease in routine use, and patients will be exposed 
to unnecessary radiation. Although the correlation between imaging scores and symptoms is 
not significant [358], Lund and Mackay et al. [359] made the most frequent use of 
quantitative assessment of chronic rhinosinusitis imaging, using CT scanning which scores 
each of the five sinuses to give bilaterally a total score between zero and 24. Lund reported 
that CT scan data provided more supportive evidence of symptom scores in chronic sinusitis 
patients [360], while MRI technique has the ability to reflect the nasal mucosa status and 
bony anatomic abnormalities within the nose with certain limitations. MRI is more better to 
CT in evaluating mucosal appearance and has been used successfully to demonstrate the 
nasal cycle [361]. 
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Hilberg et al. [362] was the first to use CT and MRI to assess the accuracy of the CSA and 
volume measurements of AR in a single cadaver head. His results have shown a significant 
correlation between CT and AR findings when the imaging was obtained perpendicular to 
the acoustic wave direction. Due to the limitations of CT in comparison with MRI, 
particularly in detecting airway fat because of its poor resolution, both techniques are not 
frequently used for upper airway evaluation of OSA patients. 
Available clinical studies showed that AR measurements have shown reliability readings, 
and demonstrated a good correlation between them and both CT and MRI findings, but 
poorer results further posterior [335, 340, 357, 363-364]. However this data cannot reflect 
the dynamic aspects of anatomical structure of the nasal cavity. 
 
1.10.2.3 Mucociliary Clearance: Saccharin Transit Time 
Mucociliary clearance (MCC) is an important host defence mechanism, from the nose and 
upper airways to the lower respiratory tract. It protects the respiratory mucosa against 
inhaled particles and microorganisms by enacting a clearance mechanism and producing 
unidirectional mucus flow toward the oropharynx [365]. The nose has an epithelium similar 
to the lower respiratory airway, and the nose is an important site to assess inflammatory 
events and other pathophysiologic mechanisms in the lower respiratory tract [366-367]. This 
importance has been reported as the MCC in the nose and bronchi were correlated [368]. 
Many factors have been shown to interfere with mucociliary clearance such as cigarette 
smoking and acute infection [369-372].  
Mechanical ventilation as mechanical stimulus may influences mucociliary clearance work. 
It results in disrupting the equilibrium of the mucous membrane and consequently leads to 
inflammation of the nasal mucosa [373]. Konrad showed that mucociliary clearance is 
impaired in patients receiving mechanical ventilation at the level of the main bronchus and 
trachea [374]. However, the observed affect may be secondary to the tracheal intubation, 
mechanical ventilation, and method of artificial airway humidification [375]. Therefore, it is 
96 
 
necessary to examine the influence of mechanical therapy such CPAP with OSA, since the 
underlying mechanism impairing MCC may differ from one illness to another.  
A number of ways to measure mucociliary clearance have been shown to be effective. 
Although the gold standard for mucociliary clearance measurement is the radiolabeled 
method first introduced by Proctor [376], a simpler and efficacious alternate method is the 
saccharin test [377]: Saccharin Transit Time (STT) has been used to assess mucociliary 
clearance in normal subjects as well as in those with various sinonasal disorders, such as 
allergic rhinitis and chronic rhinosinusitis [378]. As mentioned above, numerous studies 
have reported a good correlation between the STT in the nose and various tests of MCC in 
the tracheobronchial tree. Verra et al. [368] have reported on ciliary dyskinesia with situs 
inversus, bronchiectasis, chronic sinusitis and sterility. His results revealed that abnormal 
nasal cilia samples correlated with the bronchial biopsies. Thus, by using the easily 
performed STT to measure MCC in the nose, we have an indicator for the lower airways of 
the lung and can treat accordingly [368, 379]. 
Nasal mucociliary clearance was measured using in vivo STT. The modified technique 
described by Rutland and Cole was used [380]. STT is a simple and reliable method to 
determine the mucociliary clearance [366, 381]. The use of nasal mucociliary clearance 
avoids the need for more invasive procedures such as bronchoscopy and is feasible in stable, 
conscious, and cooperative patients. Saccharin was applied on the inferior turbinate of the 
nasal cavity under direct visualization and the time at which the subject reported a sweet 
taste was recorded in seconds using a stopwatch. During the procedure, the patient was 
asked to sit quietly with the head in a neutral position, and avoiding sniffing, sneezing, 
coughing, and drinking.  
Oliviera et al. [382] has demonstrated that in the short-term, STTs decreased significantly 
after 20 minutes of nasal CPAP in healthy individuals. This may be attributed to differences 
in the duration of nasal CPAP treatment, and suggests that nasal CPAP may provide an 
initial improvement in nasal clearance that is followed by impairment due to inflammation. 
Inflammatory and functional changes may contribute to the high incidence of symptoms and 
adverse effects associated with nasal CPAP treatment. Previous studies have reported high 
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incidences of side effects during long-term therapy, with as much as 97% occurring in a 
large series [98]. 
In this thesis, an overall measurement of mucociliary clearance was assessed using STT 
before and nasal CPAP therapy with healthy and OSA subjects. 
 
1.10.3 Methods of Assessing Lower Airway  
1.10.3.1 Spirometry 
Spirometry is the most objective test for measuring the airflow limitation in pulmonary 
diseases [174]. The measurements of spirometry are based on age, height, sex and race in 
comparison with reference value [383]. The GOLD report [245] states: “COPD is a disease 
state characterised by airflow limitation that is not fully reversible … Airflow limitation is 
measured by spirometry, as this is the most widely available, reproducible test of lung 
function.” Spirometry test is recommended in the diagnosis and evaluation of COPD [174, 
384-385]. The test is performed by asking the patient to inspire before fully exhaling as fast 
as possible for at least six seconds. The test is repeated at least three times, and the FEV1 or 
FVC values should vary by no more than 5% or 150 ml [386].  
The importance of spirometry is recognized in early detection of COPD, the prevalence and 
consequent burden of which are rapidly increasing globally [387]. However, population-
based studies relating to the relationships between lung function and OSA have rarely been 
performed, and findings are sparse [388]. In OSA patients, the abnormalities of the flow-
volume loop consistent with inspiratory flow limitation and upper airway instability during 
wakefulness are common, but their role is controversial in predicting OSA [389-391]. 
Several studies have examined pulmonary function in OSA patients [392-393]. 
Interestingly, OSA has been found to closely correlate with lower airway obstruction, 
although it is defined as an upper airway disease [394]. Chaouat et al. [395] have shown in 
their large series of unselected OSA patients that the presence of an associated chronic 
98 
 
obstructive pulmonary disease (COPD), defined by an FEV1/VC ratio <60%, occurred in 
11% of cases. 
CPAP has been widely established in the treatment of OSA [27]. However, few studies have 
evaluated the effects of this treatment on lung function [396-398]. In patients with COPD, 
CPAP has been shown to reduce the work of breathing [399], while in asthmatic patients; 
CPAP tends to reduce inspiratory muscle work [400]. But in OSA, Bonay et al. [401] has 
shown that lung function may be impaired by long-term, nasal CPAP treatment. 
Young et al. [397] has observed a reduction of total lung capacity, functional residual 
capacity in a group of OSA after 1 year of CPAP treatment. On the other hand, in patients 
with overlap syndrome, Vázquez et al. [402] have reported that CPAP treatment caused an 
improvement in FVC and maximal inspiratory pressure. These findings did not show 
significant variation in the degree of bronchial obstruction, and for this reason, these 
findings may be due to an improvement in the function of respiratory muscles. 
 
1.10.3.2 Sputum Sampling 
The purpose of sputum sampling is to obtain an adequate amount of secretions from the 
lower airways and to use this sample for assessing airway inflammation in respiratory 
disorders [403]. For many years, inhalation of hypertonic saline has been one of the most 
widely used methods for assessing a number of airway inflammatory conditions in sputum 
induction [404]. It has been advocated as the only direct, relatively non-invasive, and safe 
method for assessing airway inflammation indices [404].  
The study of cells and inflammatory mediators in airway secretions from patients with lung 
diseases has been performed in samples of spontaneously expectorated sputum obtained by 
bronchoscopy and lavage [405]. These sampling methods are limited in their applicability. 
Bronchoscopy can only be used on patients who tolerate the procedure and cannot easily be 
performed repeatedly to examine inflammatory changes in airway secretions over short 
periods of time [406]. The invasiveness of the procedure, associated costs, and restriction of 
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its use to exacerbated patients make bronchoscopy unsuitable for monitoring airway 
inflammation in clinical practice [407-408]. Furthermore, changes in induced sputum such 
as increased neutrophils and IL-6 concentration has been shown to be similar to those 
occurring in nasal lavage
 
[409]. Sputum sampling, either spontaneous or induced, was 
obtained and processed according to published guidelines [410-412], has been used as an 
alternative assessment for lower airway inflammation used in this study.   
The importance of measuring airway inflammation in COPD has been emphasised [413]. 
The pathophysiology of COPD is an inflammatory disorder which is characterised by 
neutrophilic inflammation with the presence of macrophages and lymphocytes on airway 
tissue [405]. Few studies reported on the presence of bronchial inflammation in OSA 
patients. Olopade et al. [414] was the first to report on the increase of pentane and nitric 
oxide in the exhaled air of OSA patients after sleep. Interleukin-6 in exhaled breath 
condensate (EBC) has been also shown to increase in OSA as a characteristic of airway 
inflammation [415]. However, Salerno has demonstrated the presence of lower neutrophilic 
airway inflammation using the analysis of induced sputum (Table 13) [306, 416]. 
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Table 13: Summary for the papers reporting the effect of CPAP on inflammatory markers in OSA. 
Inflammatory 
marker 
Main study  Ref Data available in 
OSA  
Effects on CPAP Comments 
Induced sputum     
Neutrophils Rubinstein, 1995
 
Salerno et al. 2004
 
[276] 
[306] 
High percentage in IS No change Data about baseline are reliable. 
The role of obesity is unclear, 
poor data on effects of CPAP 
Lymphocytes Boyd et al. 2004
 
[148] Increase in IS No data Poor evidence, few studies 
Eosinophils Kalpaklioglu et al. 
2009
 
[417] Poorly investigated No data Few data 
Exhaled gases      
FENO Olopade et al. 1997
 
Depalo et al. 2008
 
[414] 
[307] 
High concentration Unclear Studies use often 
different methods 
Exhaled 
pentane 
Agusti et al. 1999
 
[418] High concentration No data Few studies, small sample 
Exhaled CO Petrosyan et al. 2008
 
[419] High concentration Decrease of exhaled CO level Few studies, small sample 
Exhaled breath condensate     
pH Petrosyan et al. 2008
 
Antonopoulou et al. 
2008
 
[419] 
 
[420] 
Lower in EBC Increase of pH Few studies 
LT B4 Petrosyan et al. 2008
 
Goldbart et al. 2006
 
[419] 
[421] 
High concentration Decreases of LT B4 
concentration 
Few studies 
Nitrite/nitrate Petrosyan et al. 2008
 
[419] High concentration Decrease of nitrite/nitrate 
concentration 
Few studies 
8-Isoprostane Carpagnano et al. 2002
 
[415] High concentration Data unclear Few data about effects of CPAP  
 
CO, carbon monoxide; CPAP, continuous positive airway pressure; EBC, exhaled breath condensate; FENO, fractional exhaled nitric oxide; LT, 
leukotriene; OSAS, obstructive sleep apnoea syndrome. 
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With all these methods, sputum sampling is the most validated technique and thoroughly 
discussed in the literature, in terms of appropriate methodologies discussed and published 
guidelines [420-422]. Published work in this Department has previously shown that induced and 
spontaneous samples contain similar total cell counts and IL-8 concentration [423], and 
therefore samples were treated identically. 
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1.10.4 Epworth Sleepiness Scale 
The common complaint symptom with OSA patients is Daytime sleepiness [424-425]. 
Approximately 78% of OSA patients have been reported to have excessive daytime 
sleepiness (EDS) and fatigue as major complaints [426]. The cause of excessive daytime 
sleepiness results from sleep fragmentation due to repeated central nervous system arousals, 
in response to disordered breathing events. OSA may be significantly under-recognised as 
causes of excessive daytime sleepiness. One study estimated that 93 per cent of women and 
82 per cent of men with moderate to severe OSA are undiagnosed [84]. 
To evaluate daytime sleepiness, all OSA patients were measured according to the Epworth 
Sleepiness Scale (ESS). ESS is a simple, convenient and self-administered questionnaire in 
which patients rate their propensity to fall asleep in eight different situations [427]. The 
subject is required to score for the likelihood of falling asleep in eight different situations on 
a scale of 0–3 (0 being little or no chance of dozing and 3 representing a high probability of 
dozing). A score of ≥ 10 indicates abnormality and a score of > 14 suggests a significant 
degree of EDS [428-429]. Numerous studies using the ESS have demonstrated the high 
validity and reliability of the test [430-431].
 
Moreover, it is an inexpensive evaluation and 
has been translated into more than five different languages, and numerous studies have 
vouched for its validity and reliability in different languages [432-436]. 
Although the ESS is brief and simple to administer, the score is subjective and may indicate 
symptoms of fatigue rather than EDS exclusively. Due to its subjective nature, ESS alone 
cannot be used as a diagnostic tool for OSA. However, the ESS attempts to avoid biases that 
may occur during the test by asking respondents to gauge their responses based on 
propensity to sleep over the past few weeks rather than just at the time of testing [437].  
The multiple sleep latency test (MSLT) is regarded as the gold standard for objective 
determination of daytime sleepiness [438], but is not used routinely because it is expensive 
and requires the patient to remain in the sleep study all day.  
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To measure the improvement of quality of sleepiness with OSA in this thesis, we have used 
ESS before CPAP therapy and as a follow-up measure over a six-month period (Appendix 
Seven). 
 
1.11 Cytokines and Mediators Relevant to This Thesis (IL-6, IL-8 & 
MPO) 
One of the factors involved in sleep regulation is the immune system, consisting of humoral 
and cellular components. Molecules that transport the information are, beside others, the 
cytokines. Cytokines are low molecular weight protein mediators which control cell growth, 
inflammation and repair. Cytokines can be defined as the following: 
“…regulatory proteins secreted by white blood cells and a variety of other cells in the body; 
the pleiotrophic actions of cytokines include numerous effects on cells of the immune 
system and modulation of inflammatory responses”. [439] 
In the lung, the dynamic balance is maintained by pro-inflammatory and anti-inflammatory 
cytokines. For example, COPD and Asthma are examples of conditions where the balance 
of cytokines in the lung is directed to a pro-inflammatory phenotype [440-441]. However, in 
OSA the levels of inflammation of pro-inflammatory cytokines are commonly elevated in 
OSA. There is increased inflammatory cell infiltration within the tissue of upper airway in 
OSA [88, 281]. Such cytokines could alter tissue structure and function, and impair muscle 
contractility [442-443]. Therefore, evaluation of inflammatory mediators with OSA patients 
may provide insights into the mechanisms underlying inflammation, some of such cytokines 
and mediators that have active participation in the inflammatory process that has been 
selected in this thesis are discussed below:    
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Interleukin-6 
Interleukin IL-6 is a pro-inflammatory cytokine. It is secreted by macrophages, monocytes, 
T cells, B cells, fibroblasts, bone marrow stromal cells, keratinocytes, and endothelial cells 
(Figure 16) [444]. Primary basic protein secreted from eosinophils can interact with IL-1 or 
TGF to increase IL-6 release from fibroblasts [445]. 
 
Figure 16: Cells producing interleukin-6 (IL-6) and the actions of IL-6 in the body. 
 
IL-6 is important in the induction of the acute phase and augmentation of antibody 
production and is released in early inflammatory response [446]. IL-6 is a key-cytokine of 
the pro-inflammatory immuneresponse, is involved in different functions and diseases, and 
plays a role in sleep apnoea and responds to sleep deprivation [447]. In COPD, serum IL-6 
levels were elevated compared to the baseline of exacerbated COPD patients [448]. 
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Interleukin-8 
IL-8 is a chemokine and also known as CXCL8 [449]. IL8 is produced by stimulated 
monocytes, fibroblasts, macrophages, endothelial cells. In humans, the interleukin-8 protein 
is encoded by the IL8 gene [450]. The main function of IL-8 is the induction of chemotaxis 
in its target cells and activator of neutrophils. It binds to CXCR1 and CXCR2 receptors, 
resulting in an increased intracellular calcium concentration, exocytosis of neutrophil 
granules and a respiratory burst [451]. CXCR2 appears to mediate the chemotactic response. 
The primary IL-8's function is to recruit neutrophils to phagocytose the antigen, which 
triggers the antigen pattern toll-like receptors (Figure 17) [452].  
 
Figure 17: Functioning of IL- 8 in the body. 
 
IL-8 is a chemokine which serves as a chemical signal that attracts neutrophils at the site of 
inflammation, and therefore is also known as neutrophil chemotactic factor. IL-8 differs 
from all other cytokines in its ability to specifically activate neutrophil granulocytes. High 
concentrations of IL-8 levels have been reported in the airways of COPD patients [453-
454], which is significantly higher when compared to asthmatic patients [455]. IL-8 has 
been found to increase in adult OSA patients [301 ,456-457], and a cause of elevated 
cardiovascular risk [458]. 
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Myeloperoxidase (MPO)  
Myeloperoxidase is most expressed in neutrophil granulocytes. It is a lysosomal protein 
stored in azurophilic granules of the neutrophil, which causes green color in secretions rich 
in neutrophils, such as pus and some forms of mucus [459]. This enzyme is predominantly 
found in neutrophils, monocytes and some of the subtypes of macrophages. It represents 
more than 5% of total protein content of the cell in neutrophils [460]. MPO retain potent 
pro-inflammatory properties and may contribute directly to tissue injury. In the airway, 
MPO is a reflection of neutrophil activation. Increased level of serum MPO was link 
between with cardiovascular disease [461]. It was demonstrated that an increased MPO 
level in patient‟s blood serves as a risk marker for atherosclerosis [462] and coronary artery 
disease [463]. In OSA, increased salivary MPO levels were reported as may be useful as 
oropharyngeal local inflammatory marker in OSA patients [464].  
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2 
AIMS AND HYPOTHESIS 
 
HYPOTHESIS 
This thesis tests the hypothesis that non-invasive respiratory support is a pro-inflammatory 
stimulus to the upper and lower airways. This hypothesis is tested in healthy subjects, 
patients with OSA and COPD, and on a cultured human bronchial epithelial cell line 
(BEAS-2B). 
 
Aims 
(1).  At the outset of the investigation, we aimed to validate two relevant 
methodological techniques used in this thesis: 
1. To examine the validity of intersession repeatability of acoustic rhinometry 
measurements of unilateral and combined nasal parameters in a group of healthy 
subjects.   
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2. To establish the repeatability and acceptability of a novel upper airway sampling 
technique we have developed, employing a paediatric tracheostomy tube (TT). 
All details and results of this aim are introduced and discussed in Chapter 3.  
 
(2).  Is CPAP a pro-inflammatory stimulus in healthy subjects?  
 To investigate the effect of 3 hours of 7.5 cmH2O and 12.5 cmH2O, non-humidified 
nasal CPAP on airway and systemic inflammation, and the effect of physiological 
function and thus upper airway symptoms in healthy subjects.   
 To determine any relationships between the subsequent effects on the upper airway 
and lower airways, and whether there are differences between the two groups due to 
the dose-response effect.   
 To investigate whether nasal CPAP escalates the nasal symptoms, and airway and 
systemic inflammation when effect-dose of nasal CPAP is increased from 7.5 cm 
H2O to 12.5 cmH2O in healthy subjects groups, and whether there are differences 
between the two groups at baseline and at 3 hrs of continuous CPAP use.  
All details and results of this aim are introduced and discussed in Chapter 4.  
  
(3).  Is CPAP a pro-inflammatory stimulus in OSA patients?  
 To investigate the effect of non-humidified nasal CPAP on the airway and systemic 
inflammation, and the effect of physiological function in OSA at the following 
intervals: 
 Baseline (no nasal CPAP) 
 One month (with nasal CPAP) 
 Three months (with nasal CPAP) 
 Six months (with nasal CPAP)   
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 To investigate the impact of nasal CPAP therapy on the Epworth sleep score, 
compliance & periodicity questionnaire, and six-point score.    
 To investigate if symptomatic OSA patients are more likely to have airway and/ or 
systemic inflammation, and thus show less compliance to the nasal CPAP therapy.  
 
All details and results of this aim are introduced and discussed in Chapter 5.  
 
 
(4).  In vitro study: Is CPAP a pro-inflammatory stimulus to human 
bronchial epithelial cell-lines in a culture model? 
We used an in vitro cell-culture model to fulfil the following objective: 
 
To investigate the in vitro effects of 4 and 7 cmH2O CPAP exposure on interleukin (IL)-6 
and (IL)-8 production by a human bronchial epithelial cell line (BEAS-2B) over 4 time 
intervals.  
All details and results of this aim are introduced and discussed in Chapter 6.  
 
(5).  Is NIV pro-inflammatory stimulus in a matched group of COPD 
patients?  
In the final part of this thesis, we conduct a pilot study with stable COPD patients to achieve 
the following specific aim: 
 
To investigate the effect of using bilevel positive pressure airway therapy on inflammatory 
indices with stable COPD, comparing this to a COPD group, and by not using the bilevel 
positive pressure airway therapy.  
All details and results of this aim are introduced and discussed in Chapter 7. 
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3 
VALIDATION OF THE  
NASAL ASSESSMENTS 
 
This chapter describes the validation process for methodologies used for the nasal 
assessments adopted in this thesis. To reiterate the content of the previous chapter, this is a 
study of nasal obstruction using acoustic rhinometry, and upper airway sampling using a 
dilutional wash via a paediatric tracheostomy in healthy subjects and OSA. The data have 
been presented at meetings of the American Thoracic Society 2010 and European 
Respiratory Society 2010. The validation of both methodological studies has been accepted 
for publication in the Translational Research, and Clinical and Experimental 
Otorhinolaryngology [327, 350], attached as Appendix Two. 
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PART A 
VALIDATION OF ACOUSTIC 
RHINOMETRY  
 
3A.1 INTRODUCTION 
 
The nose is the natural and preferred respiratory passageway. Nasal obstruction is common 
symptom and the etiology of nasal obstruction may be anatomical, physiological or 
pathological. Nasal mucosal inflammation is the most common pathologic cause and 
besides viral upper respiratory tract infections, allergic rhinitis is the most frequent cause of 
nasal obstruction [465]. Since nasal obstruction is common in a wide range of sinonasal 
disorders, a technique to assess this work have an important role in the diagnosis and 
follow-up of conditions altering intranasal dimensions, either permanently or transiently. 
Acoustic rhinometry (AR) objectively defines nasal cavity dimensions by acoustic 
reflections as described in the introduction. AR is a static test and independent of airflow 
[466]. It estimates intranasal volume between predefined segments, and cross-sectional 
areas through identification of local changes in acoustic impedance using a sound pulse 
propagating in the nasal cavity.  
 
AR is able to detect irreversible structural changes and reversible dynamic changes, which 
has been used in many conditions in adults and children including sleep disorders [467]. 
 
The automated nature of the technique and dependency of measurements on position 
necessitates the confirmation of its repeatability in serial measurements over consecutive 
sessions only by understanding repeatability can we assess change with disease and or 
intervention. The intersession repeatability of AR remained to be clarified and this has 
important clinical implications, particularly when the method is to be used for the purpose 
of follow-up. Importantly, no previous study had examined the intersession repeatability of 
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AR using the intraclass correlation coefficient, comparing combined (mean) and individual 
nares, in healthy subjects [468-473].  The present study was therefore designed to assess the 
inter-session repeatability using the statistical approach of intra-class correlation co-efficient 
on averaged combined and separate nostril minimum cross-sectional areas and nasal 
volumes in healthy subjects. 
 
This study aimed: 
1. to define the intersession repeatability of acoustic rhinometry measurements of 
unilateral and combined nasal parameters in a group of healthy subjects. 
 
And to test the following hypothesis: 
2. that combined nasal parameters (according for changes with nasal cycle) are more 
reproducible estimates of nasal geometry over time than assessing each nostril 
separately.  
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3A.2 METHODs 
 
3A.2.1 Study Subjects  
 
Twenty healthy subjects were enrolled into the study from the London Respiratory 
Medicine Research clinic at Royal Free London NHS Foundation Trust. Inclusion criteria to 
the healthy group comprised no active respiratory or nasal diagnosis, and no nasal 
medications.   
 
3A.2.2 Measurement Protocol  
 
AR measurements were performed in accordance with a previously published protocol 
[362]. The AR device was A1 Acoustic equipment with an updated software version 0.5 
(GM Instruments, Kilwinning, UK). Measurements were obtained when the subject was in a 
sitting position and under close supervision of the operator. Each subject was instructed to 
open the mouth and stop breathing during the measurements. The sound tube was handheld 
by the subject to obtain a sealed nostril. Plate 8 shows the handling and positioning of the 
wave tube by the subject. All measurements were obtained by the same operator in the same 
air-conditioned room to provide similar conditions with regard to temperature, humidity and 
ambient noise level. Multiple recordings were taken for each subject at each visit and curves 
with obvious artefact were discarded. For each subject, measurements were repeated on five 
consecutive days. 
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Plate 8: Handling and positioning of the device by the subject (Reproduced with permission of the 
volunteer). 
 
3A.2.3 Variables 
 
Five important AR variables were assessed and examined separately to test the intersession 
repeatability of the technique: outermost minimum cross-sectional area (MCA1, cm
2
), the 
distance of MCA1 from the nasal orifice (D-MCA1, cm), innermost minimum cross-
sectional area (MCA2, cm
2
), the distance of MCA2 from the nasal orifice (D-MCA2, cm), 
and the volume of the nasal segment between the 2
nd
 and 5
th
 cm from the nasal orifice (V2-5, 
cm
3
). MCA1 corresponds to the level of nasal valve, whereas MCA2 corresponds to the 
anterior half of the inferior turbinate. In each subject on each day, areas, distances and 
volume values for each separate nostril were averaged (mean), and combined values were 
obtained by calculating the mean of the mean results from the right and left nostrils to 
correct for the variation between nostrils during the nasal cycle.  Plate 9 illustrates a typical 
rhinometry trace from one of the subjects.  
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Plate 9: An example of an acoustic rhimonetry trace. The x-axis represents distance from the nostril 
(at 0 cm), and the y-axis represents the nasal cross-sectional area (cm
2
). MCA1 and MCA2 (arrow 1) 
correspond to the nasal valve and anterior half of the inferior turbinate, respectively. D-MCA1 and 
D-MCA2 (arrow 2) correspond to the distance of MCA1 and MCA2 from the nasal orifice (x=0cm), 
respectively. The green arrow (arrow 3) indicates the segment used for the calculation of V2-5, and 
arrow 4 the nasal orifice.  
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3A.2.4 Statistical Analysis 
 
SPSS version 18.0 was used for the analysis of data. Intraclass correlation coefficients 
(ICC) were used to examine intersession repeatability of each parameter measured over five 
separate occasions for unilateral and total (combined right and left) values. ICC values were 
interpreted as follows: 0.41-0.60, moderate agreement; 0.61-0.80, substantial agreement; > 
0.80, "almost perfect agreement" [474]. In addition, the mean coefficient of variance and 
inter-item correlations were calculated for each parameter. A p value <0.05 was considered 
indicative of statistical significance. 
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3A.3 RESULTS 
 
 
Twenty healthy subjects (13 males, 7 females) without a history of nasal symptoms or 
disease were included in this study. The mean (SD) age of the subjects was 38 ± 7.1 years.  
 
Table 14 reports the repeatability estimates of combined (mean of left and right) values for 
the five different acoustic rhinometry measurements. Intraclass correlation coefficients and 
inter-item correlation coefficients indicated excellent agreement for all parameters across 
five separate sessions. All intraclass correlations were ≥0.80 confirming almost perfect 
agreement. All intraclass correlations and inter-item correlations were associated with p 
values < 0.001. The mean coefficient of variation was low (<10%) for all but MCA1 
measurements (14.5%). The coefficient of variation was particularly low for D-MCA1 
(7.4.2%), D-MCA2 (2.8%), and nasal volume (5.4%).  
 
Unilateral data from the right and left nostrils are also presented in Table 14.  Agreement 
was less good (lower intraclass correlation) than when using data from both nostrils 
combined. 
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Table 14: Repeatability for the combined (mean of left and right) and separate nostril values for 
each acoustic rhinometry variable over five days. 
 
 Variable* 
Combined 
values 
Item mean±SD Mean CV 
(%) 
Inter-item correlation 
coefficient 
Intraclass 
correlation 
coefficient 
 
COMBINED 
MCA1 (cm
2
) 0.54±0.07 14.5 0.87 0.89 
D-MCA1 (cm) 2.17±0.15 7.4 0.86 0.88 
MCA2 (cm
2
) 1.61±0.16 9.1 0.86 0.86 
D-MCA2 (cm) 4.28±0.12 2.8 0.87 0.88 
V 2-5 (cm
3
) 4.63±0.24 5.4 0.94 0.93 
 
RIGHT 
NOSTRIL 
 
MCA1 (cm
2
) 0.53±0.07 13 0.88 0.84 
D-MCA1 (cm) 2.07±0.06 9.2 0.82 0.83 
MCA2 (cm
2
) 1.59±0.18 11.1 0.83 0.84 
D-MCA2 (cm) 4.20±0.18 4.8 0.79 0.80 
V 2-5 (cm
3
) 4.60±0.25 6.5 0.92 0.91 
 
LEFT 
NOSTRIL 
MCA1 (cm
2
) 0.52±0.08 14.2 0.88 0.84 
D-MCA1 (cm) 2.12±0.13 6.4 0.83 0.81 
MCA2 (cm
2
) 1.64±0.24 15.2 0.76 0.75 
D-MCA2 (cm) 4.37±0.16 3.8 0.82 0.81 
V 2-5 (cm
3
) 4.57±0.33 7.2 0.81 0.78 
*Combined variables were calculated as the average (mean) values for the right and left nostrils.  CV, coefficient of 
variation; SD, standard deviation; MCA, minimum cross sectional area; D-MCA, distance of MCA from nasal orifice; 
V2-5, volume of nasal cavity between the 2
nd
 and 5
th
 cm from nasal orifice.  
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3A.4 DISCUSSION 
 
This is the first study to examine the intersession repeatability of acoustic rhinometry using 
ICC on averaged combined and separate nostril minimum cross-sectional areas and nasal 
volumes in healthy subjects. We showed that acoustic rhinometry provides excellent 
reproducible results, best over different sessions when combined nasal parameters values 
are used than right or left nostrils separately. This degree of repeatability has clinical 
implications with regard to the utilisation of this rapid and easy-to-use technique in the 
follow-up of conditions associated with impaired nasal patency. We reassured to the 
technique would be valid in this thesis.   
 
The measurements obtained in this study included a wide range of clinically relevant 
parameters: minimum cross sectional area at two distinct points and their corresponding 
distances from the nostrils, and the volume of the nasal cavity between the 2
nd
 and 5
th
 
centimetres. The outermost minimum cross sectional area (MCA1) corresponds to the nasal 
valve and is a good indicator of structural obstruction, whereas the innermost minimum 
cross sectional area (MCA2) corresponds to the anterior half of the inferior turbinate, which 
contains erectile tissue and therefore is a reflection of functional obstruction. Similarly, the 
region of the nasal cavity between the 2
nd
 and 5
th
 centimetres is the site of mucosal changes; 
thus this volume is also considered a reflection of functional obstruction.  
 
Several previous studies had examined the intersession repeatability of acoustic rhinometry 
measurements in both healthy individuals and in patients with nasal obstruction, but each 
had limitations, which we have attempted to address in the present study design. Similar to 
the current study, except not using combined values for nostrils, Silkoff et al. [471] 
examined the repeatability of acoustic rhinometry measurements performed on five separate 
occasions and found relatively low variation in minimal cross sectional area and nasal 
volume (0-5 cm). Measurements of minimal cross sectional area showed 8.1% and 9.7% 
variation for the right and left sides, whereas variations were even lower for nasal volumes 
(4.8% and 5.5%, respectively). Intraclass coefficients for right and left MCA were 0.91 and 
0.87, whereas corresponding figures for nasal volume were 0.86 and 0.69, respectively. This 
study, unlike ours, did not combine values from both nostrils and therefore does not account 
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for variation with nasal cycle. We hypothesised, and showed that combined results were 
more repeatable than those from individual nostrils. In a separate study, Castano et al. [468] 
examined the repeatability of acoustic rhinometry measurements in patients with 
occupational rhinitis and found low variation in both minimal cross sectional area and nasal 
volume measurements. Intersession intraclass correlation coefficients ranged from 0.80 to 
0.88 and from 0.83 to 0.94 for nasal volume and MCA, respectively. These figures are in 
agreement with the findings of this study on healthy individuals.  
 
Harar et al. [469] investigated the repeatability of acoustic rhinometry measurements on 
day-to-day basis using the minimal cross sectional area at the nasal valve level (MCA1). 
They made measurements on just two separate days and found a relatively high mean 
intersession difference (12.9%) when only one measurement was performed at each visit 
and this mean intersession difference could only be reduced to 10.85% when ten recordings 
were done for each subject at each visit. We report a slightly higher variation in minimal 
cross sectional area measurements at the nasal valve; however, intraclass correlations 
calculated using measurements on five consecutive days showed better agreement. The 
higher variation in MCA1 measurements (14.5%) may be attributed to the malpositioning of 
the device by the patient. However, intraclass correlation takes into account correlations 
between every pair of observation and thus may be regarded as a more accurate means for 
examining the repeatability of the measurements over time. Similarly, Ognibene et al. [470] 
found lower agreement between measurements obtained on two different sessions one week 
apart, with intraclass coefficient of 0.67. The high intraclass correlation coefficients 
obtained in the present study may be attributed to the relatively short duration between 
measurements in contrast to the Ognibene study, which may cause bias due to carry-over 
effect.  
 
Most previous studies have assessed parameters for the individual nasal cavity (either right 
or left) separately; however, in our study we used combined (mean) parameters from the 
two nostrils to correct for the variations between nostrils during the nasal cycle. This may 
also account for the strong agreement found in this study. Similarly, Roithman et al. [472] 
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found less intersession coefficient variation for combined parameters when compared to 
unilateral parameters, but this data does not employ the assessment of intraclass correlation. 
 
Acoustic rhinometry is a rapid, convenient and reliable technique to examine nasal patency. 
Although there are several techniques that can be utilised for this purpose, acoustic 
rhinometry has several advantages. The benefits of rhinomanometry have been 
demonstrated in many clinical settings; however, it does not give an idea on the localization 
of the obstruction. Nasal endoscopy on the other hand is not able to produce quantitative 
results, although it provides excellent visual topography. Similarly, nasal examination 
provides only subjective information on the degree of obstruction. Acoustic rhinometry has 
the ability to localize and quantify both reversible and irreversible obstruction of the nasal 
cavity. However, since it is a position dependent procedure, concerns related to the 
repeatability of measurements have arisen. Current evidence suggests that repeated 
measurements should be made in each session to obtain a reasonable level of reproducibility 
[474]. In addition, Harar et al. [469] reported better intersession repeatability when multiple 
measurements were done in each session. Intersession repeatability itself is important 
particularly when the technique is to be used for follow-up purposes. Therefore, multiple 
recordings were made in each session of this study to avoid the effects of intra-session 
variability. 
 
The accuracy of acoustic rhinometry has shown to be higher for the anterior part of the nose 
when compared to posterior part [337, 340, 475]. Tarhan et al. [475] reported that acoustic 
rhinometry overestimates cross-sectional area beyond the paranasal sinus ostia. In this 
study, both minimal cross sectional areas measured at two different levels showed similar 
repeatability, suggesting that acoustic rhinometry provides reproducible results at as far as 
the level of anterior half of the inferior turbinate. 
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3A.5 CONCLUSION 
 
Using intraclass correlations in healthy subjects, combined acoustic rhinometry 
measurements (mean of left and right nostrils) provide excellent and more reproducible 
estimates of nasal geometry over time than assessing each nostril separately, in terms of 
both localization and reversibility of pathological obstructions. The support of its use for the 
follow-up of conditions associated with structural or functional obstruction, in any to be 
described in the remainder of the thesis. 
 
123 
 
PART B 
 
VALIDATION OF NASAL LAVAGE 
SAMPLING TECHNIQUE 
 
 
3B.1 INTRODUCTION 
 
This chapter describes repeatability, importance in understanding changes with time in 
dilutions. The nose is the natural and preferred respiratory passageway. The distinction 
between the upper and lower airway is artificial and many lung diseases are associated with 
upper airway manifestations. There is therefore the need for a simple, repeatable, acceptable 
method for sampling the upper airway.  
 
As discussed earlier in section “methods of assessing upper airway” of this thesis, the nasal 
cavity is affected by many conditions including inflammatory diseases such as OSA and 
COPD. Since it is the most accessible part of the respiratory system, the cellular and 
biochemical composition of nasal specimens can be readily evaluated. To avoid obtaining 
surgical biopsy specimens that gives excellent information on cellular events, this technique 
is invasive and associated with bleeding risk, and artifacts may occur from the infiltration of 
local anesthetic, therefore, nasal secretions was considered in this thesis which may also aid 
in the diagnosis and follow-up of conditions affecting upper or lower airways, in particular 
inflammatory and allergic disorders [322-324].  
 
Nasal washing (nasal lavage) is a commonly used technique. However, unpredictable 
amounts of fluid losses through swallowing, absorption by nasal mucosa and leakage from 
the nasal orifice all contribute to a variable degree of dilution resulting in concerns related to 
the repeatability of the technique. 
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Concentrations of interleukin (IL)-6 and IL-8 in nasal secretions are good markers for the 
degree of inflammation since both take part in the inflammatory process. Cell counts 
provides information on the inflammatory status and are a good indicator of the 
effectiveness of nasal sample collection technique, which has been used in previous studies 
examining the repeatability and reliability of sample collection methods [476-477]. Finally, 
recovery volume and its variability is the main determinant for the degree of dilution. 
 
Considering these disadvantages of conventional nasal lavage techniques, we developed a 
novel and practical method for the collection of nasal secretion. The method utilises a 
paediatric tracheostomy tube with a good seal at the nasal orifice, is less time consuming, 
can be reprocessed for usage and provides comfortable test conditions.  
 
This study aimed: 
 
1. To introduce a novel concept of utilising a paediatric tracheostomy tube with a good 
seal, less time consuming, sterilised and can be reprocessed for usage and provides 
comfortable test conditions.  
 
2. To investigate the repeatability of our novel method with regards to several 
clinically and technically relevant parameters, in healthy subjects across sessions 
performed on five consecutive days. 
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3B.2 METHODS 
 
 
3B.2.1 Study Subjects  
 
Fourteen healthy subjects were enrolled in this study. Subjects were clearly instructed 
before and during the entire experimental period to follow their normal activities. Inclusion 
criteria to the healthy group comprised no active respiratory or nasal diagnosis, and no nasal 
medications.   
 
3B.2.2 Materials for Nasal Lavage Technique 
 
The nasal lavage was performed by using a Bivona Fome-Cuf Pediatric Silicone 
Tracheostomy Tubes, size I.D 2.5 mm (UK). The arrangement is illustrated in Plate 10 and 
11. 
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Plate 10: Shows the components of tracheostomy tube (Bivona Fome-Cuff Tracheostomy Tube, 
Smiths Medical, UK). 
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Plate 11: The tracheostomy tube is inserted into the nasal cavity and the Fome-cuff is inflated 
(arrow 1). Arrow 2 indicates the 10 ml syringe that contains 7 ml of 0.9% saline and arrow 3 shows 
the inflation line for the cuff. Written consent was obtained from the subject for the photograph. 
 
 
Processing of the TT describing the reprocessing protocol as recommend from the Smiths 
Medical Company (Appendix Three). 
 
 
3B.2.3 Collection of Nasal Lavage Samples 
 
After explaining the procedure, the patient was asked to bend forward, seating with 
approximately 45 degrees of angle between the chin and the chest. The paediatric 
tracheostomy tube was inserted into one of the nasal orifices and the Fome-cuff was inflated 
to achieve comfortable sealing. Then 7 ml of saline solution (0.9% NaCl) at room 
temperature was slowly instilled through the tracheostomy tube using a syringe, and then 
the solution was drawn back (Plate 11). This process was repeated once more; thus, the 
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nasal cavity was washed in and out twice. A clean funnel tube was used to collect any 
leaked fluids during the removal of the tube from the nose and this fluid was also added to 
the sample. The technique was repeated for the other nasal cavity using another syringe and 
the two recovered solutions were pooled for analysis. For each subject, measurements were 
repeated on five consecutive days. To ensure standard conditions, all sampling procedures 
were performed by the same person. Nasal wash recovery volume, cell count and cytokine 
concentrations (IL-6 & IL-8) were used to assess the intersession repeatability of the 
technique.  
 
3B.2.4 Measurements 
 
The nasal wash from both left and right nostrils was measured and recorded as the total 
pooled recovery volume (maximum 14 ml). The pooled sample was then centrifuged for 10 
minutes at 1000rpm at 4
◦
C to yield a cell pellet for a total percentage of cell types found 
within the collected sample. Aliquots of supernatant were collected and stored at – 80◦C 
until required for the analysis of inflammatory cytokines. The cell pellet was re-suspended 
in 400 to 1200 μl with phosphate-buffered saline (PBS) solution and gently mixed. A 50 μl 
aliquot was removed and stained with Trypan blue stain and counted using a Neubauer 
haemocytometer. Measurement of the supernatant inflammatory cytokines (IL-6 and IL-8) 
was carried out by a standard ELISA technique. The ELISA kits used was obtained 
commercially from R&D Systems Europe. The limits of detection were 0.70 pg/ml (IL-6), 
and 3.5 pg/ml (IL-8).  
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3B.2.4 Statistical Analysis 
 
SPSS version 18.0 (SPSS Inc, Chicago, Ill) was used for the analyses of data and data are 
expressed as mean (SD). Kolmogorov-Smirnov test was used to test normality of 
distribution. Intraclass correlation coefficients (ICCs) were used to examine intersession 
repeatability of recovery volume, cell count, and IL-6 and IL-8 levels over 5 separate 
occasions. Logarithmic transformation was performed for cytokine concentrations and cell 
count. ICC values were interpreted as follows: 0.41–0.60, moderate agreement; 0.61–0.80, 
substantial agreement; and .0.80, "almost perfect agreement" [474]. In addition, the mean 
coefficient of variance values and interitem correlations were calculated for each parameter. 
A P value <0.05 was considered indicative of statistical significance. 
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3B.3 RESULTS 
 
 
Fourteen healthy subjects (9 males, 5 females) without a history of nasal symptoms or 
disease were included in this study. The mean ± SD age of the subjects was 35 ± 7.6 years.  
Table 15 shows the repeatability estimates for cell count, cytokine concentrations and 
recovery volume over a 5 day period. Intraclass correlation coefficients and inter-item 
correlation coefficients indicated strong agreement for cell count and IL-8 concentrations. 
However, recovery volume and IL-8 levels were more variable. Nevertheless, all intraclass 
correlations and inter-item correlations were associated with p < 0.001. The mean 
coefficient of variation was very low for cell count (2%), IL-8 concentration (3%), and 
recovery volume (3%), whereas it was quite higher for IL-6 (48%). The mean percentage of 
recovery was high (87%). 
 
Table 15: Repeatability of nasal wash parameters over five consecutive days in 14 subjects. 
 
Variable* mean±SD 
Inter-item correlation 
coefficient 
Intraclass correlation 
coefficient 
Cell count (log10 cells/ml) 4.15±0.26 0.88 0.87 
IL-6 concentration (log10 pg/ml) 0.44±0.34 0.79 0.78 
IL-8 concentration (log10 pg/ml) 1.71±0.37 0.98 0.98 
Recovery volume (ml) 12.19±0.54 0.63 0.60 
Abbreviation: CV, coefficient of variation. *Data are expressed as mean 6 SD. 
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3B.4 DISCUSSION 
This study examined the intersession repeatability of a newly developed nasal lavage 
technique utilizing a paediatric tracheostomy tube. Highly repeatable results for IL-8 and 
cell count data were achieved across five separate sessions. To our knowledge only few 
studies have examined the repeatability of different nasal lavage techniques for clinically 
relevant parameters and varying results have been obtained. Our data support the use of this 
technique in subsequent chapters. 
 
Nikasinovic-Fournier et al. [324] examined a method utilizing a transparent paediatric Foley 
catheter and tested the repeatability of the method across three different measurements for a 
number of parameters including the ones used in this study. Although ICC for recovery 
volume was quite high (0.81), the mean percentage of recovery volume was somewhat less 
than that observed in our study (75% versus 87%). Repeatability of their method with 
regard to total cell count (ICC, 0.73) indicate a substantial agreement but repeatability of IL-
6 and IL-8 levels were quite low making the method unsuitable for the detection and follow-
up of these two parameters in inflammatory conditions. Better sealing of the cuff using our 
paediatric tracheostomy tube may provide more comfortable conditions for the patient and 
prevent fluid loss, both from the nasal opening and through nasopharynx. Thus, less 
variation in interleukin levels, particularly in IL-8 concentrations, observed in this study 
may be attributed to more effective sampling with this novel technique. 
 
Several studies have compared nasal lavage with other techniques for the collection of nasal 
samples [325, 476, 478-479]; however, none of them reported ICCs to evaluate 
repeatability. In addition, none of these studies has used a specific instrument for nasal 
lavage to aid in sample collection such as the paediatric tracheostomy tube used in this 
study. Riechelman et al. [325] compared four different sampling techniques: nasal lavage, 
nasal spray blow technique, filter paper method, and polyurethane foam sampler technique. 
Intra-individual variations of total protein concentration over three measurements were high 
for all four methods: 43%, 48%, 34%, and 39%, respectively. Melillo et al. [476] examined 
nasal lavage and a technique utilizing ultrasonic nebulisation of hypertonic solution and 
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tested the repeatability of ultrasonic nebulisation technique, but not the repeatability of nasal 
lavage, using the measurements obtained on two occasions in each individual. They 
reported significant and high correlations for total cell count (TCC) (r=0.81), differential 
cell count (r=0.72-0.90), and eosinophil cationic protein (ECP) (r=0.85) between two 
measurements from each individual. However, TCC and ECP results obtained by the two 
methods did not correlate and absolute TCC and ECP values were lower with nasal lavage. 
Walsh and Falsey et al. [479] compared nasal wash and nasal swab techniques in the 
detection of several virus specific IgAs and found that both techniques were reproducible 
with test-retest correlation coefficients ranging between 0.71-0.75 for nasal wash and 0.85-
0.86 for nasal swab technique. Ours is the first study using ICC, repeated on five 
consecutive days, reporting both cell counts and inflammatory markers. 
 
A concern of nasal lavage methodology is the unpredictable degree of dilution since 
unknown fractions of the instilled fluid may be swallowed, lost from the nasal opening or 
absorbed through nasal mucosa. This uncertainty may interfere with the reproducibility of 
the method and preclude its use for follow-up purposes. Accordingly, analyte concentrations 
were generally lower with nasal wash technique when compared to other techniques in the 
previous studies employing a classical nasal wash technique without the aid of a catheter 
and seal [325, 476]. The fine catheter used in this study provides comfortable conditions for 
the patients, may alleviate swallowing reflex, and through prevention of fluid loss allows 
the recovery of a relatively standard amount of lavage fluid as shown with moderate 
agreement for recovery volume and the high mean percentage of recovery. We believe that 
the high repeatability of IL-8 concentrations in our work reflects the high, and reliably 
reproducible volumes of wash fluid returned.  In addition, whilst assessing dilution may be 
desirable, there is no accepted way of achieving this and methods assessing total protein 
may indeed prevent the detection of differences between health and disease and 
inflammatory nasal conditions are also associated with protein leak into nasal lavage fluid 
as previously reported from this laboratory [321]. 
 
Nasal secretions reflect the inflammatory status of the nasal mucosa and changes have been 
shown to parallel the course of inflammatory conditions [321, 326, 480]. In addition, the 
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nasal cavity is the first part of the respiratory system to come in contact with allergens and 
airbone pollutants. Thus, examination of nasal secretions is particularly valuable in 
conditions associated with inflammation. One method for sampling nasal secretions is the 
collection of spontaneous secretions. It is practicable in patients with hypersecretion as a 
result of nasal disease. However, the amount of fluid is often insufficient for analysis, 
particularly in healthy individuals [481-483]. Absorption techniques involve the placement 
of a sampler with absorptive properties into the nasal cavity and they provide sufficient 
amounts of undiluted nasal secretions for analyses. Although several studies showed that 
these techniques are sensitive, reliable and reproducible in several settings [325, 484-485], 
placement of a foreign substance for a period of time may traumatise the mucosa and alter 
the concentrations of analytes under investigation. Nasal lavage is a useful technique for 
biochemical and cytological exploration of nasal secretions since it is a non-invasive, cheap 
and easy-to-perform method not only suitable for use in clinical trials but also in large-scale 
epidemiological studies. In addition, nasal lavage is suitable for the examination of nasal 
cytology owing to its good inter-observer variability [486]. However, the unpredictable 
degree of dilution represents a major obstacle resulting in inconsistent results across 
repetitive measurements. In addition, the degree of dilution may be problematic when 
measuring analytes in low concentrations, which often will be well below the detection limit 
of the assay [325].  
 
Biopsy sampling of nasal mucosa may represent another method suitable for the evaluation 
of cellular and biochemical events in inflammatory conditions [487-488]. Dilution is not an 
issue and cellular composition may be better evaluated. However, it is invasive, associated 
with bleeding risk, and artefacts may occur due to infiltration of local anaesthetic. In 
addition, repeated procedures are problematic, limiting its use for follow-up purposes. 
 
One important finding of this study is that we confirmed the repeatability of measurements 
obtained on five separate occasions in each individual, which is higher than the number of 
sessions used in previous studies evaluating the repeatability of nasal sampling techniques. 
Several attempts have been made to correct for the degree of dilution including the use of 
inulin (an inert polysaccharide), lithium, urea or total protein; and the latter has been 
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reported as having the least inter-subject variation repeatability [481, 489-491]. However, 
due to protein leakage through the inflamed mucosa in the inflammatory conditions of the 
respiratory system, correcting for total protein concentration while estimating cytokine 
levels may not be reliable [321, 492]. In addition, several other variables including the 
position of the subject and the duration of contact between the fluid and the nasal mucosa 
may affect the concentrations of analytes in nasal secretions. The new technique presented 
in this study attempted to standardize these conditions to improve repeatability. Very high 
intersession repeatability was found for consecutive IL-8 measurements and cell counts. IL-
6 measurements were also repeatable but the coefficient of variation was higher, and this is 
discussed below. However, there was moderate agreement between recovery volumes, 
which may be due to different amount of absorption and amount of secretion already present 
in the nasal cavity. Nevertheless, this variation does not seem to interfere with the 
repeatability of cytokine concentrations and cell counts substantially, although it may partly 
account for high variation in IL-6 measurements. In different disease states there may be 
different recovery and this will need studying. Nasal inflammatory conditions may reduce 
recovery.  
 
The greater variability of IL-6 compared to IL-8 and cellular measurements are interesting, 
and important for future studies. Dilution is unlikely to be a factor as this would have 
affected all the parameters, and our recovery volumes were reproducible. Nikasinovic-
Fournier et al. [324] also found lower intraclass correlation coefficients for IL-6 than IL-8 
(0.33 versus 0.44), suggesting greater variability for IL-6 levels in nasal secretions. To date, 
no other study has directly compared the variability of IL-6 and IL-8 concentrations in nasal 
wash samples. Thus, this high variation may be due to higher intra-individual variations of 
IL-6 in nasal secretions in normal subjects between days, possibly due to environmental 
factors, which may be a subject for further studies. This also implies that in future nasal 
studies, researchers may wish to assess IL-8 responses which appear to be inherently more 
stable.  
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3B.5 CONCLUSION 
 
The main findings of this study suggest that the newly developed nasal lavage technique 
utilizing a paediatric tracheostomy tube provides highly repeatable cytokine and cell count 
measurements over successive sessions.  This may be attributed to better sealing of the nasal 
opening to avoid fluid loss, to comfortable conditions alleviating swallowing reflex and 
fluid loss through the nasopharynx, and to accurate and precise installation of a standard 
amount of fluid. Nasal IL-8 concentration appears inherently more stable than IL-6. Our 
method may prove valuable in the diagnosis and follow-up of inflammatory conditions 
involving the upper (and lower) respiratory tract and support as of the technique in the 
studies of this thesis. 
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4 
DOSE-RESPONSE EFFECT  
OF NASAL CPAP ON 
SYMPTOMS, PHYSIOLOGY, AND 
INFLAMMATION IN HEALTHY 
SUBJECTS 
 
 
This chapter presents an investigation and analysis of short-term, dose-response effects of 
nasal CPAP on airway and systemic inflammatory indices, nasal symptoms and airway 
obstruction in healthy subjects. The results of this work have been published in the 
European Respiratory Journal in 2012 [173], as attached in Appendices One and Two. The 
data were previously presented in the 2010 and 2012 meetings of the American Thoracic 
Society. 
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4.1 INTRODUCTION 
As described in the introduction, nasal CPAP has become the gold-standard management of 
clinically significant OSA [27]. Despite its beneficial effects on airway patency, CPAP 
treatment is associated with a high prevalence of side effects [98, 285]. Some patients adapt 
to the treatment within a few weeks, others struggle for longer periods, and some 
discontinue treatment entirely with consequent detriment to their health. Although the long-
term compliance rate is generally good, 8- 15% of OSA patients refuse treatment after a 
single night of use in the laboratory setting [98, 493-495]. There are reports of many 
adverse symptoms occurring with CPAP use, including nasal congestion, sneezing, 
anosmia, itchy nose, dry nose, mouth, throat and eyes, blocked ears, and dizziness [98]. 
Thus, the initial experiences of the patient with nasal CPAP may be of great importance in 
long-term treatment compliance. 
The development of nasal symptoms with CPAP treatment may be related to the induction 
of nasal inflammation. Several clinical and experimental studies have reported on local and 
systemic inflammatory outcomes with ventilator support [298, 264, 496-500], but little is 
known about the early induction of nasal inflammation with CPAP and how this relates to 
changes in nasal physiology, symptoms and therefore compliance. In addition, reported 
symptoms and inflammatory changes may be influenced by pre-existing conditions, such as 
OSA. The investigations reported in our previous in vitro study demonstrated that 
continuous pressure applied to the airway epithelial triggers early inflammatory reaction 
originated from bronchial cells as evidenced by the increased secretion of inflammatory 
markers IL-6 and IL-8 by epithelial cells. 
We hypothesised that examining early symptoms and inflammatory changes after a short 
period of CPAP in nCPAP-naïve healthy individuals in vivo would provide complementary 
insights into the mechanisms associated with the development of adverse symptoms and the 
inflammatory response. This hypothesis forms the basis of the following two chapters.  This 
chapter comprises a dose-response analysis under two different nasal CPAP pressures.  
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This study primarily aimed: 
 to investigate in vivo the short-term effects of 3 hours of 7.5 cm H2O of non-
humidified nasal CPAP on nasal mucociliary clearance time and upper 
airways symptoms in healthy individuals. 
 to investigate the short-term effects of 3 hours of 7.5 cm H2O of  nasal CPAP 
on airway inflammatory indices in nasal CPAP-naïve, healthy individuals. 
 to investigate the short-term effects of 3 hours of 7.5 cm H2O of nasal CPAP 
on upper and lower airway obstruction. 
Secondly, after the first nasal CPAP therapy at 7.5 cm H2O pressure was administered, we 
aimed to investigate further the effects of nasal CPAP on the same clinical parameters but 
this time with nasal CPAP of 12.5 cm H2O that aimed to confirm the results and 
demonstrate a dose-response. 
 
The second study aimed 
 to examine the same aims of the first study but at 12.5 cm H2O. 
 to investigate further whether the increase of nasal CPAP pressure from 7.5 
to 12.5 cm H2O would result in increased inflammatory effect or none-effect. 
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4.2 METHODS  
 
4.2.1 Control Subjects and Protocol 
 
Thirty-one healthy non-smokers (21 male and 10 female) with no prior history of nasal 
symptoms or disease were recruited for the study.  
 
The subjects were divided into two groups for the study. One higher and one lower nasal 
CPAP fixd pressure (within the range of clinical use) were selected for the in vivo 
component of the study: 7.5 cm H2O and 12.5 cm H2O. The first group (n=22) was 
subjected to three hours of standard nasal CPAP (Respironics REMstar®) at 7.5 cm H2O 
pressure, without humidification, and through a nasal mask. The second group (n=31, 11 of 
whom had received the 7.5 cm H2O protocol six months previously) was subjected to three 
hours of nasal CPAP treatment at 12.5 cm H2O, also without humidification. A six-month 
gap was specifically chosen between the two studies to ensure that the effect of 7.5 cm H2O 
CPAP did not persist during the 12.5 cm H2O CPAP treatment.   
 
None of the subjects had clinical findings suggestive of upper and lower respiratory 
problems. Subjects with respiratory problems were excluded from the study. On being 
chosen to participate in the study a full medical history was ascertained and an examination 
was performed. Subjects then attended research clinics before the three hours of nasal CPAP 
therapy to have the following measurements taken before and after intervention: interleukin 
IL-(6), IL-8 and myeloperoxidase (MPO) levels in serum and nasal wash samples, nasal 
wash leukocyte count, lung function test, acoustic rhinometry measurements and nasal 
mucociliary clearance test using saccharin. In addition, six nasal score and other symptoms 
were questioned before and after the intervention. 
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4.2.2 Ethics and Consent 
The protocol was approved by the Research Ethics Committee at Royal Free Hampstead 
NHS Trust (study reference 09/H0720/24). Informed written consent was obtained from all 
subjects prior to their inclusion in the study.  
 
4.2.3 Study Device and Patient Interface 
 
The non-invasive respiratory support device used for the (in vivo and in vitro) studies in this 
thesis was a standard non-humidified nasal CPAP (Respironics REMstar®), and the 
interface to deliver the supportive ventilation for in vivo studies was nasal mask (Plate 7). 
The CPAP device was designed for the treatment of adult obstructive sleep apnoea (OSA) 
only.  
 
However, the mask that was intended to provide a subject interface for the application of 
non-invasive ventilation was nasal mask. The nasal mask is called Contour Deluxe
TM,
 which 
is designed to provide subjects or OSA patients with an enhanced comfort and leak control. 
The mask comes assembled with a unique one-size-fits-most head strap to enable quicker 
and easier set-up on a patient. 
 
4.2.4 Measurements 
 
4.2.4.1 Nasal and Systemic Sampling and Processing  
 
The aim of this section is to introduce the measurements and the processing techniques used 
to assess nasal and systemic inflammation in all study groups in this thesis. These 
measurements were of the amounts of nasal wash and serum samples used.  
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4.2.4.2 Nasal Wash Sampling  
 
Nasal wash samples were obtained using a dilution method [327] modified from a technique 
described by Hilding [501] as discussed and validated for repeatability in chapter three. In 
brief, a paediatric tracheostomy tube (Bivona Fome-Cuf, size I.D 2.5 mm; Smiths Medical, 
Kent, UK) was used to collect the nasal lavage. The patient was asked to bend forward, 
sitting with an approximately 45
o
 angle between the chin and the chest. The paediatric 
tracheostomy tube was inserted into one of the nasal orifices, and the cuff was inflated to 
achieve a comfortable seal. Then, 7 ml 0.9% room-temperature saline solution was instilled 
slowly through the tracheostomy tube using a syringe and drawn back. This process was 
repeated once more; thus, the nasal cavity was washed in and out twice. A clean funnel tube 
was used to collect any leaked fluids during the removal of the tube from the nose, and this 
fluid was added to the sample. The technique was repeated for the other nasal cavity using 
another syringe, and the two recovered solutions were pooled for analysis. To ensure 
standard conditions, all sampling procedures were performed by the same investigator.  
 
4.2.4.3 Nasal Wash Sampling Process for Analysis of Inflammatory 
Mediators 
 
The total portion of the pooled nasal wash fluid from both nostrils was collected in a 15 ml 
centrifuge tube and processed for the analysis of inflammatory mediators and leukocyte 
count as below. The total pooled nasal wash sample was mixed for 15 seconds on the vortex 
mixer and then centrifuged for 10 minutes at 2000 rpm at 4°C for a supernatant analysis of 
inflammatory cytokines, and the remainder to yield a cell-pellet for leukocyte count. 
Aliquots of supernatant were collected and stored at -80°C for interleukins IL-(6), IL-8 and 
MPO assay. All samples in this thesis were processed within a maximum of two hours from 
collection.   
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4.2.4.4 Nasal Wash Sampling Process for Leukocyte Count  
 
The cell pellet was re-suspended in 1 ml of phosphate-buffered saline (PBS) solution and 
gently mixed. A 50 µl aliquot was taken out into a 1.5 ml Eppendorf tube and 50 µl of 
trypan blue stain was added and carefully mixed. This suspension was then used for the 
leukocyte count using a Neubauer haemocytometer, a specimen slide which is used to 
determine the concentration of cells in a liquid sample. It is basically designed for the 
counting of blood cells but now also used to count other types of cells. A grid of 
perpendicular lines is etched into the glass of the hemocytometer chamber. This grid, an 
arrangement of squares of different sizes, allows for an easy counting of cells. This way it is 
possible to determine the number of cells in a specified volume, and thereby calculate the 
concentration of cells in the fluid overall. 
 
4.2.4.5 Serum Sampling and Processing 
 
Peripheral venous blood samples were obtained for serum measurements. A 5 milliliters of 
sample of venous blood was collected in to a sterile vacutainer, centrifuged at 2000 rpm for 
10 minutes at 4°C, and the supernatant was stored at -80°C for later analysis of 
inflammatory mediators.  
 
4.2.4.6 Samples Analysing and Reporting  
 
Measurements of the inflammatory cytokines (IL-6, IL-8 and MPO) in nasal wash 
supernatants and serum were performed by a standard ELISA technique. The ELISA kits 
were obtained from R&D Systems, Abingdon, UK.  
 
The limits of detection of the kit were 0.70 pg/ml for (IL-6), 3.5 pg/ml for (IL-8), and 1.5 
ng/ml for (MPO). 
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4.2.5 Physiological assessments   
 
The aim of this section is to introduce the measurements used in this thesis to assess the 
upper and lower airways. For nasal airway obstruction, acoustic rhinometry was used and 
for pulmonary airway obstruction, spirometry was used. For nasal mucociliary clearance, 
saccharin transit time (STT) was used to assess the function of nasal clearance. All 
measurements were conducted according to the same standardised protocols used in 
throughout this thesis, (Appendix Four).  
 
4.2.5.1 Acoustic Rhinometry 
 
 
Acoustic rhinometry measurements were performed in accordance with a previously 
published protocol [362], as discussed and validated in chapter four. Briefly, it allows one to 
measurement the relationship between a cross-sectional area and the distance of the nasal 
cavity by using a sound-pulse propagating in the nasal cavity, which reflects local changes 
in acoustic impedance: this method calculates a nasal cross-sectional area. All 
measurements were performed by the same operator in the same air-conditioned room to 
provide similar conditions with regard to temperature, humidity and ambient noise levels. 
The following five important acoustic rhinometry variables were assessed and examined 
separately: (i) outermost, minimum cross-sectional area (MCA1), (ii) D-MCA1, (iii) 
innermost, minimum cross-sectional area (MCA2), (iv) D-MCA2, and (v) V2-5. Area and 
volume values from the right and left nostrils were added together to obtain a combined 
value to account for variations in the nasal cycle.  
 
4.2.5.2 Spirometry 
 
 
Spirometry was measured and recorded using a Vitalograph 2160 (Maids Moreton, 
Buckingham, UK). A bronchodilator was not administered. The best of three attempts at 
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spirometry was measured and recorded.  We recorded forced expiratory volume in 1 second 
(FEV1), forced vital capacity (FVC), FEV1/FVC ratio and peak expiratory flow rate (PEFR). 
 
4.2.5.3 Mucociliary Clearance Time: in vivo 
 
 
Several factors affect the mucociliary function such as smoking, respiratory disorders and 
ambient pollutant gases [502-504]. Konrad et al. [374] showed that bronchial mucociliary 
clearance is impaired in patients receiving mechanical ventilation. Nasal CPAP as a 
noninvasive therapy might modify nasal mucociliary clearance and can be a risk factor for 
the defence of the respiratory airways, especially in OSA patients [285, 505-507]. The 
intolerance of CPAP would presumably occur because this therapy would lead to epithelium 
alterations and changes in the nasal mucociliary clearance. 
 
As discussed in the upper airway assessment in the introduction, although the gold standard 
for measuring mucociliary clearance is the radiolabeled method [376] saccharin transit time 
is an inexpensive, safe, simple technique, and results are similar to those obtained when 
using radioactively labelled particles [377]. STT has been documented in the literature to 
assess mucociliary clearance with various sinonasal disorders, such as allergic rhinitis and 
chronic rhinosinusitis, as well as in normal subjects [378, 508-509]. 
 
In this thesis, nasal mucociliary clearance was measured in healthy subjects and OSA using 
in vivo saccharin transit time as described by Rutland and Cole [380] which is a 
modification of Andersen‟s original description of the test.  
 
Therefore, we aimed to investigate in vivo the short- and long-term effect of nasal CPAP on 
the mucociliary clearance time in healthy subjects and OSA patients, and to correlate the 
adverse effects of this therapy with the pressure level used in this study. 
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Procedure Protocol  
 
 
During the procedure, subjects were asked to sit quietly in an upright position with the head 
in a neutral position. Subjects were asked to refrain from sniffing, sneezing, coughing, and 
drinking during the procedure. A saccharin particle, 0.5 mm diameter under direct 
visualization, was gently placed on the medial surface of the inferior turbinate of one nasal 
cavity at least 7 mm behind the turbinate's anterior end to avoid the area of mucosa where 
cilia beat in an anterior direction.  
 
The saccharin clearance time was recorded at the first sensation of sweet taste. The time 
from particle placement until the patient reports the first sensation of a sweet taste was 
measured with a stop-watch (Figure 18). If no taste sensation occurred within 60 minutes, 
then the ability to taste saccharin was confirmed by placing saccharin directly on the tongue. 
The saccharin transit time protocol is detailed in Appendix Four.  
There is no standardization in the mucociliary clearance time. Therefore, for the purpose of 
analysis, mucociliary clearance time was classified as follows: normal (up to 20 minutes); 
prolonged (21 to 30 minutes); severely prolonged (31 to 60 minutes); and failure to clear 
(over 60 minutes). These standardized times will be utilised in this thesis for other study 
groups. 
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Figure 18: Illustration of the saccharin particle placement and motion in the inferior nasal turbinate 
of a nostril. 
 
 
4.2.6 Questionnaire  
 
4.2.6.1 Assessment of Nasal Symptoms 
 
Subjects were asked to report any respiratory symptoms experienced on a regular basis 
during their visits to the research clinic before any interventions. 
 
A six-point nasal score, as used in previous work in the Department [321], was used to 
assess the presence or absence of nasal symptoms. The nasal score consists of the principal 
nasal symptoms of rhinorrhoea, which are postnasal drip, nasal congestion, sneezing, 
reduced smell and itchy nose. Other symptoms were assessed in order to determine the 
presence of nasal symptoms before and after the intervention of nasal CPAP. Results were 
binary coded as 1 or 0, respectively, and the scores were summed to yield a total score 
between 0 and 6. An example of a six-point nasal score is given in Appendix Five. 
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4.2.7 Statistical Analysis 
 
Data were analysed using GraphPad Prism 5 software (GraphPad Software Inc., La Jolla, 
CA, USA) and SPSS version 18.0 (SPSS Inc, Chicago, Ill). The Kolmogorov–Smirnov test 
of normality was applied. Paired t-tests were used to examine differences between baseline 
and post-CPAP therapy measurements. A one-way ANOVA was run to examine dose-
response differences between treatments, followed by post-hoc Tukey‟s multiple 
comparison tests. For the subgroup analysis, one-way repeated measures ANOVA for 
parametric data and Friedman test for nonparametric data were run to examine dose-
response differences between treatments as appropriate, followed by post-hoc Tukey‟s 
multiple comparison tests. Pearson (r) and Spearman (rho) correlations were conducted as 
appropriate to examine relationships between variables. A Chi-squared (x
2
) test was used to 
compare nasopharyngeal symptoms at baseline and after CPAP therapy. A P value < 0.05 
was considered statistically significant.  
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4.3 RESULTS  
 
The baseline characteristics of the subjects enrolled in the study are reported in Table 16. 
Both groups were healthy non-smokers, with a mean age between 33 and 34 years. 
 
Table 16: Baseline information of subjects enrolled in the study. Eleven patients took part in both 
protocols. 
 
Details of subjects 
studied 
7.5 cm H2O (n=22) 12.5 cm H2O (n=31) 
Mean SD Mean SD 
Age, years 33.8 5.8 33.4 5.4 
Weight, kg 70.1 6.6 71.5 7.5 
Height, cm 168.8 7.1 169.7 7.1 
BMI, kg/m
2
 25.12 1.84 24.82 2.01 
Smoking history Never-smoking Never-smoking 
Nasal symptoms None None 
Medications  None None 
BMI, body mass index; SD, standard deviation 
 
 
4.3.1 Changes in Nasal and Systemic Inflammation with CPAP 
 
The changes in serum and nasal wash inflammatory markers in response to three hours of 
nasal CPAP are reported in Table 17. Both CPAP pressures resulted in significant increases 
in nasal inflammation as assessed by nasal wash leukocyte and MPO measurements. The 
increase in nasal IL-6 and IL-8 concentrations following CPAP was only statistically 
significant at the higher pressure. Both pressures also resulted in changes in systemic 
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inflammatory markers, with significant increases in serum IL-6 concentrations and 
decreases in serum IL-8 concentrations following CPAP. There was no change in serum 
MPO concentration. The ANOVA test highlights the observed dose (pressure) responses for 
changes in inflammation with CPAP, illustrated in Figure 19. When one-way repeated 
measures ANOVA was conducted for the subset of subjects (n=11) that underwent both 
experiments (7.5 and 12.5 cm H2O), the changes in nasal wash IL-6 (p=0.038) and nasal 
wash MPO (p=0.027) remained statistically significantly. 
 
Table 17: Changes in inflammatory markers in serum and nasal wash fluid from baseline to post-
three hours of CPAP treatment. 
Data are expressed as the geometric mean (SD).  *versus baseline, paired samples t -test. 
**ANOVA: compares the baseline (mean of the two baselines in the 11 subjects who had both 
pressures) with the 22 results at 7.5 cm H2O and the 31 subjects at 12.5cmH2O  nCPAP.  IL, 
interleukin; MPO, myeloperoxidase; CPAP, continuous positive airway pressure. 
 
 
Marker                      7.5 cm H2O (n = 22) 12.5 cm H2O (n = 31)  
Baseline After CPAP P value* Baseline After CPAP P value* ANOVA** 
Inflammatory markers in serum   
IL-6, pg/ml 4.6 (3.5) 6.3 (3.5) 0.010 8.7 (4.2) 11.3 (5.8) 0.037 <0.001 
IL-8, pg/ml 20.9 (7.8) 16.5 (7.3) <0.001 14.9 (5.9) 13.0 (5.6) 0.002 0.022 
MPO, ng/ml 10.3 (8.4) 9.3 (9.4) 0.805 11.5 (8.5) 9.1 (7.2) 0.138 0.858 
Inflammatory markers in nasal wash   
Leukocyte 
count, 1000 
cells/ml 
18.8 (4.1) 20.6 (6.4) 0.024 18.2(4.7) 21.5 (6.2) <0.001 0.039 
IL-6, pg/ml 2.4 (2.8) 2.4 (3.1) 0.670 3.7 (1.5) 4.9 (1.8) 0.001 0.012 
IL-8, pg/ml 86 (114) 81 (98) 0.689 164 (90) 206 (164) 0.281 0.006 
MPO, ng/ml 1.9 (5.2) 3.4 (6.6) 0.006 2.0 (4.3) 3.8 (5.5) 0.002 0.006 
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Figure 19: CPAP is associated with a pressure-dependent alteration in nasal and systemic 
inflammatory markers, and nasal mucociliary clearance. Lines represent mean and standard error. 
Significant differences illustrated using ANOVA with post-hoc analysis. 
 
 
4.3.2 Changes in Physiology with CPAP 
 
The changes in spirometry, rhinometry and nasal mucociliary clearance are reported in 
Table 18. At both pressures, three hours of nasal CPAP treatment resulted in a significant 
slowing of nasal clearance (i.e., increased saccharin transit time) without significant changes 
in rhinometry variables. At both pressures, CPAP was associated with small but significant 
changes in FVC and PEFR (but not FEV1). 
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Table 18: Changes in lung function, rhinometry findings and nasal mucociliary clearance 
from baseline to after three hours of nCPAP treatment.   
 
Parameter                       7.5 cm H2O (n = 22) 12.5 cm H2O (n = 31)  
Baseline After CPAP P value* Baseline After CPAP P value* ANOVA** 
Lung function test   
FEV 3.03 (0.52) 3.05 (0.50) 0.093 3.07 (0.50) 3.09 (0.51) 0.596 0.751 
FEV1 % 86.31 (5.94) 86.22 (5.75) 0.506 85.74 (5.58) 86.90 (4.62) 0.091 0.370 
FVC 3.54 (0.63) 3.58 (0.63) 0.030 3.59 (0.63) 3.64 (0.61) 0.026 0.647 
FVC % 83.06 (5.62) 83.71 (5.53) 0.052 83.01 (6.18) 85.36 (4.54) 0.071 0.022 
FEV1/FVC 
ratio 
85.99 (6.00) 85.76 (6.10) 0.615 85.90 (6.49) 86.35 (6.79) 0.354 0.625 
PEFR (l) 519.00 
(71.53) 
527.27 
(62.79) 
0.024 523.81 (64.44) 553.06 (43.71) 0.002 0.007 
Acoustic rhinometry    
MCA1 0.57 (0.31) 0.60 (0.38) 0.527 0.61 (0.31) 0.59 (0.31) 0.175 0.894 
DMCA1 2.15 (0.38) 2.15 (0.34) 0.947 2.06 (0.43) 2.04 (40) 0.529 0.501 
MCA2 1.62 (0.54) 1.58 (0.45) 0.488 1.55 (0.53) 1.53 (0.50) 0.531 0.938 
DMCA2 4.23 (0.39) 4.24 (0.32) 0.884 4.22 (0.40) 4.23 (0.36) 0.568 0.823 
V2-5 4.43 (1.05) 4.51 (1.08) 0.482 4.73 (0.93) 4.82 (0.89) 0.113 0.362 
Nasal mucociliary clearance   
STT, minutes 16.31 (2.71) 17.41 (3.31) 0.035 15.30 (3.56) 16.35 (3.34) 0.045 0.011 
Data are expressed as the means (SD). *versus baseline, paired samples t -test.  **ANOVA: 
compares the baseline (mean of the two baselines in the 11 subjects who had both pressures) with 
the 22 results at 7.5 cm H2O and the 31 subjects at 12.5cmH2O  CPAP.  FEV, forced expiratory 
volume; FVC, forced vital capacity;  PEFR, peak expiratory flow rate; MCA1, outermost minimum 
cross-sectional area; DMCA1, the distance of the MCA1 from the nasal orifice; MCA2, innermost 
minimum cross-sectional area; DMCA2, the distance of the MCA2 from the nasal orifice; V2-5, the 
volume of the nasal segment between the 2nd and 5th cm from the nasal orifice; STT, saccharin 
transit time. 
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4.3.3 Changes in Nasopharyngeal Symptoms with CPAP 
 
Nasopharyngeal symptoms before and after nasal CPAP treatment are presented in Table 
19. None of the subjects had any upper airway symptoms before CPAP. The median number 
of nasopharyngeal symptoms increased significantly from 0 at baseline to 1 (0-3) after 7.5 
cm H2O CPAP (P = 0.002) and to 2 (1-3) after 12.5 cm H2O CPAP (P < 0.001). After CPAP 
at 7.5 cm H2O, 12/22 subjects (55%) experienced at least one nasal symptom; after CPAP at 
12.5 cm H2O, 21/31 subjects (68%) experienced at least one nasal symptom. There was an 
overall increase in the frequency of all of the symptoms during nasal CPAP treatment; the 
most common nasal symptom at both pressures was itchy nose. The higher the pressure, the 
more symptoms were recorded: x
2 
(P = 0.041). 
 
Table 19: Changes in nasopharyngeal symptoms following CPAP application to healthy subjects in 
vivo. 
 
 
 
CPAP 
pressure 
 
Nasopharyngeal symptoms 
Rhino-
rrhoea 
 
PND 
 
Sneezing 
 
Congestion 
 
Anosmia 
Itchy 
nose 
Nose 
Dryness 
Dry 
mouth/ 
throat 
Blocked 
Ears 
Baseline 
(Pre-CPAP) 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
7.5 cm H2O 
(n = 22) 
2 (9%) 
0 
(0%) 
5 (23%) 3 (14%) 0 (0%) 
12 
(54%) 
7 (32%) 4 (18%) 1 (4%) 
12.5  
cm H2O 
(n = 31) 
5 (16%) 
2 
(6%) 
5 (16%) 7 (23%) 0 (0%) 
17 
(55%) 
15 (48%) 
11 
(35%) 
2 (6%) 
 * Data are expressed as numbers (%) of subjects.     
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4.3.4 Relationships between Symptoms and Changes in Nasal Physiology and 
         Inflammation 
 
The data demonstrate relationships between the development of nasal symptoms, nasal 
inflammation and impaired nasal function in vivo. The greater the nasal symptoms with 
CPAP, the slower the nasal mucociliary clearance (r=0.40 p=0.025) and the greater the nasal 
inflammation as assessed by nasal wash IL-6 (r= 0.43 p=0.045), Figures 20.1 and 20.2 
respectively. The significant slowing in nasal clearance was also associated with the degree 
of nasal inflammation, as assessed by nasal MPO concentrations (r = 0.42, P = 0.049), 
illustrated in Figure 20.3. 
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Figure 20: (1) Relationship between nasal mucociliary clearance (saccharin transit time) and 
nasopharyngeal symptoms from 31 healthy subjects after 3 hours of CPAP treatment at 12.5 cm H2O 
(r = 0.40; P = 0.025). (2) Relationship between nasopharyngeal symptoms and nasal wash IL-6 
concentration in 22 healthy subjects after 3 hours of CPAP treatment at 7.5 cm H2O CPAP treatment 
(r = 0.43; P = 0.045). (3) Relationship between nasal mucociliary clearance (saccharin transit time) 
and nasal wash MPO concentration in 22 healthy subjects after three hours 7.5 cm H2O CPAP 
application (r = 0.42; P = 0.049). 
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4.4 DISCUSSION 
We report that CPAP was associated with dose (pressure)-response changes in nasal and 
systemic inflammatory markers, reduced nasal function and the development of nasal 
symptoms. The development of nasal symptoms related to the degree of functional 
impairment and nasal inflammatory response. To the best of our knowledge, this is the first 
report to examine the in vitro and in vivo effects of CPAP in this way, providing new data 
on the mechanisms of CPAP intolerance in the crucial early phase of therapy.  
 
IL-6 is an important pro-inflammatory cytokine. IL-8 is a chemokine that attracts 
neutrophils to the site of inflammation. Our in vivo findings showed a neutrophilic nature of 
inflammation. Neutrophil chemotaxis following epithelial IL-8 release is the likely 
explanation of increased leukocyte count and elevated myeloperoxidase (MPO) activity in 
nasal wash fluid samples since MPO is an enzyme abundantly present in neutrophils. The 
neutrophilic nature of CPAP-induced local inflammation has also been shown in a rat model 
in which early nasal inflammation was mediated by macrophage induced inflammatory 
protein-2 and manifested as neutrophil extravasation following five hours of 10 cm H2O 
CPAP [500]. Paradoxically, in nasal wash fluid samples, IL-8 levels remained unchanged in 
this study at both pressures and an increase in IL-6 levels was only evident in response to 
the higher pressure. This may arise from rapid consumption and binding of interleukins 
before they cross the nasal epithelium. Our study therefore suggests that CPAP itself may be 
pro-inflammatory and that this effect occurs early after initiation of therapy.  
 
In this study, even a brief period of CPAP application resulted in increased IL-6 levels in 
serum suggesting a systemic inflammatory response. However, we did not observe an 
increased systemic IL-8 concentration or MPO activity. The decrease in serum IL-8 levels 
may be due to local recruitment of leukocytes and increased consumption. Unaltered 
systemic MPO activity is plausible since MPO may predominately increase at the site of 
inflammation. Studies in OSA are even more complex as the condition itself is associated 
with up-regulated upper airway inflammation [510-511] and in such circumstances CPAP 
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may not up-regulate this further [512]. The work complements previous findings in patients 
with OSA, where CPAP is known to increase nasal inflammation [298].   
 
This in vivo nasal inflammatory response was associated with clinical and functional 
consequences in that we also demonstrated CPAP reduced nasal clearance and was 
associated with a high prevalence of new nasal symptoms. It has been suggested that the 
presence of nasal inflammation predicts patients at greater risk of discontinuing CPAP 
therapy [513] and IL-8, a potent neutrophil chemoattractant that we have shown is up-
regulated by CPAP in vitro, causes rhinorrhoea when directly instilled to the nose [514]. 
Three hours of CPAP decreased mucociliary clearance at both 7.5 and 12.5 cm H2O in 
healthy individuals. Our findings are contrary to those reported by de Oliviera et al. [382], 
who found significantly decreased STT after 20 minutes of CPAP in healthy individuals. 
This may be attributed to differences in the duration of CPAP treatment and suggests that 
CPAP may provide an initial improvement in nasal clearance that is followed by 
impairment due to inflammation. These inflammatory and functional changes may 
contribute to the high incidence of symptoms and adverse effects associated with CPAP 
treatment. In this study, more than half of the subjects experienced at least one nasal 
symptom after a single session. Previous studies have reported high incidences of side 
effects during long-term therapy, which approached 97% in a large series [98]. To assess the 
duration of symptom changes, in a subsequent pilot experiment we assessed nasal 
symptoms prior to and after 3 hours of CPAP at 12cm H2O, then again at three, six, nine 
and 24 hours later. None of the subjects had nasal symptoms prior to CPAP and all had one 
or more symptom after. A three, six, nine and 24 hours post CPAP the numbers remaining 
symptomatic were 4/5, 1/5, 1/5 and 0/5 respectively suggesting that acute nasal symptoms 
typically last for between three and six hours following initiation of CPAP. 
 
In this study, CPAP treatment did not result in any change in acoustic rhinometry 
parameters in healthy individuals; thus, it did not alter nasal patency. This was unexpected 
given the apparent nasal inflammatory response. Nasal geometry has been reported to affect 
CPAP tolerability [346]. Although the effect of short- or long-term CPAP on acoustic 
rhinometry parameters has not been investigated previously, several studies have reported 
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unaltered rhinomanometry results after long-term CPAP therapy [346, 515]. One study 
reported a reduction in airway resistance after an acute exposure to nasal CPAP for 6 hours 
in healthy CPAP-naïve individuals [282]. In this study, a small but statistically significant 
improvement was identified in lung function parameters (i.e., FVC and PEFR). This 
suggests that the CPAP applied in our subjects had a demonstrable biological effect. 
 
OSA is associated with increased cardiovascular risk [100, 516], as is increased systemic 
inflammation [517]. Whether CPAP reduces cardiovascular risk remains controversial [300-
301, 518-520], but the finding that CPAP itself, at least in the acute setting, is pro-
inflammatory is potentially important regarding the timing of the initiation of therapy. In the 
long-term, Steiropoulos et al. [299] reported significant improvements in systemic 
inflammatory markers, including total lymphocyte counts, CD4
+
 cells, TNF-α levels and 
uric acid levels after six months in patients with good compliance to CPAP therapy; 
however, no such improvements were identified in patients with poor compliance. In 
contrast, Kohler et al. [300] did not find any differences in systemic inflammatory markers, 
high-sensitive C-reactive protein (CRP), plasma IL-6, IFN-γ, and adiponectin levels 
between patients receiving therapeutic and sub-therapeutic CPAP treatments for four weeks. 
Thus, the relationships between CPAP, systemic inflammation, and the duration of therapy 
are complex.  We report small but statistically significant elevation in systemic IL-6 with 
CPAP and it is known that even small changes in long-term IL-6 concentration can be 
associated with excess cardiovascular risk [521]. The effects of acute changes are less well 
studied. 
 
The mechanisms by which CPAP may be pro-inflammatory include airway drying (i.e., not 
using humidification) or direct distension. The possible benefits of humidification have been 
controversial; an experimental study in rats failed to demonstrate any beneficial effects of 
heated humidification on nasal inflammation [522], whereas clinical and experimental 
studies have reported conflicting results on the benefits of humidification [523-524]. Most 
previous in vitro work has used direct distension [525-527], and a mouse model of airway 
stretch for ventilator-associated lung injury was associated with increased expression of the 
murine equivalent of IL-8 [497]. Stretch may affect inflammation via oxidative stress, as 
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stretch-induced IL-6 and IL-8 production can be reduced by the use of anti-oxidants to 
increase intra-cellular glutathione; production can be increased with glutathione depletion 
[528]. Our data add to the literature by reporting a direct effect of pressure rather than 
stretch. It is unlikely that the nasal epithelium is able to accommodate stretch given the 
confines of the nose within the bony structures of the skull. 
 
The strengths of our study include the careful and comprehensive assessment of symptoms, 
upper and lower airway function, and nasal and systemic inflammation, which demonstrated 
a dose response in healthy subjects. Our results have important implications for clinical 
practice. In particular, by demonstrating a relationship between nasal symptoms, 
mucociliary clearance and inflammation, it should be possible to investigate strategies to 
reduce the nasal inflammation associated with CPAP treatment, which may reduce 
symptoms and, therefore, aid compliance. Approaches include anti-inflammatory agents or 
humidification (discussed above), and we have provided further rationale for the 
development of strategies to mitigate nasal inflammation during CPAP therapy. This is 
particularly important as existing nasal corticosteroids appear clinically ineffective [529]. 
An alternative strategy might involve dose titration at the beginning of the therapy (i.e., a 
gradual increase of the pressure until attaining optimal clinical benefits with minimal side 
effects), as we have provided evidence that suggests that the inflammatory effects are dose 
(pressure)-dependent. 
 
This study also has several limitations that need to be considered. Ours was a relatively 
small sample.  Associations observed in the in vivo study do not provide direct evidence for 
a causal relationship between CPAP and airway inflammation. The design of the study may 
have been more robust with the inclusion of a sham CPAP arm but we were concerned that 
even sham CPAP might affect nasal inflammation. We cannot comment on the timing of 
resolution of inflammation associated with CPAP as we were interested primarily in 
induction of this response. Whilst we elected to measure IL-6 and IL-8 to provide 
consistency across the in vivo work, there are alternative markers including CRP and TNF-
alpha that may have provided additional insight into cardiovascular risks associated with 
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CPAP. Finally, as many of our analyses are hypothesis-generating we have not attempted to 
correct analyses for multiplicity and the results should be interpreted in the light of this. 
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4.5 CONCLUSION 
 
In conclusion, we report a high prevalence of nasal symptoms following CPAP therapy in 
healthy subjects associated with changes in nasal function and an inflammatory response in 
the nasal and systemic compartments. This study also suggests that CPAP triggers an early 
pressure-dependent inflammatory reaction, as evidenced by the increased secretion of 
inflammatory markers by cultured bronchial epithelial cells. These findings have 
implications for the adherence of patients to CPAP therapy, especially during the important 
initiation phase. Strategies to combat the initial side effects of this treatment modality and to 
improve compliance and retention might target the epithelial lining of the respiratory system 
in an attempt to address the origin of the inflammatory response. 
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5 
 
LONG-TERM EFFECTS OF 
NASAL CPAP ON SYMPTOMS, 
PHYSIOLOGY, INFLAMMATION, 
AND HEALTH-STATUS IN 
PATIENTS WITH OSA  
 
This chapter comprises an analysis of the effects of nasal CPAP on airway and systemic 
inflammatory indices, airway obstruction and nasal symptoms in OSA patients. The chapter 
also assesses the impact of nasal symptoms, machine side effects and inflammatory effect 
on daytime sleepiness and compliance of CPAP therapy. The results of this work were 
previously presented at the 2010 and 2012 meetings of the American Thoracic Society 
(Appendix One), and a manuscript is currently under review by a peer-reviewed journal. 
 
 
 
 
 
162 
 
5.1 INTRODUCTION 
 
Nasal CPAP is the established treatment for clinically significant OSA [27]. It is a 
distending mechanical split pressure applied at a continuous level throughout the respiratory 
cycle to maintain an open airway, preventing airway collapse during sleep [31, 35]. 
However, CPAP treatment is associated with a high prevalence of side effects [98, 530]. 
Adaptation period is variable ranging from weeks to longer periods and some patients 
discontinue treatment due to side effects. Although the long-term compliance rate is 
generally good, 8- 15% of OSA patients refuse treatment after a single night of use in the 
laboratory setting [493-495, 530]. Nasal congestion, sneezing, anosmia, itchy nose, dry 
nose, mouth, throat and eyes, blocked ears, and dizziness are among the adverse symptoms 
occurring with CPAP use [98].  
 
High frequency of nasal symptoms suggests that CPAP treatment may be related to the 
induction of nasal inflammation. Several clinical and experimental studies have reported on 
local and systemic inflammatory outcomes of nasal CPAP treatment [298, 300-301, 373, 
500, 512, 524]. However, a comprehensive study investigating both nasal and systemic 
inflammatory parameters, clinical symptoms together with structural and functional 
outcomes is lacking. Our previous data in previous chapter in this thesis in in vivo studies 
demonstrated that CPAP induced inflammation. Further investigation is important with 
OSA patients using CPAP therapy, therefore, this chapter will investigate the long-term 
effect of CPAP with OSA patients over six-month period.  
1. This study aimed to investigate the long-term local (nasal) and systemic 
inflammatory effects of nasal CPAP therapy in nasal CPAP naïve OSA patients 
through examination of nasal wash and serum inflammatory markers, in addition to 
examining the changes in nasal symptoms, functional and structural parameters.  
2. It aimed to investigate the changes in nasal symptoms, side-effects and impact on 
health-status associated with long-term nasal CPAP therapy in nasal CPAP-naïve 
OSA patients.  
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5.2  METHODS 
5.2.1 OSA Patients  
 
Twenty-two nasal CPAP treatment-naïve and somnogram test-confirmed obstructive sleep 
apnoea patients attending outpatient clinics at Royal Free NHS, London between November 
2009 and May 2011 were included in this study. Patients received a standard nasal CPAP 
(Respironics REMstar®) at 7.5 cm H2O (n=19) or 10 cm H2O (n=3) fixed pressure without 
humidification, through a nasal mask. The protocol was approved by the Research Ethics 
Committee at Royal Free Hampstead NHS Trust (study reference 09/H0720/24) and was 
conducted in accordance with the Declaration of Helsinki. Informed written consent was 
obtained from all subjects prior to inclusion. 
 
5.2.2 Study Device: CPAP and Patient Interface  
 
The non-invasive respiratory support device used for this study was a standard non-
humidified nasal CPAP (Respironics REMstar®), and the interface to deliver the supportive 
ventilation was nasal mask. 
 
However, the mask that was intended to provide a subject interface for the application of 
non-invasive ventilation was nasal mask. The nasal mask is called Contour Deluxe
TM,
 which 
is designed to provide subjects or OSA patients with an enhanced comfort and leak control. 
The mask comes assembled with a unique one-size-fits-most head strap to enable quicker 
and easier set-up on a patient. 
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5.2.3 Measurements  
OSA patients received nasal CPAP treatment for six months and assessments were 
performed before (baseline) and at one month, three months and at six months after the 
initiation of treatment. The following assessments were made: (i) nasal and systemic 
inflammation marker (interleukin (IL)-6, IL-8 and myeloperoxidase (MPO)) concentrations 
in serum and nasal wash samples, and nasal wash leukocyte count, and (ii) functional 
assessments (spirometry, acoustic rhinometry, and nasal mucociliary clearance). At each 
time point patients were asked to fill in a series of questionnaires regarding their nasal 
symptoms, side-effects of nasal CPAP, daytime sleepiness and compliance. 
 
5.2.3.1 Nasal Wash Sampling  
Nasal wash samples were obtained using a dilution method [327] modified from a technique 
described by Hilding [501] as discussed and validated for repeatability in chapter three. In 
brief, a paediatric tracheostomy tube (Bivona Fome-Cuf, size I.D 2.5 mm; Smiths Medical, 
Kent, UK) was used to collect the nasal lavage. The patient was asked to bend forward, 
sitting with an approximately 45
o
 angle between the chin and the chest. The paediatric 
tracheostomy tube was inserted into one of the nasal orifices, and the cuff was inflated to 
achieve a comfortable seal. Then, 7 ml 0.9% room-temperature saline solution was instilled 
slowly through the tracheostomy tube using a syringe and drawn back. This process was 
repeated once more; thus, the nasal cavity was washed in and out twice. A clean funnel tube 
was used to collect any leaked fluids during the removal of the tube from the nose, and this 
fluid was added to the sample. The technique was repeated for the other nasal cavity using 
another syringe, and the two recovered solutions were pooled for analysis. To ensure 
standard conditions, all sampling procedures were performed by the same investigator.  
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5.2.3.2 Nasal Wash Sampling Process for Analysis of Inflammatory 
Mediators 
The total portion of the pooled nasal wash fluid from both nostrils was collected in a 15 ml 
centrifuge tube and processed for the analysis of inflammatory mediators and leukocyte 
count as below. The total pooled nasal wash sample was mixed for 15 seconds on the vortex 
mixer and then centrifuged for 10 minutes at 2000 rpm at 4°C for a supernatant analysis of 
inflammatory cytokines, and the remainder to yield a cell-pellet for leukocyte count. 
Aliquots of supernatant were collected and stored at -80°C for interleukins IL-(6), IL-8 and 
MPO assay. All samples in this thesis were processed within a maximum of two hours from 
collection.   
 
5.2.3.3 Nasal Wash Sampling Process for Leukocyte Count  
The cell pellet was re-suspended in 1 ml of phosphate-buffered saline (PBS) solution and 
gently mixed. A 50 ul aliquot was taken out into a 1.5ml Eppendorf tube and 50 ul of trypan 
blue stain was added and carefully mixed. This suspension was then used for the leukocyte 
count using a Neubauer haemocytometer. 
 
5.2.3.4 Serum Sampling and Processing 
Peripheral venous blood samples were obtained for serum measurements. A 5 ml of sample 
of venous blood was collected in to a sterile vacutainer, centrifuged at 2000 rpm for 10 
minutes at 4°C, and the supernatant was stored at -80°C for later analysis of inflammatory 
mediators.  
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5.2.3.5 Samples Analysing and Reporting  
Measurements of the inflammatory cytokines (IL-6, IL-8 and MPO) in nasal wash 
supernatants and serum were performed by a standard ELISA. The ELISA kits were 
obtained from R&D Systems, Abingdon, UK.  
 
The limits of detection of the kit were 0.70 pg/ml for (IL-6), 3.5 pg/ml for (IL-8), and 1.5 
ng/ml for MPO. 
 
5.2.4 Physiological Assessments 
 
For nasal airway obstruction, acoustic rhinometry was used and pulmonary airway 
obstruction, spirometry were used. For nasal mucociliary clearance, STT was used to assess 
the function of nasal clearance. All measurements were conducted on the same standardised 
protocols in the studies in this thesis.  
 
5.2.4.1 Acoustic Rhinometry 
 
Acoustic rhinometry measurements were performed in accordance with a previously 
published protocol [362], as discussed and validated in chapter three. Briefly, It allows 
measurement of the relationship between cross-sectional area and the distance of the nasal 
cavity by a sound-pulse propagating in the nasal cavity which reflected by local changes in 
acoustic impedance to calculate nasal cross-sectional area. All measurements were 
performed by the same operator in the same air-conditioned room to provide similar 
conditions with regard to temperature, humidity and ambient noise levels. The following 
five important acoustic rhinometry variables were assessed and examined separately: (i) 
outermost minimum cross-sectional area (MCA1), (ii) D-MCA1, (iii) innermost minimum 
cross-sectional area (MCA2), (iv) D-MCA2, and (v) V2-5. Area and volume values from 
the right and left nostrils were summed to obtain a combined value to account for variations 
with the nasal cycle. 
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5.2.4.2 Spirometry 
 
Spirometry was measured and recorded using a Vitalograph 2160 (Maids Moreton, 
Buckingham, UK). A bronchodilator was not administered. The best of three attempts at 
spirometry was measured and recorded.  We recorded forced expiratory volume in 1 second 
(FEV1), forced vital capacity (FVC), FEV1/FVC ratio and peak expiratory flow rate (PEFR). 
 
5.2.4.3 Mucociliary Clearance Time: in vivo 
 
Via the aforementioned process we aimed to investigate in vivo the long-term effect of nasal 
CPAP on the mucociliary clearance time with OSA patients. The protocol of the study has 
been discussed in Chapter Four. 
 
5.2.5 Questionnaires 
 
At each evaluation visit, diary cards, nasal symptoms using a six-point nasal score, Epworth 
sleepiness scale (ESS), and compliance and periodicity questionnaires were collected for 
six-month periods.   
5.2.5.1 Diary Cards 
 
Patients also recorded daily, on diary cards, their hours of CPAP use and any change in 
respiratory symptoms and treatments over time. These diary cards were modified versions 
of diary cards that have been used successfully by the London COPD cohort [531-535] and 
others for years [427, 536-539].  
 
This diary card data also enable calculation of an individual patient‟s compliance to CPAP 
therapy and any other changes in symptoms that may cause the interruption of CPAP 
compliance. 
 
At recruitment, patients are taught how to record on diary cards their daily hours of CPAP 
use, and any changes in symptoms and treatments, using the detailed instructions at the back 
page of the dairy cards. Patients are reviewed after the use of CPAP therapy after one 
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month, three months and six months in the research clinic, to monitor compliance with data 
collection, and record changes in medication. 
 
An example of a diary card and the instructions provided to the OSA patients are presented 
in Appendix Six. 
 
5.2.6 Assessment of Nasal Symptoms 
Subjects were asked to report any respiratory symptoms experienced on a regular basis 
during their visits to the research clinic. The six-point nasal score has been discussed in 
Chapter Four.  
 
5.2.7 Epworth Sleepiness Scale 
ESS is a simple, self-administered questionnaire which provides a measurement of the 
subject's general level of daytime sleepiness, as discussed in the introduction to this thesis. 
In this study, ESS was administered to the OSA patients at recruitment visit before using 
CPAP therapy and during their follow up visits of using CPAP for six months. An example 
of a six-point nasal score is given in Appendix Five. 
 
5.2.8 Compliance and Periodicity Questionnaire 
The compliance and periodicity questionnaire was designed to study the adverse effects and 
the compliance with CPAP therapy in the OSA patients at baseline and during each visit 
made by patients.  
The questionnaire asked about compliance and periodicity of the use of nasal CPAP. Side-
effects examined in detail included adverse effects of the nasal mask, discomfort to the 
bridge of the nose, and air leaks near the eyes or over the face. The questionnaire also asked 
about dryness of the nose or mouth in the mornings on wakening, symptoms of sinusitis, 
nasal drip, sneezing, nasal congestion, nasal bleeding and air swallowing. The questionnaire 
is detailed in Appendix Eight. 
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5.2.9 Statistical Analysis 
 
Data were analysed using GraphPad Prism 5 software (GraphPad Software Inc., La Jolla, 
CA, USA) and SPSS version 18.0 (SPSS Inc, Chicago, Ill).. The Kolmogorov–Smirnov test 
of normality was applied. Normally distributed data were expressed as means with standard 
deviations (SD), and skewed data for inflammatory indices were rendered normal by log10 
transformation. Pearson (r) and Spearman (rho) correlations were conducted as appropriate 
to examine relationships between variables. To evaluate the change in inflammatory and 
physiological indices over time, one-way repeated measures ANOVA was run to examine 
differences between treatments, followed by post-hoc Bonferroni multiple comparison tests. 
To evaluate the changes in 6-point nasal score over time, a Friedman test was used and 
further post hoc tests were done using Wilcoxon Signed Rank test with Bonferroni 
correction. ESS scores were analysed with repeated measures ANOVA with Greenhouse-
Geisser correction with further post-hoc tests conducted with a Bonferroni correction. A P 
value < 0.05 was considered statistically significant. A P value < 0.05 was considered 
statistically significant. 
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5.3 RESULTS 
 
5.3.1 Patient Characteristics 
 
The baseline demographics of the 22 patients enrolled into the study are shown in Table 20. 
The study cohort had a mean age of 59.5 ± 7.5; a mean BMI of 34.6 ± 8.6; 13 were male 
(59%) and 9 were female (61%). At the time of recruitment, 22.7% were current smokers. 
Figure 21 shows the study sequence and the reurtiemnt of OSA patients in the study.  
 
Table 20: Characteristics of the OSA patients*. 
 
Details of subjects 
studied 
 
Mean SD 
Age, years 59.5 7.5 
BMI (kg/m2) 34.6 8.6 
AHI (events/h) 30.2 15.9 
Neck circumference  37.2 1.5 
CPAP (cm H2O) 7.84 0.87 
* at the time of recruitment; BMI, body mass index;  
AHI, apnoea hypopnoea index; SD, standard deviation 
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Figure 21: Flowchart of the OSA patients in the study. 
 
 
5.3.2 Changes in Nasal and Systemic Inflammation with CPAP 
 
Changes in systemic and nasal inflammatory parameters over time are shown in Table 21. 
Figure 22-A shows post-hoc analysis and Figure 22-B shows data plotted as tends within 
patients individually. Among systemic inflammatory parameters, only serum MPO level 
showed significant change at the end of study with significantly lower levels compared to 
baseline and 1 month. On the other hand, all inflammatory parameters measured in nasal 
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wash samples showed significant change throughout the study period. Nasal wash IL-6 
levels showed an initial decrease at 1 month followed by a gradual increase thereafter. Nasal 
wash IL-8 and cell count started to increase after 1 month. Increased nasal wash MPO levels 
on the other hand was only evident at the end of the study period. Cell count showed 
gradual increase.   
 
Table 21: Changes in inflammatory markers in serum and nasal wash fluid at baseline and after one 
month, three months and six months visits of nasal CPAP treatment. 
 
Data are expressed as mean (SD). One-way ANOVA repeated measure. *Post hoc Bonferroni 
multiple comparison tests. ** P value < 0.05 was considered statistically significant. IL, interleukin; 
MPO, myeloperoxidase; CPAP, continuous positive airway pressure. 
 
 
 
 
 
 
Marker (n = 22)            After nasal CPAP        ANOVA 
Baseline One month Three months  Six months P value 
Inflammatory markers in serum  
IL-6, log10 pg/ml 0.80 (0.38) 0.83 (0.41) 0.79 (0.38) 1.08 (0.29) 0.052 
IL-8, log10 pg/ml 1.32 (0.14) 1.27 (0.11) 1.26 (0.22) 1.35 (0.21) 0.30 
MPO, log10 ng/ml 2.84 (0.31) 2.87 (0.20) 2.73 (0.20) 2.59 (0.24) 0.002 
Inflammatory markers in nasal wash sample  
Leukocyte count, 
log10 cells/ml 
4.14 (0.14) 4.16 (0.13) 4.29 (0.14) 4.34 (0.17) < 0.001 
IL-6, log10 pg/ml 0.55 (0.29) 0.35 (0.26) 0.71 (0.22) 0.72 (0.23) < 0.001 
IL-8, log10 pg/ml 1.95 (0.41) 1.96 (0.35) 1.98 (0.37) 2.30 (0.21) 0.003 
MPO, log10 ng/ml 2.05 (0.35) 1.90 (0.37) 1.94 (0.30) 2.20 (0.24) 0.019 
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Figure 22-A: Effect of nasal CPAP in systemic and nasal inflammatory markers. Lines represent 
mean and standard error. Significant differences illustrated using ANOVA with post-hoc analysis. 
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Figure 22-B: Effect of nasal CPAP in systemic and nasal inflammatory markers. Date plotted as 
trends within patients individually. Significant differences illustrated using ANOVA with post-
hoc analysis. 
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5.3.3 Changes in Physiology with CPAP 
 
Among physiological parameters studied, only FVC (l), MCA2 and nasal mucociliary 
clearance showed significant change (Table 22, Figures 23 and 24). Increase in FVC was 
evident after 3 months. An increased MAC2 value was detected only at 6 months when 
compared to baseline. On the other hand, saccharin transit time increased gradually starting 
from the first month. Saccharin transit time has shown to be slower with an increase in nasal 
inflammation as evident by nasal wash IL-6 concentration, (Figure 25). 
 
Table 22: Changes in lung function, rhinometry findings and nasal mucociliary clearance at 
baseline and after one month, three months and six months visits of nasal CPAP treatment. 
 
 
Parameter 
(n = 22)            After nasal CPAP        ANOVA 
Baseline One month Three months  Six months P value 
Lung function test  
FEV (l) 2.93 (0.41) 2.93 (0.44) 3.17 (0.53) 2.94 (0.52) NS 
FEV1 % 84.01 (5.38) 86.96 (4.19) 85.99 (4.29) 84.72 (4.69) NS 
FVC (l) 3.22 (0.43) 3.42 (0.50) 3.78 (0.66) 3.71 (0.58) 0.001 
FVC % 82.79 (4.42) 82.18 (4.08) 81.54 (5.67) 83.96 (4.93) NS 
FEV1/FVC ratio 84.93 (6.11) 84.72 (6.57) 85.63 (6.67) 85.13 (5.71) NS 
PEFR (l) 505.2 (59.81) 537.1 (60.42) 549.7 (50.10) 537.0 (56.96) NS 
Acoustic rhinometry   
MCA1 0.44 (0.12) 0.42 (0.12) 0.40 (0.11) 0.41 (0.11) NS 
DMCA1 2.15 (0.32) 2.13 (0.27) 2.24 (0.23) 2.20 (0.36) NS 
MCA2 1.67 (0.28) 1.79 (0.53) 1.97 (0.42) 1.98 (0.52)  0.021 
DMCA2 4.32 (0.42) 4.27 (0.44) 4.49 (0.56) 4.35 (0.53) NS 
V2-5 5 (1.01) 4.87 (0.95) 5.12 (0.75) 5.18 (0.80) NS 
Nasal mucociliary clearance 
STT, seconds 16.82 (4.61) 20.14 (4.97) 21.06 (4.14) 21.95 (3.81) < 0.001 
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Data are expressed as mean (SD). One-way ANOVA repeated measure. *Post hoc Bonferroni 
multiple comparison tests. ** P value < 0.05 was considered statistically significant. FEV, forced 
expiratory volume; FVC, forced vital capacity;  PEFR, peak expiratory flow rate; MCA1, outermost 
minimum cross-sectional area; DMCA1, the distance of the MCA1 from the nasal orifice; MCA2, 
innermost minimum cross-sectional area; DMCA2, the distance of the MCA2. 
 
 
 
 
 
Figure 23: Effect of nasal CPAP in rhinometry findings. Lines represent mean and standard error. 
Significant differences illustrated using ANOVA with post-hoc analysis. 
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Figure 24: Effect of nasal CPAP in lung function. Lines represent mean and standard error. 
Significant differences illustrated using ANOVA with post-hoc analysis. 
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Figure 25: Correlation between nasal wash IL-6 levels and saccharin transit time.  
 
 
5.3.4 Compliance with CPAP  
 
According to patient diary card records there was no significant change in the average daily 
use of nasal CPAP during the six month study period (Table 23). Recorded dairy card nasal 
CPAP usage was slightly higher than the average self-reported daily use of nasal CPAP 
(5.05 h ± 0.62) recorded at each study visit. 59% of patients reported to use nasal CPAP 
every night. The rate of lack of benefit of the machine decreased during the study period, 
with six patients (27%) reporting lack of benefit at one month, 4 (18%) at three months and 
only 2 patients (9%) reporting lack of benefit at six months (Figure 26).  
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Table 23: Daily hours of nasal CPAP use according to patient diary cards. 
Daily average nasal CPAP use Mean (SD) 
At one month visit (hours) 5.28 (0.66) 
At 3 months visit (hours) 5.02 (0.63) 
At six months visit (hours) 5.21 (0.56) 
 
 
 
 
Figure 26: Variation in rate of lack of benefit from CPAP use with time. 
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5.3.5 Changes in Nasal Symptoms with CPAP 
 
Table 24 shows the frequency of each condition of six-point nasal score at different time 
points. Six-Point nasal score increased significantly in relation to time throughout the study 
period (Friedman Test, Χ2(3) = 15.205, p = 0.002; Figure 27). Whereas at the baseline and 1 
month time points most patients recorded no conditions on the Six-Point Scale, at 6 months 
most patients were experiencing one or more of the conditions on the scale. Further post-
hoc Wilcoxon Signed Rank tests with a Bonferroni correction (p < 0.05/6 < 0.0083) 
revealed a significant increase in the Six-Point Scale score between baseline and 6 months 
(p = 0.006).   
 
The most commonly reported intra-nasal side-effects with nasal CPAP use were dry nose 
and dry mouth, reported by more than 50% of patients after nasal CPAP use, followed by 
rhinorrhoea and nasal blockage (Figure 28.1). A small number of patients reported 
sneezing, blood-stained mucus and epistaxis (Figure 28.1).  Reported side–effects of the 
nasal mask included mask discomfort, air leak, sore eyes and nasal pain (Figure 28.2) 
whilst the most commonly reported machine-related side-effect was noise, Figure 28.3. A 
significant negative correlation was found between reduced compliance and increased report 
of nasal mask side-effects (r = -0.79, p=0.035; Figure 29).  
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Table 24: Frequency of the number of conditions for each time point for the Six-Point 
Nasal Scale. Conditions recorded on the scale rhinorrhoea, postnasal drip, nasal congestion, 
sneezing, reduced smell, and itchy nose. 
 
No. of  
Conditions 
Time Points 
Baseline 1 month 3 months 6 months 
0 14 12 11 5 
1 6 6 4 8 
2 2 1 4 5 
3 0 1 2 2 
4 0 1 0 0 
5 0 1 1 2 
6 0 0 1 0 
 
 
 
 
Figure 27: Six-Point Scale from baseline to 6 months. A Friedman Test showed that there was a 
statistically significant effect of time on Six Point Scale score (x
2
(3)= 15.205, p=0.002). Further post-hoc 
Dunns tests revealed a significant increase in the Six-Point Scale score between baseline and 6 months 
(p=0.006). 
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Figure 28: (1) Intra-nasal side effects by use of nasal CPAP. (2) Side-effects due to nasal mask. (3) 
Nasal CPAP-related side effects. 
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Figure 29: Correlation between compliance and side-effects due to the nasal mask. 
 
5.3.6 Changes to Sleep Quality with CPAP  
 
A statistically significant effect on time was observed in relation to the ESS score (F(2.187, 
45.929) = 12.514, p < 0.0005; Figure 30). The ESS score progressively decreased 
throughout the study period from an initial mean score of 10.8 ± 1.1 at baseline. At one 
month the mean ESS score had decreased by 2.0 ± 0.9 (p = 0.221) compared to baseline, 
whilst at three and six months statistically significant decreases of 2.5 ± 0.8 (p = 0.041) and 
4.7 ± 0.9 (p < 0.0001) were observed respectively. Significant decreases in the ESS scores 
were also observed between the one month and six month time points (2.7 ± 0.8, p = 0.016) 
and between three and six months (2.3 ± 0.7, p = .028). Analysis for potential correlations 
between inflammatory cytokine levels and sleep quality identified a significant positive 
correlation between increased IL-6 levels in nasal wash and reduced sleep quality according 
to the Epworth Sleepiness Scale (r = 0.492, p = 0.023; Figure 31).  
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Figure 30: ESS score from baseline to 6 months. Data are mean ± standard error. * denotes 
statistically significantly different from baseline. 
$
 denotes statistically significantly different from 1 
month to 6 months. † denotes statistically significant difference from 3 months to 6 months. 
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Figure 31: Correlation between nasal wash IL-6 concentrations with ESS. 
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5.4 DISCUSSION 
We report that long-term use of nasal CPAP induces local nasal inflammation as evidenced 
by increased levels of all inflammatory markers in nasal wash fluid samples. Parallel to 
these changes, patients experienced increase of nasal symptoms with time at the end of the 
study compared to baseline, further confirming local inflammatory nature of nasal CPAP. 
Commonly reported side-effects were in line with previous studies [173, 98] and included 
dry nose and mouth, rhinorrhoea and nasal blockage. Patients also reported significant 
problems related to the mask, particularly discomfort and pain in the nose and eyes, and 
related to the machine itself, although only a small proportion found that the machine was 
preventing themselves or their partner from sleeping. Systemic inflammatory markers on the 
other hand did not change significantly, except for a significant improvement in serum MPO 
levels. Our findings provides insight on the mechanisms of CPAP intolerance in the crucial 
early phase of therapy and complements our previous study of short-term in vivo and in 
vitro effect of CPAP on healthy subjects and culture work [173] and other findings in 
patients with OSA, which suggests that CPAP increases nasal inflammation [512]. 
 
Several studies have tested the local inflammatory effects of nasal CPAP treatment. In an 
experimental study, the short-term mechanical stimulus triggered by nasal CPAP resulted in 
increase in neutrophils and overexpression of macrophage inflammatory protein-2 in tissue 
samples of rats [500]. Inflammatory effects of nasal CPAP treatment have also been shown 
in patients with OSA, both in the long- and short term [301, 373, 512, 524]. Skoczynski et 
al. [298] demonstrated significant increase in total cell count of nasal wash samples after 
short-term CPAP treatment in sleep apnoea syndrome patients qualifying for CPAP 
treatment, but not in patients with mild to moderate disease or in healthy controls. 
Constantinidis et al. [505] showed fundamental changes in nasal epithelium of subjects that 
underwent 3-10 months of nasal CPAP treatment on electron microscopic examination, 
including modifications in epithelial cell shape, conglutination and clumping of the 
microvilli and the appearance of immunocompetent cells. On the other hand, Lacedonia et 
al. [512] showed high levels of nasal neutrophilic inflammation among OSA patients before 
administration of nasal CPAP, when compared to controls. However, this nasal 
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inflammatory profile did not change in patients after 60 days of nasal CPAP treatment. This 
study evaluated several important inflammatory markers in nasal wash fluid and all of them 
increased after long-term nasal CPAP treatment, providing additional evidence supporting 
its local inflammatory nature. 
 
In this study, long-term treatment did not change systemic inflammatory parameters 
measured in the serum, except for a decrease in MPO levels. In the long-term, Steiropoulos 
et al. [299] reported significant improvements in systemic inflammatory markers, including 
total lymphocyte counts, CD4
+
 cells, TNF-α levels and uric acid levels after six months in 
patients with good compliance to CPAP therapy; however, no such improvements were 
identified in patients with poor compliance. In contrast, Kohler et al. [300] did not find any 
differences in systemic inflammatory markers, high-sensitive CRP, plasma IL-6, IFN-γ, and 
adiponectin levels between patients receiving therapeutic and sub-therapeutic CPAP 
treatments for four weeks. Thus, the relationships between CPAP, systemic inflammation, 
and the duration of therapy are complex. OSA itself may cause systemic inflammation and 
adequate nasal CPAP therapy may improve the condition. 
 
The increase in nasal inflammatory markers was associated with clinical and functional 
consequences. We also demonstrated that CPAP reduced nasal clearance and was associated 
with an increase in 6-point nasal score. Our findings are contrary to those reported by de 
Oliviera et al. [382] in the short-term, who found significantly decreased STTs after 20 
minutes of nasal CPAP in healthy individuals. This may be attributed to differences in the 
duration of nasal CPAP treatment, and suggests that nasal CPAP may provide an initial 
improvement in nasal clearance that is followed by impairment due to inflammation. 
Inflammatory and functional changes may contribute to the high incidence of symptoms and 
adverse effects associated with nasal CPAP treatment. Previous studies have reported high 
incidences of side effects during long-term therapy, which approached 97% in a large series 
[98]. 
 
In this study, despite apparent inflammatory response, nasal CPAP treatment did not result 
in any change in acoustic rhinometry parameters in OSA patients, except for an increased 
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MCA2 value after 6 months of treatment. Bossi et al. [515] have reported unaltered 
rhinomanometry results after long-term nasal CPAP therapy. Another study reported a 
reduction in airway resistance after an acute exposure to nasal nasal CPAP for 6 hours in 
healthy CPAP-naïve individuals [282]. Lack change in nasal geometry in the long term may 
be explained by adaptation. Additionally, a significant FVC improvement was identified in 
this study, indicating a demonstrable biological effect. 
 
The mechanisms by which CPAP may be pro-inflammatory include airway drying (i.e., not 
using humidification) or direct distension. However, the possible benefits of humidification 
have been controversial. An experimental study in rats failed to demonstrate any beneficial 
effects of heated humidification on nasal inflammation [522], whereas clinical and 
experimental studies have reported conflicting results on the benefits of humidification 
[523-524].  
 
The presence of side effects was significantly associated with reduced compliance, 
demonstrating the importance of identifying improved strategies for reducing nasal CPAP-
related adverse effects. Interestingly however, long-term nasal CPAP use was also 
associated with a reduction in the reported lack of benefit and an improvement in sleep 
quality. These findings suggest that if patients are able to tolerate side effects into the longer 
term, the perceived benefit and improvement to sleep quality may shift the balance towards 
patients being more complaint with therapy. This is reflected in the compliance data, which 
show that overall hours of nasal CPAP use did not change during the study period 
suggesting that for many patients worsening side effects may be balanced by improvements 
to sleep quality. Alternative strategies to improve compliance may therefore involve 
improving patients‟ tolerance of side effects. Studies of treatment compliance in other 
diseases have found that patients who are prepared for side effects and educated on how to 
manage them are more likely to adhere [540]. Strategies to improve nasal CPAP adherence 
may therefore also focus on improved communication between patients‟ and their 
physicians, and encouragement of physicians to openly discuss potential side effects and 
how these can be managed.  
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Our previous studies, and those of other groups, have demonstrated significant associations 
between the long-term use of nasal CPAP and increased local (nasal) inflammation, 
including levels of the cytokines IL-6 and IL-8 [173, 298, 300, 373, 500, 512]. In this study 
we found a significant correlation between increased IL-6 levels in nasal wash samples and 
reduced sleep quality. These results demonstrate that local inflammation is not only 
associated with an increase in side effects and reduced compliance but also with reduced 
sleep quality. Hence, strategies to reduce nasal inflammation and associated side effects 
may also improve sleep quality, which in turn may encourage patients to continue nasal 
CPAP thereby further improving compliance. 
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5.5 CONCLUSION 
 
The results of this study have important implications for clinical practice by demonstrating a 
relationship between the presence of side-effects and reduced compliance, and between 
increased inflammation and reduced quality of sleep. These findings underline the need for 
further investigation of strategies to reduce the nasal inflammation associated with CPAP 
treatment in an attempt to improve compliance. Such strategies may target the epithelial 
lining of the nose to address the origin of the inflammatory response. In addition, 
educational and support strategies to improve patients‟ tolerance of side effects may further 
increase compliance with nasal CPAP treatment for OSA patients. 
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6 
 
IN VITRO STUDY: 
EFFECT OF CPAP ON HUMAN 
CULTURED BRONCHIAL 
EPITHELIAL CELLS 
 
This chapter presents an alternative approach to the investigation of the upper and lower 
airway through in vitro study of a human bronchial epithelial cell line, grown in a cell-
culture system. It reports the analysis of the effect of short-term exposure of CPAP on the 
bronchial cell lines. The work has been published in the European Respiratory Journal [137] 
attached as Appendices One and Two, and has been presented at the American Thoracic 
Society in 2012.   
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6.1  INTRODUCTION 
 
The upper airway wall, and more specifically its mucosa, is subjected to a continuous 
mechanical compression by nasal CPAP that triggers a biological response in the airways 
[496, 500], and induces an inflammatory process [291].  
 
Several clinical and experimental studies have reported on the local and systemic 
inflammatory outcomes in association with CPAP treatment or mechanical ventilation in 
general with relatively less emphasis on the cascade of local events in response to 
continuous high pressure at the level of bronchial epithelium [298-299, 497-500]. Cell 
culture studies on the other hand are scarce and mainly focused on stretch injury rather than 
air pressure. However, we also sought to investigate the similarity or otherwise the effects 
on different level of mechanical pressures using CPAP on a bronchial epithelial cell line.  
 
This chapter reports a novel study of a human bronchial epithelial cell line (BEAS-2B), 
grown in a cell-culture system, assessing release of the inflammatory cytokines IL-6 and IL-
8 over 4 time intervals using CPAP therapy.   
 
Therefore, we wished to determine whether CPAP is associated with pressure- and time-
dependent release of inflammatory cytokines from cultured human bronchial epithelial cells, 
in an attempt to provide insight into mechanisms associated with early local inflammation 
taking place at the beginning of CPAP treatment. 
 
This study aimed to examine in vitro the secretion of two key interleukins (IL)-6 and IL-8 
by bronchial epithelial cell cultures (BEAS-2B) in response to continuous positive air 
pressure during several hours of application, and at two separate pressures (low-and high- 
response) 
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6.2 METHODS 
 
6.2.1 Study Materials  
 
All chemicals and reagents were of tissue culture grade and, unless otherwise stated, were 
obtained from the Sigma – Aldrich Chemical Co. (Poole, UK). Enzyme-linked 
immunosorbent assay (ELISA) kits used for the measurement of cytokines were purchased 
from R&D Systems Europe Ltd (Abingdon, UK). 
 
6.2.2 Culture of Bronchial Epithelial Cells 
 
6.2.2.1 Cell Culture: BEAS-2B Cells. 
 
BEAS-2B cells, a virus-transformed human bronchial epithelial cell line, were obtained 
from American Type Culture Collection (Manassas, VA, USA) [541]. The cell-lines were 
cultured in 75 cm culture flasks in complete culture Medium 199 containing 1% (v/v) 
antibiotic / antimycotic solution composed of penicillin, streptomycin and amphotericin B 
(Sigma, UK). The antibiotic / antimycotic solution contained 10,000 units penicillin G, 10 
mg streptomycin and 25 mcg amphotericin B per millilitre. When the cells became fully 
confluent the culture medium was removed and the cells were washed with 10 ml of sterile 
phosphate buffered saline (PBS). The PBS was then discarded after which 2-3 ml 
Trypsin/EDTA (Ethylenediaminetetraacetic acid)(0.25%, w/v) was added for 3 to 5 minutes 
to disperse the cells, to enable them to be transferred to 6 cm Falcon „Primera‟ culture 
dishes (Becton Dickinson, Oxford, UK). Cultures were then incubated (Galaxy R;Wolf 
Laboratories, York, UK) in 2 ml fresh, sterile, complete culture medium containing 10% 
foetal calf serum (Sigma - Aldrich), 5 ml antibiotic / antimycotic solution, and 4 ml of each 
of the following: bovine pancreatic insulin (2.5 mcg/ml), human transferrin (2.5 mcg/ml), 
hydrocortisone (0.36 mcg/ml) and L-glutamine (0.02 mg/ml) made up to a final volume of 
500 ml in Medium 199 and filter sterilised through a 0.22 μm syringe filter. Cells were then 
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incubated for one to three days at 37
o
C in 95% air in 5% CO2. The appearance of the cells at 
this stage is illustrated as Plate 12. 
 
 
 
 
Plate 12: Appearance of bronchial epithelial cells during culture. 
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6.2.3 Cell-Culture Exposure Experiments 
 
 
6.2.3.1 Experimental Protocol 
  
Cultured BEAS-2B was independently exposed in vitro with CPAP pressure in a chamber at 
0, 4 and 7 cm H2O for one, two, three, or four hours after which the release of cytokine 
concentration was measured in the culture medium. The protocol is summarized as Figure 
32. 
 
 
 
 
Figure 32: The experimental protocol of cell-culture exposure. 
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Ten tissue culture dishes size (60 x 15 mm) were used at each time-point. The day prior to 
the experiment, complete medium was removed and replaced with 2 ml of 199 
medium/antibiotics and incubated at 37
o
C in 95% air in 5% CO2 overnight, and replaced the 
next morning before the experiment with fresh 5 ml 199 medium/antibiotics. The cells were 
then incubated for 5 minutes and 125 µl aliquots of cell culture supernatant were removed at 
zero time before any pressure application and stored at -80
o
C for later analysis.  
 
The experimental equipments are shown in diagrammatic form as Figure 33. CPAP 
(REMstar®), at a fixed pressure of 4 or 7 cm H2O, was applied by incubating the cells in a 
air-tight chamber (4.6 l capacity) for the appropriate time, with 10 replicates per time point. 
The machine leak alarm was monitored to ensure that pressure was being delivered to the 
cells. The air-tight chamber was placed inside a 60-litre capacity acrylic SI.60 incubator 
(Stuart Scientific, Redhill, England, UK) to ensure conditions of controlled temperature 
reflecting that occurring in the nasal airway (31-33ºC), and close to 98% humidity (in 
contrast to our in vivo studies) by placing a tissue culture dish size (150 mm diameter) with 
20 ml of sterile water in the chamber. Humidity was monitored using a Hygro-thermometer. 
 
 
Figure 33: Diagrammatic form for the experimental equipments. 
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At the end of each time-interval for the allocated pressure, and at which point the 
experiment was terminated, 1 ml cell culture supernatant aliquots were removed. The 
remaining medium was then removed and the cells were harvested by scraping the cells in 1 
ml of 199 medium only. All experimental medium and cell scrapes were stored at -80
o
C for 
later analysis. Control experiments, not exposed to CPAP were also run for each of the four 
time points. 
 
6.2.3.2 Physical Manipulations 
 
Under standard conditions, the exposure polycarbonate chamber was tilted gently, at 
intervals of 2.5 s, to an angle of 10
o
 from the horizontal in each quarter of the horizontal 
plane on a Luckham 4RT rocking table (Luckham Ltd, Burgess Hill, England, UK), thereby 
momentarily displacing approximately half the medium covering the surface of the culture 
plate during each tilt to expose the cells to the pressurized gas air, humidified air. To ensure 
that the temperature was kept stable at 37
o
C during exposure, the entire system was placed 
in a 60-litre capacity acrylic SI.60 incubator (Stuart Scientific, Redhill, England, UK), as in 
Plate 13.  
198 
 
 
 
Plate 13: Set-up of cell-culture experimental equipments. 
 
Pressure exposure of BEAS2B was homogenously distributed in the chamber. To the best of 
our knowledge, this had never been studied before and we designed and conducted our 
experiments carefully. According to the kinetic theory of gases, since the gas particles are 
always in motion the gas will diffuse homogenously over the cell chamber to occupy all 
available space. In addition, the cell chamber was sealed to keep the number of gas 
molecules, N, constant. The other experimental constants were volume, V, and temperature, 
T. This means that since N, V and T are constants, the gas law P V = N K T results in a 
constant pressure inside the chamber. To ensure this experimentally, the cell chamber was 
supplied with CPAP at a constant 4 or 7 cm H2O. The platform will not produce any 
considerable turbulent flow since the gauge pressure (4 or 7 cm H2O) is only slightly above 
atmospheric pressure. We therefore believe that the chamber pressure is uniformly 
distributed, transmitted to the cells and independent of the medium covering the cell 
surface. Finally, in an attempt to mimic the mechanical and physiological conditions of the 
199 
 
intranasal cavity, a rocking platform displacing approximately half of the medium covering 
the surface of the culture plate during each tilt was employed to directly expose the cells to 
pressurised, humidified air.  
 
6.2.4 Measurements of Inflammatory Cytokines in Cell-Culture Supernatant 
 
The cell-culture supernatant samples were analysed for IL-6 and IL-8 by ELISA kits. To 
account for differences in sizes of the culture, cytokine concentration were expressed 
accounting for total cellular protein. Total cell protein concentrations were measured by a 
modified Lowry assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA) [542]. This assay is 
based on the treatment of the protein content of a sample with a copper reagent which reacts 
with phenolic amino acids producing a measurable blue colour. Total protein content is 
determined spectrophotometrically. All results were expressed as pg cytokine/µg cellular 
protein, and Figure 34 shows the best-fit line standard curve of our analysed kits. 
 
 
Figure 34: Standard curve graph involving the best-fit line. 
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6.2.5 Statistical Analysis 
Data were analysed using GraphPad Prism 5 software (GraphPad Software Inc., La Jolla, 
CA, USA) and SPSS version 18.0 (SPSS Inc, Chicago, Ill). The Kolmogorov–Smirnov test 
of normality was applied. One-way ANOVAs were run to examine dose-response 
differences between cell culture responses to CPAP over several hours of application, 
followed by post-hoc Tukey‟s multiple comparison tests. Multiple linear regression analyses 
were performed to determine a set of independent variables (time and pressure) that 
predicted in vitro cytokine productions. A P value < 0.05 was considered statistically 
significant.  
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6.3 RESULTS 
 
6.3.1 Time-Dependent Changes in IL-6 and IL-8 Concentrations 
 
CPAP was associated with both time- and pressure (dose)-dependent release of the 
inflammatory cytokines IL-6 and IL-8 from cultured BEAS-2B cells in vitro. These data are 
reported in Table 25 and illustrated in Figure 35 and 36. 
 
Table 25 shows that in vitro data of CPAP was associated with both a time, and pressure 
(dose)-dependent release of inflammatory cytokines from cultured BEAS-2B cells in vitro. 
At 4 and 7 cm H2O, IL-6 and IL-8 concentrations after 1, 2, 3 and 4 hours of CPAP were 
significantly raised ANOVA p=<0.001. 
 
 
Table 25: CPAP is associated with time and pressure dependent release of IL-6 and IL-8 from 
cultured BEAS-2B cells in vitro. 
 
IL-6 pg/g of protein 
                
Mean (SD) 
  
ANOVA 
1 hour 2 hours 3 hours 4 hours P value* 
Baseline 0.01 (0.001) 0.01 (0.002) 0.01 (0.015) 0.01 (0.002) 0.334 
Control (no CPAP) 0.01 (0.002) 0.01 (0.003) 0.01 (0.004) 0.01 (0.002) 0.743 
CPAP 4 cm H2O 0.01 (0.005) 0.02 (0.005) 0.02 (0.005) 0.02 (0.008) 0.017 
CPAP 7 cm H2O 0.03 (0.005) 0.07 (0.014) 0.08 (0.016) 0.10 (0.051) <0.001 
ANOVA P= <0.001 <0.001 <0.001 <0.001  
Posthoc 4 vs control† 0.012 0.016 0.09 0.649  
Posthoc 7 vs control† <0.001 <0.001 <0.001 <0.001  
Posthoc 4 vs 7 control† <0.001 <0.001 <0.001 <0.001  
202 
 
Data are expressed as the means (SD). One-way ANOVA test. † Post hoc Tukey‟s multiple 
comparison tests. * P value < 0.05 was considered statistically significant. 
 
 
In linear regression analysis, both pressure and time independently contributed to release of 
IL-6 and IL-8 (IL-6 adjusted R
2
=0.55, p<0.001;IL-8 adjusted R
2=0.60, p<0.001 time β 
0.278 and 0.399, pressure β 0.694 and 0.671 respectively). 
 
In the group that did not receive positive pressure, neither IL-6 (p=0.12) nor IL-8 (p=0.36), 
Figure 35 (A) concentrations changed significantly over time. At 4 cmH2O pressure, IL-6 
secretion significantly increased at 2 hours compared to baseline and high concentrations 
were maintained until the end of the experiment (p<0.0001 for overall difference), and the 
time course of IL-6 concentrations was similar at 7 cmH2O (p=0.0009), Figure 35 (B). 
Similarly, IL-8 secretion significantly increased at two hours compared to baseline and 
maintained thereafter, at both 4 and 7 cmH2O pressure (overall p<0.0001 for both 
conditions as in Figure 35 (C). 
 
 
 
 
IL-8 pg/g of protein    
Baseline 0.01 (0.003) 0.01 (0.004) 0.02 (0.02) 0.01 (0.004) 0.470 
Control (no CPAP) 0.01 (0.011) 0.01 (0.004) 0.01 (0.006) 0.02 (0.009) 0.569 
CPAP 4 cm H2O 0.04 (0.03) 0.09 (0.022) 0.11 (0.014) 0.15 (0.040) <0.001 
CPAP 7 cm H2O 0.06 (0.013) 0.09 (0.030) 0.11 (0.022) 0.14 (0.062) <0.001 
ANOVA P= <0.001 <0.001 <0.001 <0.001  
Posthoc 4 vs control† 0.005 <0.001 <0.001 <0.001  
Posthoc 7 vs control† <0.001 <0.001 <0.001 <0.001  
Posthoc 4 vs 7 control† <0.001 <0.001 <0.001 <0.001  
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204 
 
21 (C) 
 
 
Figure 35: Time-dependent changes in IL-6 and IL-8 concentrations. 
 
 
6.3.2 Effect of Pressure-Dependent Level on the Secretion of Inflammatory 
         Mediators      
 
 
When the means of all measurements done under each pressure level were compared, 
secretion of IL-6 by cell cultures subjected to 7 cm H2O were significantly higher when 
compared to the cultures that received 4 cm H2O pressure and the cultures received no 
pressure at all (p<0.0001 for overall difference) as in Figure 36 (A).  
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22 (A)                                                                      
  
 
 22 (B) 
 
Figure 36: Effect of pressure-dependent level on the secretion of inflammatory mediators. 
 
 
However, IL-8 concentrations did not change significantly between positive pressure 
groups, although both 4 and 7 cm H2O groups had significantly higher secretion compared 
to the no pressure group as in Figure 36 (B). 
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6.4 DISCUSSION 
 
This study obtained direct evidence for the increased secretion of IL-6 and IL-8 by 
bronchial epithelial cells in response to continuous positive air pressure, providing a 
plausible explanation for the origin of the early inflammatory side effects of nasal CPAP 
observed in substantial number of patients at the onset of treatment. This study is unique in 
examining the early inflammatory consequences of continuous [low-to-high] pressure using 
bronchial epithelial cell culture. In contrast, most experimental studies so far have focused 
on systemic inflammatory markers or lung microvasculature. Previous cell culture studies 
on the other hand, used different models utilising mechanical stretch rather than applying 
direct air pressure [525-527]. To the best of our knowledge, this is the first report to 
examine in vitro effects of CPAP in this way.  
  
Findings from the in vitro component of this study provided direct evidence for cytokine 
(IL-6 and IL-8) secretion by bronchial epithelial cells in response to CPAP in a pressure- 
and time-dependent manner. IL-6 is an important pro-inflammatory cytokine. IL-8 is a 
chemokine serving as a chemical signal that attracts neutrophils to the site of inflammation. 
 
Most information on the inflammatory effects of CPAP comes from studies conducted with 
obstructive sleep apnoea patients. Nasal CPAP treatment seems to induce an inflammatory 
response at the early stages of treatment [298], partly explaining the high incidence of side 
effects at the onset of treatment [98]. However, in the long-term, these effects seem to be 
offset by the improvement of the obstructive sleep apnoea [299, 301], which itself is 
inflammatory in nature, and by tolerance of the patient, resulting in acceptable compliance 
rates in the long term [98, 298].  
 
Early inflammatory effects of airway distention through lung hyperinflation have already 
been demonstrated in healthy individuals. Administration of up to 20 cm H2O CPAP by a 
face mask for a short period of time resulted in increased serum concentrations of several 
cytokines including the ones investigated in the present study (TNF-α, IL-1β, IL-6, IL-8, IL-
10, and IL-12), which returned to normal concentrations after 12 hours [264]. 
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Most evidence on the potential inflammatory effects of mechanical ventilation in general 
comes from experimental studies using various animal models. In a mouse model, 
strain/injury induced by mechanical ventilation was associated with an increase in 
concentrations of a murine equivalent of IL-8 and its receptors [497]. In another animal 
study, all measured inflammatory mediators including plasma interleukin (IL)-1α, IL-1β, 
tumor necrosis factor- α, IL-6, and IL-10 were increased progressively in lung tissue with 
increasing duration of mechanical ventilation [498]. Even low mechanical ventilation 
pressures have been found to contribute increased lung cytokine response in another 
experimental study [499]. 
 
Lim et al. [496] examined the degree of leukocyte recruitment to the airway in the 
postcapillary venules of mechanically ventilated rats and found increased leukocyte 
recruitment after 1 hour of PEEP application, which was inhibited by the blockage of 
endothelin receptor and selectin, suggesting an ongoing pro-inflammatory process. In 
another animal study, PEEP induced changes in rat trachea were investigated with findings 
suggesting an important role for P-selectin and ICAM-I in the observed leukocyte 
recruitment in postcapillary endothelium after airway distention. The effects of nasal CPAP 
on nasal mucosa has been investigated in a rat model and five hours of 10 cm H2O nasal 
CPAP resulted in early nasal inflammation mediated by macrophage inflammatory protein-2 
that manifested itself by neutrophil extravasation [500]. Macrophage inflammatory protein-
2 is a rodent chemokine homologous to human interleukin-8. 
 
Studies on cytokine release from human lung cell cultures in response to conditions that 
resemble increased airway pressure are relatively scarce. Based on evidence from such 
studies, lung microvascular and alveolar endothelial cells appear to produce metalloproteins 
and IL-8 -a powerful chemokine for neutrophil activation-, respectively, upon stretch injury 
[525-527]. However, none of these studies has used positive pressure application as in the 
present study, which may better mimic the effects of continuous positive airway pressure. 
 
When a distending force is applied to the airways, it is primarily withstood by the fibre 
system located in the basal membrane and all the cells that are attached to this extracellular 
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structure have to accommodate their shape. In the meantime, up-regulation of inflammatory 
cytokines may occur through interplay between signaling molecules. Taking this potential 
mechanism into account, the present study mainly focused on the molecular aspects of 
possible local inflammatory responses at the level of bronchial epithelium to increased 
pressure; we therefore utilised an isolated cell culture model. Although stress/strain 
relationship in cell culture may not be equivalent to that is observed in vivo due to the 
complex architecture of the bronchial wall as well as the absence of vascular and fibrous 
structures, we believe that the available data may be considered as offering a unique 
perspective to explain the distinct role of bronchial epithelium in the cascade of 
inflammatory events, since it represents the first structure to come into contact with high 
pressure.  
 
Both interleukins tested in this study are markers of early inflammation. Interleukin-6 is an 
important pro-inflammatory cytokine that takes part in the induction of acute phase response 
of inflammation. IL-8 is a powerful chemokine for neutrophil activation. In this study, the 
secretion of both interleukins increased in response to pressure stimuli starting from the 
second hour of the experiment and the same concentrations of secretion were maintained 
throughout the whole duration of the study. On the other hand, IL-6 concentrations seem to 
be dependent on the amount of pressure with high IL-6 concentrations less than 7 cmH2O 
compared to 4 cmH2O. However, such a difference between pressure concentrations is not 
evident for IL-8 concentrations. These findings suggest that continuous pressure applied 
throughout the bronchial tree triggers an inflammatory response within the first few hours 
mainly originated from bronchial epithelial cells. Chemokine production on the other hand 
seem to be pressure independent with an early rise regardless of the level of pressure, 
whereas pro-inflammatory process appears to be more powerful under higher pressure 
concentrations.  
 
The mechanisms by which CPAP may be pro-inflammatory include airway drying (i.e., not 
using humidification) or direct distension. The possible benefits of humidification have been 
controversial, and our in vitro work, in which cells were exposed to high-humidity, 
demonstrates that drying or the absence of humidification alone cannot be solely responsible 
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for the pro-inflammatory changes observed. An experimental study in rats failed to 
demonstrate any beneficial effects of heated humidification on nasal inflammation [522], 
whereas clinical and experimental studies have reported conflicting results on the benefits of 
humidification [523-524]. Stretch may affect inflammation via oxidative stress, as stretch-
induced IL-6 and IL-8 production can be reduced by the use of anti-oxidants to increase 
intra-cellular glutathione; production can be increased with glutathione depletion [528]. 
Stretch induced IL-8 and IL-6 production were significantly inhibited when intracellular 
GSH was increased by antioxidants and productions of these interleukins were decreased 
when intracellular GSH was depleted, suggesting that oxidant release may play a role in 
lung cell stretch-induced cytokine release, and antioxidants, may protect lung cells against 
this injury. However, these experimental data need to be tested in clinical setting. 
 
Our data add to the literature by reporting a direct effect of pressure rather than stretch. It is 
unlikely that the nasal epithelium is able to accommodate stretch given the confines of the 
nose within the bony structures of the skull. The pressures we selected for the in vitro work 
were necessarily different from the in vivo work, as higher pressures in vitro resulted in 
excessive evaporation of the cell culture fluid. Our results have important implications for 
clinical practice. 
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6.5 CONCLUSION 
 
The findings of this study states that continuous pressure applied to the airway epithelial 
triggers early inflammatory reaction originated from bronchial cells as evidenced by the 
increased secretion of inflammatory markers IL-6 and IL-8 by epithelial cells. These 
findings have implications for the adherence of patients to CPAP therapy, especially during 
the important initiation phase. Future strategies to combat the initial side effects of this 
treatment modality and to improve compliance and treatment retention may targets 
epithelial lining of respiratory system, in an attempt to address the origin of inflammatory 
response. 
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7 
PILOT STUDY: AIRWAY AND 
SYSTEMIC INFLAMMATION IN 
PATIENTS WITH STABLE COPD 
 
This chapter presents an analysis of airway and systemic inflammatory indices in two 
matched groups of patients with stable COPD. The first group uses NIV whereas the other 
group never used NIV. This chapter is a pilot study. 
   
7.1 INTRODUCTION 
In previous chapters, we investigated the in vivo and in vitro effect of CPAP on 
inflammatory indices. The results revealed that the CPAP induces early airway and systemic 
inflammation [173]. COPD is a chronic lung inflammatory disease with significant extra-
pulmonary effects which may contribute to disease severity in individual patients [231, 
244], and greater lower airway inflammation in the stable state [543]. However, the effect of 
NIV on stable COPD patients has not been investigated with inflammatory markers. 
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Therefore, this chapter presents an investigation of the effect of NIV on inflammatory 
indices in patients, compared to a matched patient group which never received NIV therapy.   
COPD affects approximately 5% of the adult population and is one of the leading causes of 
acute respiratory failure [544]. Bilevel positive pressure airway therapy has become a 
mainstay treatment for patients with an acute exacerbation of their COPD (AECOPD). Its 
use is supported by strong evidence from both  observational and interventional studies 
which demonstrate the benefit of this therapy in reducing mortality, complications, length of 
hospital stay and need for intubation for patients with AECOPD [545-549]. For patients 
with severe, stable COPD, the role of nocturnal bilevel positive pressure airway therapy as a 
long-term management strategy is more controversial. However, there is a growing body of 
evidence suggesting that long-term use of bilevel positive pressure airway therapy is 
associated with improvements in physiological parameters, including blood gas data and 
pulmonary hyperinflation, as well as exercise endurance and subjective symptom scores 
[550-553]. Bilevel positive pressure airway therapy may therefore also favourably impact 
long-term survival in these patients.  
Several clinical and experimental studies have demonstrated local and systemic 
inflammatory responses to the use of ventilator support [298, 264, 496-500]. In our own 
study we have demonstrated that CPAP use in healthy subjects and in cell-cultures is 
associated with dose-dependent up-regulation of nasal inflammatory markers [173]. This 
inflammatory response may be a result of stretch stress imposed on pulmonary parenchyma 
by hyperinflation, resulting in release of inflammatory cytokines by alveolar macrophages 
[265-266, 554-557]. To date, clinical studies have focused on the inflammatory response to 
NIV in healthy subjects without evidence of inflammatory activity. It is currently unknown 
whether use of bilevel positive pressure airway therapy in COPD, a disease that is 
associated with local airway and systemic inflammation, causes further up-regulation of the 
inflammatory response.  
We hypothesised that in patients with COPD, bilevel positive pressure airway therapy 
therapy would be associated with an increased airway and systemic inflammatory response, 
compared with COPD patients who are not using bilevel positive pressure airway therapy.  
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This study aimed to compare the effect of bilevel positive pressure airway therapy on 
airway and systemic inflammation in COPD patients that had used bilevel positive pressure 
airway therapy for more than three months with a matched group that had never used bilevel 
positive pressure airway therapy. 
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7.2 METHODS 
7.2.1 Study Subjects 
Ten patients with moderate COPD were enrolled into the study from the London COPD 
cohort. Five of the 10 patients had been on bilevel positive pressure airway therapy for more 
than three months whilst the other five patients had never used this therapy.  The protocol 
was approved by the Research Ethics Committee at Royal Free Hampstead NHS Trust 
(study reference 09/H0720/24) and was conducted in accordance with the Declaration of 
Helsinki. Informed written consent was obtained from all subjects prior to their inclusion in 
the study. 
Samples of sputum (induced), nasal wash and serum were obtained at a single clinic visit. 
The following assessments were made: nasal and systemic inflammation (interleukin (IL)-6, 
IL-8 and myeloperoxidase (MPO) concentration in serum and nasal wash samples), and 
nasal wash leukocyte count. 
 
7.2.2 Measurements  
7.2.2.1 Nasal and Systemic Inflammation 
Measurements of the inflammatory cytokines (interleukin (IL)-6, IL-8 and MPO) in nasal 
wash supernatants and serum were performed using a standard ELISA technique, as 
discussed in previous chapters.  
 
7.2.3 Physiological Assessments 
The best of three attempts at spirometry was recorded using a Vitalograph 2160 (Maids 
Moreton, Buckingham, UK). We recorded forced expiratory volume in 1 second (FEV1), 
forced vital capacity (FVC), FEV1/FVC ratio and peak expiratory flow rate (PEFR). 
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7.2.4 Statistical Analysis 
 
Data were analysed using GraphPad Prism 5 software (GraphPad Software Inc., La Jolla, 
CA, USA). The Kolmogorov–Smirnov test of normality was applied. Independent t-tests 
were conducted to compare the matched COPD groups. A P value less than 0.05 was 
considered statistically significant. 
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7.3 RESULTS 
 
The baseline and clinical characteristics of the two groups (five subjects per group) enrolled 
in the study are described in Table 26. The majority of subjects were male. Both groups had 
similar mean ages, smoking history and spirometry assessment results.  
 
Table 26: Clinical characteristics of the two groups of matched moderate COPD patients. Each matched 
group includes five COPD patients. Group one had used bilevel positive pressure airway therapy 
therapy for more than three months and the other group never used bilevel positive pressure airway 
therapy. Data is expressed as mean (SD). 
 
 COPD BILEVEL 
POISITIVE THERAPY 
 USED 
n =5 
COPD  
NO THERAPY  
USED 
n =5 
Age (years) 72.1 (7.1) 67.6 (6.9) 
Male gender 3 4 
FEV1 (l) 1.19 (0.39) 1.34 (0.2) 
FEV1 (% predicted) 46.6 (12.1) 45.2 (11.2) 
FVC (l) 2.42 (0.87) 2.9 (0.62) 
FEV1/FVC (%) 44.5 (14.2) 41.6 (13.9) 
Smoking (pack years) 44.6 (24.1) 43.8 (23.3) 
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7.3.1 Relationship of NIV Therapy to Nasal and Systemic Inflammation in 
COPD Patients 
Inflammatory markers in sputum, nasal and serum samples were compared between COPD 
patients who used bilevel positive pressure airway therapy and those who had never used 
this therapy. Results are presented in Table 27. No significant differences were observed 
between patients who used bilevel positive pressure airway therapy and those who had 
never used this therapy in the levels of inflammatory markers in the sputum, nasal wash or 
serum. Small, but statistically insignificant, increases in nasal wash leukocyte counts and 
IL-8 levels, and in sputum inflammatory markers were observed.  
 
Table 27: Comparison of sputum, nasal wash and serum from two groups of stable COPD patients 
(five patients using bilevel positive pressure airway therapy and five who had never used this 
therapy). Data is reported as mean (SD).  Comparisons use unpaired t-tests.  
 
 COPD  
(BILEVEL POISITIVE 
THERAPY 
 Group) 
COPD  
(NO THERAPY 
Group) 
 
UNPAIRED 
 n=5 n=5  
 Mean (SD) Mean (SD) p= 
SPUTUM    
Leukocyte Count (log10 cells/ml) 5.87 (0.44) 6.19 (0.39) 0.26 
IL-6 (log10 pg/ml) 1.28 (0.67) 1.80 (0.52) 0.21 
IL-8 (log10 pg/ml) 3.42 (0.14) 3.39 (0.17) 0.16 
MPO (log10 ng/ml) 3.80 (0.10) 3.30 (0.66) 0.14 
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NASAL WASH    
Leukocyte Count (log10 cells/ml) 4.95 (0.74) 3.88 (0.86) 0.068 
IL-6 (log10 pg/ml) 0.42 (0.38) 0.41 (0.18) 0.96 
IL-8 (log10 pg/ml) 2.34 (0.39) 1.82 (0.54) 0.13 
MPO (log10 ng/ml) 2.18 (0.21) 2.10 (0.30) 0.65 
SERUM    
IL-6 (log10 pg/ml) 0.49 (0.16) 0.53 (0.24) 0.78 
IL-8 (log10 pg/ml) 1.10 (0.23) 1.10 (0.17) 0.99 
MPO (log10 ng/ml) 2.94 (0.06) 2.91 (0.08) 0.54 
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7.4 DISCUSSION 
The main finding of this pilot study was that the use of bilevel positive pressure airway 
therapy in patients with stable COPD did not cause an increase in local or systemic 
inflammatory responses compared with patients who had never used this therapy. To the 
best of our knowledge, this is the first study to examine the inflammatory response to non-
invasive supportive ventilation in COPD patients. 
COPD is characterised by a progressive and not fully reversible limitation to airflow, 
accompanied by an abnormal inflammatory response mediated by macrophages, 
lymphocytes and neutrophils together with various chemokines, cytokines and proteinases. 
This inflammatory activity contributes directly to disease pathogenesis through the 
remodelling of pulmonary tissues and also plays an important role in the comorbidity often 
observed in COPD patients [558]. Notably, increased expression of inflammatory 
mediators, including IL-6, has been associated with reduced lung function and poorer 
prognosis in COPD [559]. Moreover, increased systematic IL-6 concentration is associated 
with increased cardiovascular risk [521]. Avoiding potential additional triggers of 
inflammation may therefore have an important impact on disease progression and outcome.   
There is increasing evidence that the use of non-invasive ventilation methods may be 
beneficial to patients with stable COPD. However, such interventions may stretch the lung 
parenchyma beyond its physiological limits due to the application of high pressure to the 
airways. This can lead to modulation of the expression pattern of inflammatory and anti-
inflammatory molecules in the lung and drive a lung-injury induced inflammatory response. 
A number of studies in healthy patients with no underlying inflammatory activity 
corroborate this theory, demonstrating increased leukocyte recruitment and cytokine 
infiltration both locally and systemically in response to mechanical ventilation [298, 265-
266, 555]. As increased inflammatory activity has been associated with poorer long-term 
prognosis and increased comorbidities in COPD, these studies suggest the use of bilevel 
positive pressure airway therapy may amplifies COPD-specific inflammatory activity and 
worsen prognosis and systematic health. This would counteract the potential long-term 
benefit to lung function. Our study therefore examined whether the levels of key 
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inflammatory molecules involved in COPD pathogenesis were amplified in patients who 
had used bilevel positive pressure airway therapy for more than 3 months. However, in 
contrast to the results observed in patients with healthy lung-function, we were unable to 
detect any differences in the inflammatory responses of COPD patients who used 
ventilatory support when compared with those who did not. Notably, these results are in line 
with a recent study which examined the impact of bilevel positive pressure airway therapy 
on systemic inflammatory response and lung structure in patients undergoing a 
subarachnoid block for small or medium surgical procedures [560]. The researchers found 
no difference between the inflammatory response of patients receiving a single lung 
hyperinflation manoeuvre and a control group, suggesting lung hyperinflation did not 
further amplify the systemic inflammatory response triggered by the surgical procedure. 
Similarly, Puls and colleagues et al. [265] were unable to detect changes in the systemic 
levels of either inflammatory or anti-inflammatory cytokines in patients with atelactasis 
following lung hyperinflation.  
In contrast, a recent study in patients with acute respiratory distress syndrome (ARDS) 
found an association between the use of mechanical ventilation and an increase in cytokine 
levels both systemically and locally in the lung [557]. The authors concluded that 
inflammation in response to ventilator therapy may partially explain the high rate of 
multiple organ failure and mortality observed in ARDS patients. These high rates are 
despite the apparent improvement in management provided through the use of mechanical 
ventilation support. Notably, a further study demonstrated a reduction in mortality rate with 
concommittant use of lung protection strategies to reduce the stress insult caused by 
hyperinflation on the lungs [561]. These studies suggest strategies to avoid lung injury 
whilst providing mechanical ventilation should be further explored in chronic lung disease. 
This study has several limitations which must be considered. Most notably, the sample size 
was low. Whilst no statistical associations could be detected with this sample size, an 
increase in sample size may provide sufficient power to identify statistically significant 
differences in inflammatory activity between the two populations. In this study we have 
measured the activity of IL-6, IL-8 and MPO, important inflammatory molecules in COPD. 
However, there are additional markers which may have provided further insight into the 
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inflammatory effects of bilevel positive pressure airway therapy in COPD and associated 
comorbidity risk. Further work may therefore explore a wider range of inflammatory 
markers in a larger study population.  
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7.5 CONCLUSION 
 
This study has found that the use of bilevel positive pressure airway therapy in patients with 
COPD does not have an additive effect on disease-specific inflammation. The ability to 
adjust inspiratory and expiratory pressures independently with bilevel positive pressure 
airway therapy may result in fewer symptomatic and hence inflammatory effects compared 
with the delivery of constant pressure as with those of CPAP. However, with the conflicting 
current literature in this field and given the limitations of this study, further investigation to 
draw a definitive conclusion on the potential inflammatory effects of bilevel positive 
pressure airway therapy in patients with stable COPD is warranted.  
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8 
CONCLUSIONS AND SUGGESTIONS 
FOR FUTURE STUDIES 
 
 
The upper and lower airways are anatomically distinct, but are interrelated in many ways. 
Similarities between them include common triggers, pathogenic mechanisms, many of the 
inflammatory cells and mediators, as well as treatment modalities.  
This thesis was undertaken to test the hypothesis that the non-invasive respiratory support is 
a pro-inflammatory stimulus to the upper and lower airways. This hypothesis was tested on 
human bronchial epithelial cell-lines, healthy subjects, and OSA and COPD patients. 
This chapter summarises the main findings of this thesis, with reference to the stated 
hypothesis and aims of chapter two, and concludes with suggestions for future studies based 
on the present results of this thesis. 
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8.1 CONCLUSIONS  
The key findings of this thesis study may be summarised thus: 
1. CPAP resulted in early induction of inflammation. 
 
2. CPAP was associated with both time- and pressure (dose)-dependent release of the 
inflammatory cytokines IL-6 and IL-8 from cultured BEAS-2B cells in vitro. 
 
3. In linear regression analysis, both CPAP pressure and time independently 
contributed to release of IL-6 and IL-8 from cultured BEAS-2B cells in vitro. 
 
4. In vitro study demonstrated that even when cultured BEAS-2B cells were exposed to 
high-humidity, the drying or the absence of humidification alone cannot be solely 
responsible for the pro-inflammatory changes observed. 
 
5. Acoustic rhinometry provides highly repeatable measurements of nasal patency, 
which is best for combined (mean) nasal parameters. This property makes it suitable 
for use in the diagnosis and follow-up of conditions associated with nasal 
obstruction, either structural or functional. 
 
6. The newly developed nasal lavage technique utilizing a paediatric tracheostomy tube 
provides highly repeatable cytokine and cell-count measurements over successive 
sessions.   
 
7. In healthy subjects, both 7.5 and 12.5 cm H2O of nasal CPAP pressures over three 
hours resulted in significant increases in nasal inflammation as assessed by nasal 
wash leukocyte and MPO measurements. 
 
8. Only a higher pressure, measured at 12.5 cm H2O of nasal CPAP pressure, 
administered over three hours, and to healthy subjects, resulted in an increase in 
nasal IL-6 and IL-8 concentrations. 
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9. Further evidence shows that both pressures also resulted in changes in systemic 
inflammatory markers, with significant increases in serum IL-6 concentrations and 
decreases in serum IL-8 concentrations following three hours of nasal CPAP. 
 
10. Physiologically, at both pressures (7.5 and 12.5 cm H2O), three hours of nasal CPAP 
treatment resulted in a significant slowing of nasal clearance (i.e. increased saccharin 
transit time). 
 
11. There was also association at both pressures (7.5 and 12.5 cm H2O) of nasal CPAP 
with small but significant changes in FVC and PEFR. 
 
12. There was an overall increase in the frequency of all of the symptoms during nasal 
CPAP treatment in healthy subjects. The higher the pressure, the more symptoms 
were recorded. 
 
13. In vivo data demonstrated relationships between the development of nasal 
symptoms, nasal inflammation and impaired nasal function. The greater the nasal 
symptoms with CPAP, the slower the nasal mucociliary clearance and the greater the 
nasal inflammation. 
 
14. Long-term use of nasal CPAP induces local nasal inflammation in OSA patients as 
made evident by the significant changes occurring within all inflammatory 
parameters used to measure nasal wash samples. 
 
15. There was a relationship between physiological changes and inflammation in OSA 
patients. Saccharin transit time has been shown to be slower with an increase in 
nasal inflammation in OSA patients, as made evident by nasal wash IL-6 
concentration. 
 
16. The same significant improvement in lung function in healthy subjects is also seen in 
OSA patients after six months of CPAP therapy, as made evident by an increase in 
FVC. 
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17. OSA patients experienced an increase in nasal symptoms with time compared to 
baseline, further confirming the local, inflammatory nature of nasal CPAP. 
 
18. The ESS score progressively decreased throughout the study period. 
 
19. Patients also reported significant problems related to the mask, particularly 
discomfort and pain in the nose and eyes, as well as problems relating to the 
machine itself, although only a small proportion found that the machine was 
preventing themselves or their partner from sleeping. 
 
20. There was a significant, positive correlation between inflammatory cytokine levels 
and daytime sleepiness: increased IL-6 levels in nasal wash was found to correlate 
with reduced sleep quality according to the Epworth Sleepiness Scale 
 
21. Long-term nasal CPAP use was also associated with a reduction in the reported lack 
of benefit and an improvement in sleep quality. 
 
22. Compliance data showed that overall hours of nasal CPAP use did not change during 
the six month period, suggesting that, for many patients, worsening side effects may 
undermine improvements to sleep quality. 
 
23. These results demonstrated that local inflammation is not only associated with an 
increase in side effects and reduced compliance but also with reduced sleep quality 
which in turn impacts on quality of life for OSA patients. 
 
24. In the pilot study of matched COPD groups, the results showed no changes in the 
inflammatory markers but further investigation may be needed in order to draw a 
definitive conclusion. This is due to the limitations stated in the study, e.g. sample 
size. 
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Therefore, with regard to the specific aims of the thesis, described in chapter 2: 
 
 Is CPAP a pro-inflammatory stimulus to human bronchial epithelial cell-lines 
in a culture model? 
Yes, CPAP proved to be a pro-inflammatory stimulus to bronchial epithelial cells. 
The results of CPAP exposure to the cell-culture experiments demonstrated that 
there was both time- and pressure (dose)-dependent release of the inflammatory 
cytokines IL-6 and IL-8. This direct evidence of the effect of pressure, rather than 
stretch for the increased inflammatory cytokines, exerted by bronchial epithelial 
cells in response to CPAP, provided a plausible explanation for the origin of the 
early inflammatory side effects of nasal CPAP observed in a substantial number of 
patients at the onset of treatment as we have reported in our in vivo study [173]. 
 
 Is CPAP a pro-inflammatory stimulus in healthy subjects? 
In two healthy subjects groups with no prior history of nasal symptoms or disease, 
one exposed to higher and one to lower CPAP pressure, CPAP was associated with 
dose (pressure)-response changes in nasal and systemic inflammatory markers, 
reduced nasal function, and the development of nasal symptoms after receiving three 
hours of CPAP therapy. The development of nasal symptoms related to the degree of 
functional impairment and nasal inflammatory response. The greater the nasal 
symptoms with CPAP in those healthy subjects, the slower the nasal mucociliary 
clearance and the greater the nasal inflammation as assessed by nasal wash IL-6. Our 
in vivo findings are in line with the in vitro findings, particularly with regard to the 
neutrophilic nature of inflammation. 
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 Is CPAP a pro-inflammatory stimulus in OSA patients?  
We report that CPAP results in the release of inflammatory mediators from the in 
vitro study and in healthy control subjects. CPAP was also associated with changes 
in nasal and systemic inflammatory markers, reduced nasal function and the 
development of nasal symptoms [173]. All these findings are also in line with the 
OSA findings. Yes, long-term use of nasal CPAP induces local nasal inflammation 
with OSA patients, as evidenced by increased levels of all inflammatory markers in 
nasal wash fluid samples. Parallel to these changes, patients experienced an increase 
of nasal symptoms over time compared to the baseline, further confirming the local, 
inflammatory nature of nasal CPAP. Commonly reported side-effects were in-line 
with previous studies [173, 98] and included dry nose and mouth, rhinorrhoea and 
nasal blockage. Patients also reported significant problems related to the mask, 
particularly discomfort and pain in the nose and eyes, and related to the machine 
itself, although only a small proportion found that the machine was preventing 
themselves or their partner from sleeping. Our findings provide insight into the 
mechanisms of CPAP intolerance in the crucial, early phase of therapy and 
complement our previous study of the short-term in vivo and in vitro effect of CPAP 
on healthy subjects and culture work [173] and other findings in patients with OSA, 
which suggests that CPAP increases nasal inflammation [299]. 
 
 Is NIV a pro-inflammatory stimulus in a matched group of COPD patients? 
As in stable COPD, there is a relationship between the degree of upper and lower 
airway inflammation at exacerbation. This pilot matched study of ten COPD patients 
(5 patients with no bilevel positive pressure airway therapy and the other five on 
bilevel positive pressure airway therapy) has shown no changes in local or systemic 
inflammatory indices in both groups. Notably, this finding is in line with a recent 
study which examined the impact of this therapy on systemic inflammatory response 
and lung structure and showed no changes in inflammatory markers in patients 
undergoing a subarachnoid block for small or medium surgical procedures [560].  
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However, more research is needed in order to draw a definitive conclusion regarding 
the potential inflammatory effects of bilevel positive pressure airway therapy in 
patients with stable COPD. We draw attention to the fact that the sample size in the 
study was low and whilst no statistical associations could be detected with this 
sample size, an increase in sample size may suffice to identify statistically 
significant differences in inflammatory activity between the two groups. 
 
 Subsidiary aims to validate acoustic rhinometry and a novel upper airway 
sampling methodological techniques used in this thesis: 
3. To examine the validity of intersession repeatability of acoustic rhinometry 
measurements of unilateral and combined nasal parameters in a group of healthy 
subjects.   
We examined the intersession repeatability of acoustic rhinometry using ICC on 
averaged combined and separate nostril minimum cross-sectional areas and nasal 
volumes in healthy subjects. We showed for the first time that acoustic 
rhinometry provides excellent reproducible results, best over different sessions 
when combined nasal parameters values are used, as opposed to right or left 
nostrils separately. This finding advocates use of such an approach for the 
follow-up of conditions associated with structural or functional obstructions. 
4. To establish the repeatability and acceptability of a novel upper airway sampling 
technique we have developed, employing a paediatric tracheostomy tube (TT). 
We examined the intersession repeatability of a newly developed nasal lavage 
technique utilizing a paediatric tracheostomy tube. To our knowledge, few 
studies have examined the repeatability of different nasal lavage techniques for 
clinically relevant parameters and varying results have been obtained. The main 
findings of this study suggest that the newly developed nasal lavage technique 
utilizing a paediatric tracheostomy tube provides highly repeatable cytokine and 
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cell count measurements over successive sessions, with a better sealing of the 
nasal opening and comfort. 
 
8.2  SUGGESTIONS FOR FUTURE STUDIES 
The following is a set of suggestions for further research in the field..   
 
 To perform a comprehensive evaluation of sham-CPAP effects in healthy 
subjects with and without sham-CPAP. This would give a better 
understanding of the mechanism and origin of the inflammatory effects. The 
use of sham-CPAP is currently the placebo intervention of choice in RCTs 
evaluating the effectiveness of CPAP treatment [562-563].  
 A thorough assessment and evaluation is needed of recovery from symptoms 
and changes in mediators after CPAP therapy in healthy subjects. 
 Further work is required to explore the role of humidification. Although we 
showed that in in vitro work, exposure of cell-cultures to high-humidity 
demonstrated that drying or the absence of humidification alone cannot be 
solely responsible for the pro-inflammatory changes observed. Also an 
experimental study in rats failed to demonstrate any beneficial effects of 
heated humidification on nasal inflammation [522], whereas clinical and 
experimental studies have reported conflicting results on the benefits of 
humidification. Therefore, this needs to be investigated carefully in two 
controlled groups with and without humidification. 
 In addition to the acute inflammatory markers we selected for our study 
which provided us with the answers to the hypothesis and aims of this thesis, 
it is also important to further investigate other cardiovascular risk biomarkers 
such as hsCRP and TNF-alpha. It is important to mention that the major 
stimulus to CRP release is IL-6 and this is the reason we selected IL-6 rather 
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than CRP, together with the fact that it is also produced by epithelial cells 
(unlike CRP) making direct comparison between our in vitro and in vivo data 
possible using this marker 
 A nasal steroids trial study, we believe, is needed to investigate whether 
nasal steroids would help to alleviate the nasal symptoms and thus reduce 
nasal inflammation, which in turn improves compliance.  A study by Strobel 
showed no effect of nasal steroids on nasal symptoms in CPAP. This was 
disappointing from a clinical perspective, but the study did not assess nasal 
inflammatory markers and it remains possible that a different anti-
inflammatory compound that is effective in reducing nasal inflammation may 
reduce troublesome nasal symptoms [529].   
 Further studies should be carried out which compare the different forms of 
CPAP delivery interface with OSA patients, compared to the effect of CPAP 
on symptoms and inflammation, and which establishes whether the response 
to therapy differs between subgroups in terms of sleep daytime sleepiness, 
symptoms and adherence with CPAP usage based on the severity of OSA. 
 Further work is required to explore the role of patient education on the 
compliance by sleep/respiratory specialist at the point of initial CPAP 
equipment delivery and subsequent necessary follow up care.  
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APPENDIX 3 
Binova Reprocessing Instructions 
 
 
Smiths Medical International  
Hythe Kent CT21 6JL UK 
Tel +44 (0)1303 260551 
Fax +44 (0)1303 266761  
www.smiths-medical.com 
 
PRODUCT INFORMATION NOTICE 
ALTERNATIVE RE-PROCESSING OF PORTEX
®
  BIVONA
®
 TRACHEOSTOMY 
TUBES 
 
 
 
This Product Information Notice is intended to advise users that they can apply the alternative re-processing 
instructions below to all Portex
®
 Bivona
®
 Tracheostomy Tubes that are recommended for re-processing.  
These alternative re-processing instructions have been validated to ensure that there will be no adverse 
effect to the product and they will be included in future IFUs accompanying the product. 
 
This Product Information Notice only affects the re-processing portion of the IFU. All other aspects 
of the IFU that accompanies the product must be complied with. 
 
ALTERNATIVE RE-PROCESSING INSTRUCTIONS 
 
 
WARNINGS: 
  
1. During re-processing, removal of all encrustations and other biological material is vital to 
removing bacterial contamination from the product. This must be carried out before 
disinfection is attempted.  
2. During re-processing, aggressive scrubbing of the tube or use of hard bristled brushes or 
sharp wire-mounted swabs may damage the surface of the tube.  
3. Sanitization should be undertaken within the two hour period before tube re-insertion. Once 
removed from the above process there is a risk that the tubes, particularly if left in a warm moist 
environment, will re-colonize with bacteria.  
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CAUTIONS: 
  
1. Bivona
®
 Silicone tracheostomy tubes are designed for single patient use and these 
instructions for re-processing assume that the product will only be re-used on the same 
patient.   
2. These products have been validated up to 121 oC. Do not expose the product to temperatures in 
excess of this temperature or product integrity may be compromised. Do not use deep vacuum 
“flash” or pulse vacuum cycles.   
3. Following cleaning, handle the product only by the neck flange or connector to avoid 
subsequent contamination of the part of the tube that will enter the patient.   
4. Do not re-process decannulation cap to prevent compromise of cap.  
 
Hospital or sterilization service re-processing: 
  
Step 1 Cleaning: 
 
a. Following removal from the patient, the device should be placed in a suitable container and 
marked clearly with the patient‟s reference/identifier. Tracking of the device should be 
conducted in accordance with local hospital procedures for the re-processing of single patient 
use devices.  
b. Following the instructions for use for an enzymatic solution (preferably using a neutral non-
coloured and non-scented cleaner e.g. Ruhof 345APANS Endozyme AW Plus No Scent), 
remove all biological material from the tracheostomy tube, by soaking and gentle manual 
cleaning.  
c. Inspect for any residual contamination and, if necessary, remove it by repeat soaking in 
enzymatic solution and then light rubbing with a soft cleaning implement.   
d. Inspect the product for any signs of damage. Discard the product if there is any sign of  
damage.  
 
Step 2: Method 1 Sanitization Instructions: 
  
a. Place the product and its obturator separately in an HTM 2030/ISO 15883-2 compliant 
washer/disinfector/dryer. Follow the manufacturer‟s instructions for a thermal disinfection 
cycle giving a minimum A0 value of 600 (ref. ISO 15883-2). Ensure that the wash reaches all 
parts of the product to be cleaned. This will mean flushing through the tube bore and talk 
attachment tube (if fitted).   
b. Using aseptic technique, inspect the dry/disinfected product for any signs of damage. Discard 
the product if there is any sign of damage.   
c. Store product in sealed plastic bag or container, marked with the patient‟s reference/identifier.  
 
Alternate Step 2: Method 2 Sterilization Instructions: 
  
a. Insert the obturator into the tube and wrap in protective lint-free cloth or place them 
in a sterilization pouch.   
b. Sterilize in a gravity displacement steam autoclave at 121° C (250° F) for 40 minutes.  
c. Using aseptic technique, inspect the dry/disinfected product for any signs of damage. Discard 
the product if there is any sign of damage.   
Store product in sealed plastic bag or container, marked with the patient‟s reference/identifier. 
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HOSPITAL WARD OR HOME-CARE RE-PROCESSING  
 
Step 1 Cleaning: 
  
a. Following removal, place the tube in a sealed plastic bag or container until ready to clean it. 
This will avoid drying out and hardening of secretions.   
b. Soak the tracheostomy tube and its obturator, separately, in a container of warm water 
containing a mild soap solution for a period of 60 minutes. Ensure that the wash reaches all 
parts of the product to be cleaned. This may mean using a syringe to flush through the talk 
attachment tube (if fitted) and manipulating small tubes to ensure that the liquid does fully fill 
the bore.  
c. Remove any contamination with a lint-free swab. Small tracheostomy tube bores can be 
cleaned by pulling a small portion of a lint-free swab through the tube.   
d. Inspect for any residual contamination and, if necessary, repeat the soak and clean operations.  
e. Rinse the tube inside and outside with clean warm water, flushing thoroughly with water and 
then air dry.  
f. Store in a clean sealed plastic bag or container.  
 
Step 2 Sanitization: 
  
a. Remove the tube and the obturator from its container and place in a pan of rapidly boiling 
clean water.   
b. Cover the pan and REMOVE IT FROM THE HEAT. Allow the water to cool to “hand hot” 
before removing the parts.   
c. Handle the obturator by its handle and the tube by its neck flange.  
 
 
 
C.S. Turnbull  
Senior Development Manager 
Smiths Medical International 
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APPENDIX 4 
 
SACCHARIN TRANIST TIME PROTOCOL
* 
 Maintaining sterile technique. 
 Explain the procedure to the patient.  
 Prepare procedure equipments: pure saccharin tables; forceps for particle placement; 
stopwatch for calculating the time (minutes & seconds); power handle rhinoscope 
for direct visualisation. 
 Maintain a stable environment (temperature 21-24°C) for all tests. 
 Have the subject blew his/her nose gently to remove any excess secretions before the 
test. 
 The most patent nostril verified by inspection not to be obstructed will be chosen for 
the test. 
 A standardised measure of saccharin (a 5 mg particle; ~ 0.5 mm in diameter) is 
gently placed, using a forceps, at the front of the subject's inferior nasal turbinate of 
a nostril. 
 The participants remained seated with their head tipped slightly forward (about 15o 
forward, to prevent the saccharin from falling to the back of their noses) while 
breathing normally (not forced), without sneezing, coughing, eating or blowing their 
nose during the test. 
 After successful placement of saccharin particle, at this time, the stopwatch was 
started. Subjects were requested to stop the stopwatch when they first detected a 
sweet taste.    
 Saccharin clearance time is recoded. 
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Note: saccharin test will not be collected at a time of acute exacerbation of nasal symptoms 
or upper airway infection.  
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APPENDIX 5 
 
SIX-POINT NASAL SCORE 
Study group & number:  
Patient number:  
Visit number:  
Date: 
 
On most days of the week are you troubled by 
 
PROBLEM 
 
Score  
Rhinorrhoea (runny nose)  
Post-nasal drip (The excess mucus accumulates in 
the throat or back of the nose.) 
 
Sneezing  
Congestion (blocked nose)  
Anosmia (reduced smell)   
Itchy nose  
                                                                                 
                                                                                   
Total score 
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APPENDIX 6 
DIARY CARD AND INSTRUCTION, OSA VERSION 
NAME         Month:_______ 2009 
NEXT 
APPOINTMENT 
Study Number/Group         
WORSENING SYMPTOMS? 
CALL US 
/        / 09 
.      am 
Non-invasive respiratory support: OSA study 
DATE 1mon 2 tue 3 wed 4 thu 5 fri 6 sat 7 sun 8 mon 9 tue 10 wed 11 thu 
Peak Flow            
CHANGE in Symptoms            
CHANGE in Treatment            
Hours out of the home            
Hours of Machine use 
D: 
 
L: 
D: 
 
L: 
D: 
 
L: 
D: 
 
L: 
D: 
 
L: 
D: 
 
L: 
D: 
 
L: 
D: 
 
L: 
D: 
 
L: 
D: 
 
L: 
D: 
 
L: 
DATE 12 fri 13 sat 14 sun 15 mon 16 tue 17 wed 18 thu 19 fri 20 sat 21sun 22 mon 
Peak Flow            
CHANGE in Symptoms            
CHANGE in Treatment            
Hours out of the home            
Hours of Machine use 
D: 
L: 
D: 
L: 
D: 
L: 
D: 
L: 
D: 
L: 
D: 
L: 
D: 
L: 
D: 
L: 
D: 
L: 
D: 
L: 
D: 
L: 
DATE 23 tue 24 wed 25 thu 26 fri 27sat 28 sun 29 mon 30 tue 31 wed 
Peak Flow          
CHANGE in Symptoms          
CHANGE in Treatment          
Hours out of the home          
Hours of Machine use 
D: 
 
L: 
D: 
 
L: 
D: 
 
L: 
D: 
 
L: 
D: 
 
L: 
D: 
 
L: 
D: 
 
L: 
D: 
 
L: 
D: 
 
L: 
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Instructions for filling in the DIARY CARDS 
EVERY DAY… 
 
1. After taking morning medications record the best of 3 attempts at the PEAK  
FLOW blowing test in the box on the sheet. 
 
2. Please record any WORSENING of chest and nose symptoms from your usual 
daily level. The symptoms we are interested in are listed below, just put the 
appropriate letter in the box on the sheet.  Continue recording until the symptom 
has gone away or got back to the level you consider 'normal'. 
 
Letter Symptom 
A Increased BREATHLESSNESS. 
B1 Increased SPUTUM COLOUR. 
B2 Increased SPUTUM AMOUNT. 
D Increased WHEEZE or CHEST TIGHTNESS. 
E1 SORE THROAT. 
E2 Increased COUGH. 
F FEVER. 
Z Sneezing  
V Runny nose 
C Congestion (Blocked nose)  
M Mucus from nose running from back of the nose and throat  
T Increased itchy nose  
                                        
3. Please record any CHANGE to your usual treatment for as many days as it 
applies. Again, just put the appropriate letter in the box on the sheet. 
Letter Treatment 
H I am in Hospital. 
I I am taking more than usual INHALED STEROID (red / brown).  
HOW MANY PUFFS? eg. I2 for 2 puffs more than usual. 
R I needed to take extra RELIEVER (blue / green / grey / nebuliser). 
HOW MANY PUFFS? Write, eg 'R3' for 3 puffs, 'R2' for 2 etc 
S I am taking STEROID (Prednisolone) TABLETS. 
HOW MANY TABLETS? Write, eg 'S6' for 6 tablets, 'S5' for 5 etc 
G  I am taking ANTIBIOTIC TABLETS. 
PLEASE RECORD WHICH (write the name on the diary card). 
 
4. Please estimate the time that you were out of your own home on the previous day. 
 
5. Finally, please estimate the hours for the machine use during night when gets dark (use 
letter D from dark) and day when still light (use the letter L from light).        
 
The secretary will answer the phone and we can usually arrange to see you later the same 
day or the following morning. It is best to phone first-thing in the morning. 
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APPENDIX 7 
 
EPWORTH SLEEP SCORE 
                                                                           ROYAL FREE HAMPSTEAD                                         
                                                    NHS Trust 
Study group/number: _________________________ 
Today’s date: ________________________________ 
Visit number: _______________________________ 
Patient number: _____________________________          
 
The following scale is called Epworth sleep score (ESS). This test is an effective instrument used 
to measure excessive sleepiness or excessive daytime sleepiness. By filling your Epworth Score, 
you get an index for whether you may be suffering from sleep apnea, based on your quality of 
life. 
 
It is important that you answer each question as best you can. 
 
 
Situation  
Score Your Daytime Sleepiness in situation 
0 = would 
never fall 
asleep  
1 = slight 
chance of 
falling asleep  
2 = moderate 
chance of 
falling asleep 
3 = high 
chance of 
falling 
asleep 
Sitting and reading     
Watching television     
Sitting inactive in a public place     
As a passenger in a car for an 
hour without a break 
    
Lying down to rest in the 
afternoon when circumstances 
permit 
    
Sitting and talking to someone     
Sitting quietly after a lunch 
without alcohol 
    
In a car, while stopped for a few 
minutes in the traffic 
    
 
TOTAL SCORE 
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APPENDIX 8 
COMPLIANCE & PERIODICITY 
QUESTIONNAIRE 
Study group & number:  
Patient number:  
Visit number:  
 
Date: 
 
The questionnaire will ask about the compliance and periodicity of the use of nasal 
CPAP. It also examines side-effects and symptoms in detail.  
 
Please answer the following questions: 
When did you start using your NIV/CPAP machine? 
___________________________________ 
Do you use your NIV/CPAP machine every night? 
_____________________________________ 
No. of hours used each night ______________ 
 
A - Do you currently suffer from any of the following? 
 
 
Nasal blockage     Yes            No 
Dryness in nose     Yes            No 
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Nose bleeds     Yes            No 
Pain over bridge of nose   Yes            No 
Excessive sneezing    Yes            No 
Blood stained mucus from nose   Yes            No 
Runny nose     Yes            No 
Dry mouth/throat in the mornings  Yes            No 
Mucus in throat     Yes            No 
Dizziness     Yes            No 
Sore eyes     Yes            No 
Facial pains     Yes            No 
Eczema      Yes            No 
Hayfever     Yes            No 
Asthma      Yes            No 
Blocked ears     Yes            No 
B - Have you had any of the above problems in the past? (before 
starting the NIV/CPAP treatment) 
What is your experience of the following? 
                
Noise of machine (Noisy)       Yes           No 
Comfort of mask (Comfortable)      Yes           No 
Air leaking from mask        Yes           No 
Air leaking from your mouth      Yes           No 
Skin reaction to mask        Yes           No 
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Breakdown of skin over nose (i.e. Pressure sore)    Yes           No 
Have you taken any inhalers/spray for nasal stuffiness?    Yes           No 
Do you sleep in a separate room to your spouse/partner?   Yes           No 
Do you have sleep disturbance because of the machine?               Yes           No 
Treatment benefit from the machine use      Yes            No 
 
Any other experiences/problems? 
 
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________  
 
 
 
 
 
 
 
 
 
 
 
